<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005284.pub3" GROUP_ID="RENAL" ID="996804072010315904" MERGED_FROM="" MODIFIED="2014-05-02 10:52:12 +1000" MODIFIED_BY="[Empty name]" REVIEW_NO="096" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.2">
<COVER_SHEET MODIFIED="2014-05-02 10:51:44 +1000" MODIFIED_BY="Narelle Willis">
<TITLE>Treatment for peritoneal dialysis-associated peritonitis</TITLE>
<CONTACT>
<PERSON ID="C0FCCDA082E26AA201557EE88E84CC8B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kathryn</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Wiggins</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>kate.wiggins@mh.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>0400175423</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Departments of Nephrology and General Medicine</DEPARTMENT>
<ORGANISATION>Royal Melbourne Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Melbourne</CITY>
<ZIP/>
<REGION>VIC</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-05-02 10:51:44 +1000" MODIFIED_BY="Narelle Willis">
<PERSON ID="65703978595573372637111109061948" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Angela</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Ballinger</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Student</POSITION>
<EMAIL_1>balan836@student.otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Otago Christchurch</ORGANISATION>
<ADDRESS_1>2 Riccarton Ave</ADDRESS_1>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP>8041</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19787" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Suetonia</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Palmer</LAST_NAME>
<SUFFIX>MBChB</SUFFIX>
<POSITION/>
<EMAIL_1>suetonia.palmer@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Otago Christchurch</ORGANISATION>
<ADDRESS_1>2 Riccarton Ave</ADDRESS_1>
<ADDRESS_2>PO Box 4345</ADDRESS_2>
<CITY>Christchurch</CITY>
<ZIP>8140</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 21626008</PHONE_1>
<PHONE_2/>
<FAX_1>+64 3 3253368</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="C0FCCDA082E26AA201557EE88E84CC8B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kathryn</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Wiggins</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>kate.wiggins@mh.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>0400175423</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Departments of Nephrology and General Medicine</DEPARTMENT>
<ORGANISATION>Royal Melbourne Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Melbourne</CITY>
<ZIP/>
<REGION>VIC</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4552" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jonathan</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Craig</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1>
<EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1>Edward Ford Building A27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>2006</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16113" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Johnson</LAST_NAME>
<SUFFIX/>
<POSITION>Nephrologist</POSITION>
<EMAIL_1>david_johnson@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1>Ipswich Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3240 5080</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3240 5480</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1EE7AE3C82E26AA200DA2AF37607F40F" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Nicholas</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Cross</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Nick.Cross@cdhb.govt.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Christchurch Public Hospital</ORGANISATION>
<ADDRESS_1>Private Bag 4710</ADDRESS_1>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 3 3640640 ext 88952</PHONE_1>
<PHONE_2/>
<FAX_1>+ 64 3 3640942</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION>Editor and Regional Coordinator</POSITION>
<EMAIL_1>strippoli@negrisud.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-04-17 18:45:58 +1000" MODIFIED_BY="Ruth Mitchell">
<UP_TO_DATE>
<DATE DAY="5" MONTH="3" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="3" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="9" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-05-02 10:42:19 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-05-02 10:42:19 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>Minor copy edits made to study names to match Renal Group's Specialised Register</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-05-02 10:41:37 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-05-02 10:41:37 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Review updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-05-02 10:41:34 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>New studies identified</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-18 14:18:23 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="11" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-02-19 19:04:40 +1100" MODIFIED_BY="Suetonia Palmer">
<INTERNAL_SOURCES MODIFIED="2012-02-19 19:04:40 +1100" MODIFIED_BY="Suetonia Palmer">
<SOURCE MODIFIED="2012-02-19 19:04:40 +1100" MODIFIED_BY="Suetonia Palmer">
<NAME>The research team acknowledges the support received from the Cochrane Renal Group in the conduct of this review</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-02-19 19:03:42 +1100" MODIFIED_BY="Suetonia Palmer">
<SOURCE MODIFIED="2012-02-19 19:03:42 +1100" MODIFIED_BY="Suetonia Palmer">
<NAME>Suetonia Palmer</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION>
<P>received an unrestricted fellowship from Amgen Dompe, administered by the Consorzio Mario Negri Sud</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-02-19 19:03:31 +1100" MODIFIED_BY="Suetonia Palmer">
<NAME>Angela Ballinger</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION>
<P>Received a summer student scholarship from the Division of Medical Sciences, Unversity of Otago to complete the update of this review</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-03-05 14:15:53 +1100" MODIFIED_BY="Narelle Willis">
<TITLE MODIFIED="2013-05-09 10:51:14 +1000" MODIFIED_BY="Suetonia Palmer">What is the best treatment to manage peritonitis in people on peritoneal dialysis?</TITLE>
<SUMMARY_BODY MODIFIED="2014-03-05 14:15:53 +1100" MODIFIED_BY="Narelle Willis">
<P>People with advanced kidney disease can be treated with peritoneal dialysis (PD) which involves a catheter being permanently inserted into the lining around the abdominal organs (the peritoneum) through the abdominal wall. Sterile fluid is drained in and out several times each day. The peritoneal lining enables movement of salts and toxins that accumulate when kidney function cannot maintain usual function. Wastes from the bloodstream are moved into the dialysis fluid and removed with the fluid as it is drained from the body.</P>
<P>The most common serious complication of PD is infection of the peritoneal lining - peritonitis. Effective treatment is necessary to reduce risk of recurrent infection, needing to stop PD, poor peritoneal membrane function, and potentially prolonged hospital admission or death.</P>
<P>This review of interventions for PD-associated peritonitis identified 42 studies (2433 participants). Many studies were small, out-dated, of poor quality, and had inconsistent definitions and dosing regimens. In general, information about the best treatment of peritonitis in people on PD may be insufficient to guide therapy.</P>
<P>We found that intraperitoneal antibiotics appear to improve treatment responses compared with IV antibiotics. Glycopeptides may increase likelihood of cure compared with first generation cephalosporins. There appears to be no certain role for routine peritoneal lavage (washing) or use of clot-breaking (fibrinolytic) agents.</P>
<P>New and larger randomised controlled trials that compare the effects of IV versus intraperitoneal antibiotics and different antibiotic types on patient-relevant outcomes including adequate assessment of treatment harms are still needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-03-05 17:41:37 +1100" MODIFIED_BY="Narelle Willis">
<ABS_BACKGROUND MODIFIED="2014-03-05 14:15:16 +1100" MODIFIED_BY="Narelle Willis">
<P>Peritonitis is a common complication of peritoneal dialysis (PD) that is associated with significant morbidity including death, hospitalisation, and need to change from PD to haemodialysis. Treatment is aimed to reduce morbidity and recurrence. This is an update of a review first published in 2008.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-02-20 08:26:15 +1100" MODIFIED_BY="Suetonia Palmer">
<P>To evaluate the benefits and harms of treatments for PD-associated peritonitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-03-05 15:08:40 +1100" MODIFIED_BY="Narelle Willis">
<P>For this review update we searched the Cochrane Renal Group's Specialised Register to March 2014 through contact with the Trials Search Co-ordinator using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE and EMBASE, and handsearching conference proceedings.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-03-05 17:39:13 +1100" MODIFIED_BY="Narelle Willis">
<P>We included randomised controlled trials (RCTs) and quasi-RCTs assessing the treatment of peritonitis in PD patients (adults and children). We included any study that evaluated: administration of an antibiotic by different routes (e.g. oral, intraperitoneal (IP), intravenous (IV)); dose of an antibiotic agent; different schedules of administration of antimicrobial agents; comparisons of different regimens of antimicrobial agents; any other intervention including fibrinolytic agents, peritoneal lavage and early catheter removal.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-06-20 18:38:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multiple authors independently extracted data on study risk of bias and outcomes. Statistical analyses were performed using the random effects model. We expressed summarised treatment estimates as a risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) with 95% CI for continuous outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-03-05 17:41:37 +1100" MODIFIED_BY="Narelle Willis">
<P>We identified 42 eligible studies in 2433 participants: antimicrobial agents (36 studies); urokinase (4 studies), peritoneal lavage (1 study), and IP immunoglobulin (1 study). We did not identify any optimal antibiotic agent or combination of agents. IP glycopeptides (vancomycin or teicoplanin) had uncertain effects on primary treatment response, relapse rates, and need for catheter removal compared to first generation cephalosporins, although glycopeptide regimens were more likely to achieve a complete cure (3 studies, 370 episodes: RR 1.66, 95% CI 1.01 to 2.72). For relapsing or persistent peritonitis, simultaneous catheter removal and replacement was better than urokinase at reducing treatment failure rates (RR 2.35, 95% CI 1.13 to 4.91) although evidence was limited to a single small study. Continuous and intermittent IP antibiotic dosing schedules had similar treatment failure and relapse rates. IP antibiotics were superior to IV antibiotics in reducing treatment failure in one small study (RR 3.52, 95% CI 1.26 to 9.81). Longer duration treatment (21 days of IV vancomycin and IP gentamicin) had uncertain effects on risk of treatment relapse compared with 10 days treatment (1 study, 49 patients: RR 1.56, 95% CI 0.60 to 3.95) although may have increased ototoxicity.</P>
<P>In general, review conclusions were based on a small number of studies with few events in which risk of bias was generally high; interventions were heterogeneous, and outcome definitions were often inconsistent. There were no RCTs evaluating optimal timing of catheter removal and data for automated PD were absent.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-03-05 14:15:47 +1100" MODIFIED_BY="Narelle Willis">
<P>Many of the studies evaluating treatment of PD-related peritonitis are small, out-dated, of poor quality, and had inconsistent definitions and dosing regimens. IP administration of antibiotics was superior to IV administration for treating PD-associated peritonitis and glycopeptides appear optimal for complete cure of peritonitis, although evidence for this finding was assessed as low quality. PD catheter removal may be the best treatment for relapsing or persistent peritonitis.</P>
<P>Evidence was insufficient to identify the optimal agent, route or duration of antibiotics to treat peritonitis. No specific antibiotic appears to have superior efficacy for preventing treatment failure or relapse of peritonitis, but evidence is limited to few trials. The role of routine peritoneal lavage or urokinase is uncertain.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-04-15 19:32:22 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-03-05 16:46:02 +1100" MODIFIED_BY="Narelle Willis">
<P>Peritoneal dialysis (PD) is an effective form of renal replacement therapy for people with advanced kidney disease. However, peritonitis continues to represent a significant complication of PD (<LINK REF="REF-Voinescu-2002" TYPE="REFERENCE">Voinescu 2002</LINK>) despite the introduction of effective prevention strategies such as disconnect and double bag systems (<LINK REF="REF-Bazzato-1980" TYPE="REFERENCE">Bazzato 1980</LINK>; <LINK REF="REF-Monteon-1998" TYPE="REFERENCE">Monteon 1998</LINK>; <LINK REF="REF-Strippoli-2004" TYPE="REFERENCE">Strippoli 2004</LINK>). The reported incidence of peritonitis episodes varies from one in nine patient-months to one in 53 patient-months (<LINK REF="REF-Grunberg-2005" TYPE="REFERENCE">Grunberg 2005</LINK>; <LINK REF="REF-Kawaguchi-1999" TYPE="REFERENCE">Kawaguchi 1999</LINK>). Risk factors for peritonitis include diabetes mellitus (<LINK REF="REF-Oxton-1994" TYPE="REFERENCE">Oxton 1994</LINK>), race (<LINK REF="REF-Juergensen-2002" TYPE="REFERENCE">Juergensen 2002</LINK>; <LINK REF="REF-Lim-2005" TYPE="REFERENCE">Lim 2005</LINK>), obesity (<LINK REF="REF-McDonald-2004" TYPE="REFERENCE">McDonald 2004</LINK>), temperate climates (<LINK REF="REF-Alves-1993" TYPE="REFERENCE">Alves 1993</LINK>; <LINK REF="REF-Szeto-2003" TYPE="REFERENCE">Szeto 2003</LINK>), and depression (<LINK REF="REF-Troidle-2003" TYPE="REFERENCE">Troidle 2003</LINK>). In addition, some studies have shown that PD modality may influence peritonitis rates, although other studies have not confirmed this (<LINK REF="REF-Huang-2001" TYPE="REFERENCE">Huang 2001</LINK>; <LINK REF="REF-Oo-2005" TYPE="REFERENCE">Oo 2005</LINK>).</P>
<P>PD-associated peritonitis results in significant morbidity, and in some cases, mortality. Catheter removal becomes necessary in cases not responding to antibiotic therapy. This may be temporary and followed by a return to PD, or permanent, resulting in technique failure. Ultrafiltration failure can occur both acutely due to increases in capillary permeability (<LINK REF="REF-Ates-2000" TYPE="REFERENCE">Ates 2000</LINK>; <LINK REF="REF-Smit-2004" TYPE="REFERENCE">Smit 2004</LINK>) and in the longer term result in technique failure (<LINK REF="REF-Coles-2000" TYPE="REFERENCE">Coles 2000</LINK>; <LINK REF="REF-Davies-1996" TYPE="REFERENCE">Davies 1996</LINK>). In many countries, peritonitis is a leading cause of permanent transfer to haemodialysis. Peritonitis is prevalent among patients with encapsulating sclerosing peritonitis and may be a causal factor (<LINK REF="REF-Kawanishi-2005" TYPE="REFERENCE">Kawanishi 2005</LINK>; <LINK REF="REF-Rigby-1998" TYPE="REFERENCE">Rigby 1998</LINK>). In some patient groups peritonitis is thought to increase overall mortality rates (<LINK REF="REF-Fried-1996" TYPE="REFERENCE">Fried 1996</LINK>). It is estimated that PD-associated peritonitis results in death in 6% of affected patients (<LINK REF="REF-Troidle-2006" TYPE="REFERENCE">Troidle 2006</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-01-08 13:19:08 +1100" MODIFIED_BY="[Empty name]">
<P>Early and effective management of peritonitis is important to reduce the risk of adverse outcomes such as catheter removal (<LINK REF="REF-Choi-2004" TYPE="REFERENCE">Choi 2004</LINK>; <LINK REF="REF-Heaf-2004" TYPE="REFERENCE">Heaf 2004</LINK>). The mainstay of treatment is antimicrobial therapy, although adjunctive therapies have been employed including the use of fibrinolytic agents (<LINK REF="STD-Innes-1994" TYPE="STUDY">Innes 1994</LINK>; <LINK REF="REF-Pickering-1989" TYPE="REFERENCE">Pickering 1989</LINK>), peritoneal lavage (<LINK REF="STD-Ejlersen-1991" TYPE="STUDY">Ejlersen 1991</LINK>) and routine early catheter removal.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-03-05 14:11:28 +1100" MODIFIED_BY="Narelle Willis">
<P>Current guidelines recommend the use of antibiotics which cover gram positive and gram negative organisms in cases of peritonitis (<LINK REF="REF-CARI-2005" TYPE="REFERENCE">CARI 2005</LINK>; <LINK REF="REF-Piraino-2005" TYPE="REFERENCE">Piraino 2005</LINK>). However, several questions about the optimal treatment of PD-associated peritonitis remain unanswered, particularly with respect to choice, route of administration (<LINK REF="REF-Passadakis-2001" TYPE="REFERENCE">Passadakis 2001</LINK>) and duration of antimicrobial therapy. Many treatment regimens are based on continuous ambulatory PD (CAPD) and their applicability to automated PD (APD) is untested (<LINK REF="REF-Fielding-2002" TYPE="REFERENCE">Fielding 2002</LINK>). The optimal total duration of antimicrobial therapy, and the duration of systemic (intraperitoneal (IP) or intravenous (IV)) treatment is also unclear, as are the roles of peritoneal lavage and urokinase. The majority of studies performed have focused on the outcomes of empirical antibiotic therapy, with little consideration of treatment initiated once organism identification and sensitivities are available.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-04-15 19:32:22 +1000" MODIFIED_BY="[Empty name]">
<P>To address existing uncertainties, we performed a systematic review of randomised controlled trials (RCT) evidence examining the effectiveness of different treatment options for PD-associated peritonitis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-03-05 14:15:59 +1100" MODIFIED_BY="Narelle Willis">
<P>To evaluate the benefits and harms of treatments for PD-associated peritonitis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-03-05 16:53:47 +1100" MODIFIED_BY="Narelle Willis">
<SELECTION_CRITERIA MODIFIED="2014-03-05 16:49:35 +1100" MODIFIED_BY="Narelle Willis">
<CRIT_STUDIES MODIFIED="2014-03-05 14:16:05 +1100" MODIFIED_BY="Narelle Willis">
<P>All RCTs and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) on the effect of any interventions, including anti-infective agents, fibrinolytic agents, peritoneal lavage and early catheter removal, for the treatment of peritonitis in PD patients were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-03-05 14:16:37 +1100" MODIFIED_BY="Narelle Willis">
<P>Adult and paediatric patients who were receiving PD (CAPD or APD) and developed PD-associated peritonitis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-03-05 16:49:35 +1100" MODIFIED_BY="Narelle Willis">
<P>Studies looking at the use of any antimicrobial agent, fibrinolytic agent, peritoneal lavage, IP immunoglobulin or early catheter removal were included. Interventions could be tested directly against each other or compared to placebo/no treatment. The following could be included:<BR/>
</P>
<UL>
<LI>Studies of the same antibiotic agent administered by different routes (e.g. IP versus oral, IP versus IV).</LI>
<LI>Studies comparing the same antibiotic agent administered at different doses.</LI>
<LI>Studies comparing different schedules of administration of antimicrobial agents (in particular regimens involving single daily dosing versus more than one daily dose).</LI>
<LI>Comparisons of different regimens of antimicrobial agents.</LI>
<LI>Studies comparing different treatment durations with the same antimicrobial agents.</LI>
<LI>Studies comparing any other intervention including fibrinolytic agents, peritoneal lavage, IP immunoglobulin administration, and early catheter removal.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-03-05 16:43:26 +1100" MODIFIED_BY="Narelle Willis">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-03-05 16:43:13 +1100" MODIFIED_BY="Narelle Willis">
<OL>
<LI>Primary peritonitis treatment failure (failure to achieve a clinical response, defined as resolution of symptoms and signs, by day 4 to 6)</LI>
<LI>Complete cure (clinical or microbiological improvement or both with no subsequent relapse)</LI>
<LI>Peritonitis relapse (reoccurrence of peritonitis due to the same organism with the same antibiotic sensitivities within 28 days of completing treatment)</LI>
<LI>Death due to peritonitis (all-cause mortality data were also collected)</LI>
<LI>Toxicity of antibiotic treatments (ototoxicity, decline in residual kidney function, rash, nausea and vomiting, convulsions, other).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-03-05 16:43:26 +1100" MODIFIED_BY="Narelle Willis">
<OL>
<LI>Time to peritonitis relapse</LI>
<LI>Need to change antibiotic following culture results</LI>
<LI>Catheter removal or replacement or both</LI>
<LI>Hospitalisation (duration of hospital stay) and hospitalisation rate (number of patients hospitalised)</LI>
<LI>Technique failure (transfer from PD to haemodialysis or transplantation due to peritonitis).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-03-05 15:47:05 +1100" MODIFIED_BY="Narelle Willis">
<ELECTRONIC_SEARCHES MODIFIED="2014-03-05 15:47:05 +1100" MODIFIED_BY="Narelle Willis">
<P>For this update we searched the Cochrane Renal Group's Specialised Register and EMBASE to 5 March 2014 without language restriction.</P>
<P>The Cochrane Renal Group&#8217;s Specialised Register contains studies identified from:</P>
<OL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of renal-related journals and the proceedings of major renal conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected renal journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>.</P>
<P>Please refer to our review published in 2008 for the original search strategies used (<LINK REF="REF-Wiggins-2008" TYPE="REFERENCE">Wiggins 2008</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-03-05 15:36:13 +1100" MODIFIED_BY="Narelle Willis">
<OL>
<LI>Reference lists of clinical practice guidelines, review articles and relevant studies.</LI>
<LI>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-03-05 16:53:47 +1100" MODIFIED_BY="Narelle Willis">
<STUDY_SELECTION MODIFIED="2014-03-05 15:12:42 +1100" MODIFIED_BY="Narelle Willis">
<P>The original review was undertaken by four authors in 2008 and seven authors in 2014. The search strategies described were used to obtain titles and abstracts of studies that might be relevant to the review. The titles and abstracts were screened independently by multiple authors, who discarded studies that were not eligible based on the inclusion criteria for this review; however studies and reviews that might include relevant data or information on additional published or unpublished studies were retained initially and their full-text version was analysed.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-03-05 16:53:47 +1100" MODIFIED_BY="Narelle Willis">
<P>Four authors independently assessed the retrieved abstracts, and if necessary, the full text of these studies to determine eligibility. Data extraction was carried out independently by the same authors using standard data extraction forms. Studies reported in non-English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions these data were used Disagreements were resolved in consultation among authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-11-19 12:55:17 +1100" MODIFIED_BY="[Empty name]">
<P>The following items were independently assessed by two authors using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?</LI>
<UL>
<LI>Participants and personnel</LI>
<LI>Outcome assessors</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-11-19 13:55:46 +1100" MODIFIED_BY="[Empty name]">
<P>Results were expressed as risk ratio (RR) with 95% confidence intervals (CI) for all categorical outcomes of the individual studies. </P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2014-03-05 15:48:01 +1100" MODIFIED_BY="Narelle Willis">
<P>Any further information or clarification required from the authors was requested by written or electronic correspondence and relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention-to-treat (ITT), as-treated and per-protocol (PP) population was performed. Attrition rates, for example drop-outs, losses to follow-up and withdrawals were investigated. Issues of missing data and imputation methods (for example, last-observation-carried-forward (LOCF)) were critically appraised (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-04-18 16:49:39 +1000" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-04-18 16:50:48 +1000" MODIFIED_BY="[Empty name]">
<P>It was planned that if sufficient RCTs were identified an attempt would be made to assess funnel plot asymmetry due to small study effect, as this may be indicative of publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). There were however too few included studies to construct meaningful funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-11-19 13:55:54 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment effects were summarised using a random-effects model. For each analysis, the fixed-effect model was also evaluated to ensure robustness of the model chosen and susceptibility to outliers. Where continuous scales of measurement were used to assess the effects of treatment (time to peritonitis relapse, days of hospitalisation, measures of residual kidney function) the mean difference (MD) was used.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-03-05 14:18:25 +1100" MODIFIED_BY="Narelle Willis">
<P>Subgroup analysis was planned to explore how possible sources of heterogeneity (paediatric versus adult population, age, gender, cause of end-stage kidney disease, body mass index, diabetes mellitus, duration of dialysis, PD modality (CAPD versus APD), previous peritonitis episodes, type of dialysate and micro-organism isolated) might influence treatment effect.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-04-18 16:50:04 +1000" MODIFIED_BY="[Empty name]">
<P>We aimed to perform sensitivity analyses to explore the influence of the following factors on effect size:</P>
<UL>
<LI>repeating the analysis excluding unpublished studies</LI>
<LI>repeating the analysis taking account of risk of bias</LI>
<LI>repeating the analysis excluding any very long or large studies to establish how much they dominate the results</LI>
<LI>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
<P>Data were however insufficient to perform these analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-03-05 16:56:23 +1100" MODIFIED_BY="Narelle Willis">
<P>The literature search undertaken for <LINK REF="REF-Wiggins-2008" TYPE="REFERENCE">Wiggins 2008</LINK> retrieved 1684 reports of which 1617 were excluded. Analysis of the remainder identified 36 studies (2089 participants, 2480 peritonitis episodes) published in 42 reports. For this update the Cochrane Renal Group's Specialised Register identified 62 reports of potential studies and two ongoing studies. After full text review a further six eligible studies (344 participants, 533 peritonitis episodes) were identified taking the total number of unique RCTs to 42 (58 reports; 2433 participants, 3013 episodes of peritonitis). Search results are summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]">
<P>We identified 36 studies (1949 patients) that considered the use of antimicrobial agents. There were 14 studies that compared different routes of antibiotic administration - IP versus IV (3 studies, 156 participants: <LINK REF="STD-Bailie-1987" TYPE="STUDY">Bailie 1987</LINK>; <LINK REF="STD-Bennett_x002d_Jones-1987" TYPE="STUDY">Bennett-Jones 1987</LINK>; <LINK REF="STD-Vargemezis-1989" TYPE="STUDY">Vargemezis 1989</LINK>) and IP versus oral (11 studies, 601 participants: <LINK REF="STD-Bennett_x002d_Jones-1990" TYPE="STUDY">Bennett-Jones 1990</LINK>; <LINK REF="STD-Boeschoten-1985" TYPE="STUDY">Boeschoten 1985</LINK>; <LINK REF="STD-Chan-1990" TYPE="STUDY">Chan 1990</LINK>; <LINK REF="STD-Cheng-1991" TYPE="STUDY">Cheng 1991</LINK>; <LINK REF="STD-Cheng-1993" TYPE="STUDY">Cheng 1993</LINK>; <LINK REF="STD-Cheng-1997" TYPE="STUDY">Cheng 1997</LINK>; <LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK>; <LINK REF="STD-Gucek-1994" TYPE="STUDY">Gucek 1994</LINK>; <LINK REF="STD-Lye-1993" TYPE="STUDY">Lye 1993</LINK>; <LINK REF="STD-Raman-1985" TYPE="STUDY">Raman 1985</LINK>; <LINK REF="STD-Tapson-1990" TYPE="STUDY">Tapson 1990</LINK>).</P>
<P>Different IP antibiotic classes or combinations or both were tested head-to-head in 17 studies (<LINK REF="STD-Bowley-1988" TYPE="STUDY">Bowley 1988</LINK>; <LINK REF="STD-de-Fijter-2001" TYPE="STUDY">de Fijter 2001</LINK>; <LINK REF="STD-Drinovec-1988" TYPE="STUDY">Drinovec 1988</LINK>; <LINK REF="STD-Flanigan-1991" TYPE="STUDY">Flanigan 1991</LINK>; <LINK REF="STD-Friedland-1990" TYPE="STUDY">Friedland 1990</LINK>; <LINK REF="STD-Gucek-1997" TYPE="STUDY">Gucek 1997</LINK>; <LINK REF="STD-Hernandez-2004" TYPE="STUDY">Hernandez 2004</LINK> <LINK REF="STD-Jim_x00e9_nez-1996" TYPE="STUDY">Jiménez 1996</LINK>; <LINK REF="STD-Khairullah-2002" TYPE="STUDY">Khairullah 2002</LINK>; <LINK REF="STD-Klaus-1995a" TYPE="STUDY">Klaus 1995a</LINK>; <LINK REF="STD-Leung-2004" TYPE="STUDY">Leung 2004</LINK>; <LINK REF="STD-Lui-2005" TYPE="STUDY">Lui 2005</LINK>; <LINK REF="STD-Lupo-1997" TYPE="STUDY">Lupo 1997</LINK>; <LINK REF="STD-Merchant-1992" TYPE="STUDY">Merchant 1992</LINK>; <LINK REF="STD-Wale-1992" TYPE="STUDY">Wale 1992</LINK>; <LINK REF="STD-Were-1992" TYPE="STUDY">Were 1992</LINK>; <LINK REF="STD-Wong-2001" TYPE="STUDY">Wong 2001</LINK>). These included three studies (234 participants) that compared glycopeptides to first generation cephalosporins (<LINK REF="STD-Flanigan-1991" TYPE="STUDY">Flanigan 1991</LINK>; <LINK REF="STD-Khairullah-2002" TYPE="STUDY">Khairullah 2002</LINK>; <LINK REF="STD-Lupo-1997" TYPE="STUDY">Lupo 1997</LINK>); and five studies (421 participants) that compared intermittent and continuous IP antibiotic dosing (<LINK REF="STD-Boyce-1988" TYPE="STUDY">Boyce 1988</LINK>; <LINK REF="STD-Choy-2001" TYPE="STUDY">Choy 2001</LINK>; <LINK REF="STD-Lye-1995" TYPE="STUDY">Lye 1995</LINK>; <LINK REF="STD-Klaus-1995a" TYPE="STUDY">Klaus 1995a</LINK>; <LINK REF="STD-Velasquez_x002d_Jones-1995" TYPE="STUDY">Velasquez-Jones 1995</LINK>).</P>
<P>There were six studies that investigated adjunctive therapies: urokinase versus placebo (<LINK REF="STD-Gadallah-2000c" TYPE="STUDY">Gadallah 2000c</LINK>; <LINK REF="STD-Innes-1994" TYPE="STUDY">Innes 1994</LINK>; <LINK REF="STD-Tong-2005a" TYPE="STUDY">Tong 2005a</LINK>); catheter removal or replacement or both (<LINK REF="STD-Williams-1989" TYPE="STUDY">Williams 1989</LINK>), peritoneal lavage (<LINK REF="STD-Ejlersen-1991" TYPE="STUDY">Ejlersen 1991</LINK>), and IP immunoglobulin (<LINK REF="STD-Coban-2004" TYPE="STUDY">Coban 2004</LINK>). Data for automated PD were absent.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-03-05 16:59:08 +1100" MODIFIED_BY="Narelle Willis">
<P>We excluded 49 studies (67 reports). Reasons for exclusion were: not RCTs (19); not appropriate population (24); not peritonitis treatment (2); not appropriate outcomes (4).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]">
<P>We have summarised the risk of bias of included studies in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. In general, risks of bias were in high in most studies. Overall, both blinding and selective reporting were assessed at high risk of bias. Suboptimal reporting in many studies meant that risks of bias were assessed as unknown.</P>
<ALLOCATION MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]">
<P>Random generation sequence was assessed as low risk in four studies (10%) (<LINK REF="STD-Chan-1990" TYPE="STUDY">Chan 1990</LINK>; <LINK REF="STD-Cheng-1991" TYPE="STUDY">Cheng 1991</LINK>; <LINK REF="STD-Lui-2005" TYPE="STUDY">Lui 2005</LINK>; <LINK REF="STD-Tapson-1990" TYPE="STUDY">Tapson 1990</LINK>); allocation concealment was adequate in 7/42 (17%) studies (<LINK REF="STD-Cheng-1991" TYPE="STUDY">Cheng 1991</LINK>; <LINK REF="STD-Cheng-1998" TYPE="STUDY">Cheng 1998</LINK>; <LINK REF="STD-Friedland-1990" TYPE="STUDY">Friedland 1990</LINK>; <LINK REF="STD-Klaus-1995a" TYPE="STUDY">Klaus 1995a</LINK>; <LINK REF="STD-Lui-2005" TYPE="STUDY">Lui 2005</LINK>; <LINK REF="STD-Tapson-1990" TYPE="STUDY">Tapson 1990</LINK>; <LINK REF="STD-Wong-2001" TYPE="STUDY">Wong 2001</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-03-03 15:10:35 +1100" MODIFIED_BY="Narelle Willis">
<P>Only three (7%) studies clearly blinded participants and investigators (<LINK REF="STD-Cheng-1991" TYPE="STUDY">Cheng 1991</LINK>; <LINK REF="STD-Innes-1994" TYPE="STUDY">Innes 1994</LINK>; <LINK REF="STD-Tong-2005a" TYPE="STUDY">Tong 2005a</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-05-09 11:25:33 +1000" MODIFIED_BY="[Empty name]">
<P>Percentages of participants lost to follow-up ranged from 0% to 64.5%.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-03-05 17:03:27 +1100" MODIFIED_BY="Narelle Willis">
<P>Reporting of outcomes was assessed as low risk in only six (14%) studies (<LINK REF="STD-de-Fijter-2001" TYPE="STUDY">de Fijter 2001</LINK>; <LINK REF="STD-Friedland-1990" TYPE="STUDY">Friedland 1990</LINK>; <LINK REF="STD-Lye-1993" TYPE="STUDY">Lye 1993</LINK>; <LINK REF="STD-Merchant-1992" TYPE="STUDY">Merchant 1992</LINK>; <LINK REF="STD-Tong-2005a" TYPE="STUDY">Tong 2005a</LINK>; <LINK REF="STD-Wong-2001" TYPE="STUDY">Wong 2001</LINK>).</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]">
<P>There were no significant differences in the results of analyses performed using random and fixed-effects models. The results presented therefore refer to those obtained using a random-effects model. Subgroup analyses and evaluations for bias from small-study effects were not performed because the small numbers of participants and studies made the power of these analyses too small to assess. Few data were available on the pharmacokinetics of many commonly used antibiotics when administered intraperitoneally.</P>
<SUBSECTION>
<HEADING LEVEL="3">Intravenous (IV) versus intraperitoneal (IP) antimicrobial agents</HEADING>
<P>
<LINK REF="STD-Bennett_x002d_Jones-1987" TYPE="STUDY">Bennett-Jones 1987</LINK> reported a statistically significant increase in the primary treatment failure rate for IV versus IP vancomycin and tobramycin (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2 (75 participants): RR 3.52, 95% CI 1.26 to 9.81). It is noteworthy that in the study by <LINK REF="STD-Bailie-1987" TYPE="STUDY">Bailie 1987</LINK>, in which IP versus IV administration of a loading dose of vancomycin followed by an IP maintenance dose were compared, there were no primary treatment failures reported in either group. <LINK REF="STD-Vargemezis-1989" TYPE="STUDY">Vargemezis 1989</LINK> also looked at IP versus IV administration of vancomycin; however, reporting limitations made it difficult to interpret meaningful results.</P>
<P>
<LINK REF="STD-Bailie-1987" TYPE="STUDY">Bailie 1987</LINK> reported no significant differences in the incidence of rash (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.1 (20 participants): RR 5.00, 95% CI 0.27 to 92.62) or infusion pain (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (20 participants): RR 3.00, 95% CI 0.14 to 65.90) between IV and IP vancomycin. <LINK REF="STD-Bennett_x002d_Jones-1987" TYPE="STUDY">Bennett-Jones 1987</LINK> reported no significant difference in hypotension (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.2 (76 participants): RR 5.26, 95% CI 0.26 to 106.11) between IV and IP vancomycin and tobramycin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral versus IP administration of the same antimicrobial agent</HEADING>
<P>Oral administration of quinolone antibiotics (ciprofloxacin, ofloxacin) had uncertain effects on primary treatment failure compared to IP administration (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (2 studies, 83 participants): RR 1.34, 95% CI 0.71 to 2.56; P = 0.37; I²= 0%) and relapse (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (2 studies, 83 participants): RR 3.38, 95% CI 0.74 to 15.35; P = 0.11; I² = 0%). Assessment of low-quality evidence indicated that IP quinolone therapy may increase complete cure (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> (2 studies, 83 participants): RR 1.66, 95% CI 0.98 to 2.83; P = 0.06; I² = 0%) compared with oral treatment, although therapy failure rates were high in both arms of these studies (52.4% and 31.7% in the oral and IP groups, respectively).</P>
<P>
<LINK REF="STD-Cheng-1993" TYPE="STUDY">Cheng 1993</LINK> reported no significant differences in catheter removal rates (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (48 participants): RR 2.00, 95% CI 0.19 to 20.61), hospitalisation rates (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK> (48 participants): RR 1.00, 95% CI 0.51 to 1.95), or nausea and vomiting (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK> (48 participants): RR 0.50, 95% CI 0.05 to 5.15) between oral and IP cephalosporin (cephradine) therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral versus IP administration of different antimicrobial agents</HEADING>
<P>Comparison of oral versus antibiotic regimens had uncertain effects on risks of failure to achieve complete cure (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> (8 studies, 510 participants): RR 1.06, 95% CI 0.80 to 1.40; P = 0.69; I² = 0%). Subgroup analysis showed this was similar for oral quinolones versus IP aminoglycoside/glycopeptide combinations (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>.1 (5 studies, 304 participants): RR 1.19, 95% CI 0.83 to 1.72), oral quinolones versus IP cephalosporins (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>.2 (2 studies, 148 participants): RR 1.00, 95% CI 0.55 to 1.81), and oral cephradine versus IP cefuroxime (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>.3 (58 participants): RR 0.77, 95% CI 0.40 to 1.46). Similarly, primary treatment failure (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> (7 studies, 472 participants): RR 1.04, 95% CI 0.64 to 2.15; P = 0.86; I² = 0%), relapse (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>
<I> (</I>5 studies, 304 participants): RR 1.17, 95% CI 0.64 to 2.15; P = 0.61; I² = 2%), catheter removal (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK> (2 studies, 170 participants): RR 1.18, 95% CI 0.49 to 2.87; P = 0.71; I² = 0%), hospitalisation rate (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK> (1 study, 45 participants): RR 0.70, 95% CI 0.30 to 1.63), all-cause mortality (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK> (1 study, 46 participants): RR 0.36, 95% CI 0.02 to 8.46), and microbiological eradication (not defined by investigators)<I> </I>(<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK> (1 study, 39 participants): RR 1.26, 95% CI 0.46 to 3.46) were equivalent in both groups. There was an increased risk of nausea and vomiting with oral antibiotics compared to IP antibiotics (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>.1 (3 studies, 158 participants): RR 9.91, 95% CI 1.89 to 51.99; P = 0.007; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral versus IP administration of the same or different antimicrobial agent(s)</HEADING>
<P>When all studies that compared oral versus IP administration of an antimicrobial agent were combined, treatment failure rates of oral versus IP administration were similar without evidence for between-trial heterogeneity (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> (9 studies, 555 participants): RR 1.12, 95% CI 0.79 to 1.60; P = 0.52; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Low versus high dose antibiotic</HEADING>
<P>
<LINK REF="STD-Merchant-1992" TYPE="STUDY">Merchant 1992</LINK> reported low dose imipenem (total 1 g IP daily) was associated with a significant increase in failure to achieve complete cure (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> (30 participants): RR 4.38, 95% CI 1.27 to 15.06) and the number relapsing (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK> (28 participants): RR 12.00, 95% CI 1.60 to 90.23) compared with high dose imipenem (total 2 g IP daily). High dose imipenem had an uncertain effect on seizures (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK> (30 participants): RR 0.60, 95% CI 0.03 to 11.23). However this study was not powered to detect seizures and the protocol was changed mid-study from high dose to low dose imipenem because two participants in the imipenem group had seizures.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intermittent versus continuous IP antimicrobial agents</HEADING>
<P>The effects of intermittent compared with continuous dosing on complete cure (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK> (4 studies, 338 participants): RR 0.92, 95% CI 0.64 to 1.33; P = 0.65; I² = 0%), primary treatment failure (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK> (5 studies, 522 participants): RR 1.11, 95% CI 0.77 to 1.62; P = 0.57; I² = 0%) and risk of relapse (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK> (4 studies, 338 participants): RR 0.76, 95% CI 0.45 to 1.28; P = 0.31; I² = 0%) were uncertain. <LINK REF="STD-Choy-2001" TYPE="STUDY">Choy 2001</LINK> reported no significant difference in catheter removal rates between groups (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK> (20 participants): 0.98, 95% CI 0.43 to 2.24). The only side-effect evaluated was vancomycin-induced rash (<LINK REF="STD-Boyce-1988" TYPE="STUDY">Boyce 1988</LINK>); effects of continuous compared with intermittent dosing were uncertain (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK> (51 participants): RR 0.70, 95% CI 0.05 to 10.57).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">First generation cephalosporin versus glycopeptide-based regimens</HEADING>
<P>Achievement of complete cure was significantly more likely with a glycopeptide-based regimen than one based on cephalosporins (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK> (3 studies, 370 participants): RR 1.66, 95% CI 1.01 to 2.72; P = 0.04; I² = 41%). This was true for both vancomycin (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>.1 (2 studies, 305 participants): RR 1.51, 95% CI 1.03 to 2.22; P = 0.26; I² = 20%) and teicoplanin-based regimens (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>.2 (1 study, 65 participants): RR 9.65, 95% CI 1.04 to 20.58). Despite the overall advantage of glycopeptides on complete cure, effects on primary treatment failure (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK> (2 studies, 305 participants): RR 1.14, 95% CI 0.69 to 1.87; P = 0.38; I² = 0%), relapse (<LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK> (3 studies, 350 participants): RR 1.68, 95% CI 0.84 to 3.36; P = 0.14; I² = 0%), catheter removal (<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK> (2 studies, 305 participants): RR 0.95, 95% CI 0.41 to 2.19; P = 0.90; I² = 52%) and microbiological eradication (<LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK> (1 study, 45 participants): RR 0.83, 95% CI 0.62 to 1.13) were uncertain likely due to the lack of power within the meta-analysis.</P>
<P>It is noteworthy that these results were largely influenced by <LINK REF="STD-Flanigan-1991" TYPE="STUDY">Flanigan 1991</LINK> in which the cephazolin dose used was 50 mg/L, which is below the dose currently recommended in the International Society for Peritoneal Dialysis (ISPD) guidelines of 125 mg/L (<LINK REF="REF-Li-2010" TYPE="REFERENCE">Li 2010</LINK>). In contrast, <LINK REF="STD-Khairullah-2002" TYPE="STUDY">Khairullah 2002</LINK> found no difference in cure rates for vancomycin and cephazolin (50% and 40% complete cure for glycopeptides and cephalosporins respectively) when a higher cephalosporin dose was used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Teicoplanin versus vancomycin-based IP antibiotic regimens</HEADING>
<P>Primary treatment failure was less likely with teicoplanin than vancomycin (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK> (2 studies, 178 participants): RR 0.36, 95% CI 0.13 to 0.96; P = 0.04), however, effects on complete cure were uncertain (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK> (2 studies, 178 participants): RR 0.67, 95% CI 0.40 to 1.15; P = 0.14; I² = 0%). The risk of relapse rates was also similar for both agents (<LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK> (2 studies, 178 participants): RR 1.01, 95% CI 0.49 to 2.11; P = 0.97; I² = 0%). There was no significant heterogeneity associated with either outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Different regimens of oral antibiotics</HEADING>
<P>Effects of oral rifampicin and ofloxacin (regimen 2) compared with oral ofloxacin alone (regimen 1) (<LINK REF="STD-Chan-1990" TYPE="STUDY">Chan 1990</LINK>) in achieving a complete cure (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK> (74 participants): RR 0.88, 95% CI 0.35 to 2.17) and catheter removal (<LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK> (74 participants): RR 2.00, 95% CI 0.19 to 21.11) were uncertain. <LINK REF="STD-Chan-1990" TYPE="STUDY">Chan 1990</LINK> also reported there was no differences in the need to change antibiotics following culture results (<LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK> (74 participants): RR 0.33, 95% CI 0.04 to 3.06), nausea and vomiting (<LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>.1 (74 participants): RR 3.00, 95% CI 0.13 to 71.34) and rash (<LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>.2 (74 participants): RR 3.00, 95% CI 0.13 to 71.34) between the two regimens. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fibrinolytic agents versus non-urokinase or placebo</HEADING>
<P>Studies of IP urokinase found uncertain effects for benefit of urokinase versus placebo on complete cure in persistent peritonitis (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK> (88 participants): RR 1.23, 95% CI 0.84 to 1.79), or primary response to treatment in the setting of resistant peritonitis (<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK> (2 studies, 99 participants): RR 0.63, 95% CI 0.32 to 1.26; P = 0.19; I² = 33%). Resistant CAPD peritonitis was defined as either persistent infection or recurrent infection (<LINK REF="STD-Innes-1994" TYPE="STUDY">Innes 1994</LINK>) or as persistence of symptoms and signs of peritonitis together with turbid peritoneal dialysate 48 hours after the initiation of antibiotic treatment (<LINK REF="STD-Tong-2005a" TYPE="STUDY">Tong 2005a</LINK>). Persistent infection was defined as no resolution of peritonitis within four days of treatment with antibiotics active against the bacteria isolated (<LINK REF="STD-Innes-1994" TYPE="STUDY">Innes 1994</LINK>). Relapse and catheter removal were uncertain with urokinase, either in the setting of persistent peritonitis (<LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>.1; <LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>.1) or initiation of fibrinolytic therapy at the time peritonitis was diagnosed (<LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>.2; <LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>.2). <LINK REF="STD-Tong-2005a" TYPE="STUDY">Tong 2005a</LINK> reported no significant difference in all-cause mortality (<LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Urokinase versus simultaneous catheter removal and replacement</HEADING>
<P>In <LINK REF="STD-Williams-1989" TYPE="STUDY">Williams 1989</LINK>, a study of participants presenting with a second recurrence of peritonitis, simultaneous catheter removal and replacement was better than urokinase in reducing recurrent episodes of peritonitis (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK> (37 participants): RR 2.35, 95% CI 1.13 to 4.91).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Peritoneal lavage</HEADING>
<P>
<LINK REF="STD-Ejlersen-1991" TYPE="STUDY">Ejlersen 1991</LINK> investigated the effects of peritoneal lavage (2 L exchanges during the initial 24 hours, no dwell time with dialysis fluid (60 L) containing vancomycin 20 mg/L and netilmicin) plus nine further days antibiotic treatment compared with continued prolonged exchanges (2 rapid exchanges containing vancomycin (40 mg/L) followed by routine CAPD schedule including antibiotics for 10 days. This study reported no significant differences between lavage and usual care for complete cure (<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK> (36 participants): RR 2.50, 95% CI 0.56 to 11.25), relapse of peritonitis with subsequent laparotomy and colostomy (<LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK> (36 participants): RR 2.50, 95% CI 0.56 to 11.25), technical failure (<LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK> (36 participants): RR 3.00, 95% CI 0.13 to 69.09), or adverse events (<LINK REF="CMP-012.04" TYPE="ANALYSIS">Analysis 12.4</LINK> (36 participants): 3.00, 95% CI 0.13 to 69.09).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intraperitoneal immunoglobulin</HEADING>
<P>
<LINK REF="STD-Coban-2004" TYPE="STUDY">Coban 2004</LINK> reported the use of IP immunoglobulin was associated with a statistically significant reduction in numbers of exchanges executed for the dialysate white cell count to fall below 100/mL (<LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK> (24 participants): MD -7.30 exchanges, 95% CI -8.12 to -6.48). There were no treatment failures and no relapses in any participants in this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Head-to-head studies</HEADING>
<P>Of the 12 studies in which different regimens of IP antibiotics were compared head-to-head, the only statistically significant outcome was reported by <LINK REF="STD-de-Fijter-2001" TYPE="STUDY">de Fijter 2001</LINK>: rifampicin/ciprofloxacin was better than cephradine in reducing treatment failure (<LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>.7 (98 participants) RR 0.50, 95% CI 0.28 to 0.89).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Duration of antibiotic treatment</HEADING>
<P>
<LINK REF="STD-Altmann-1984" TYPE="STUDY">Altmann 1984</LINK> compared duration of antibiotic treatment (vancomycin and gentamicin for 10 versus 21 days) and reported uncertain effects on risk of relapse (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK> (49 participants): RR 1.56, 95% CI 0.61 to 3.95). It is noteworthy that five participants, all of whom received more than 21 days of gentamicin, developed clinical evidence of vestibular damage versus no patients who received a 10-day course of treatment.</P>
<P>It was not possible to tabulate a summary of findings because there were insufficient studies for each analysis.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-03-05 17:29:03 +1100" MODIFIED_BY="Narelle Willis">
<SUMMARY_OF_RESULTS MODIFIED="2014-03-05 17:24:04 +1100" MODIFIED_BY="Narelle Willis">
<P>This review found that in generally low-quality evidence, IP antibiotic therapy may lower risks of primary treatment failure compared with IV antibiotics in two small studies.</P>
<P>The benefits of intermittent dosing of some antibiotics (vancomycin, gentamicin, ceftazidime and teicoplanin) compared with continuous therapy in the treatment of peritonitis, and of IP versus oral antibiotics, are uncertain.</P>
<P>In a single small study of participants presenting with a second recurrence of peritonitis, simultaneous catheter removal and replacement was superior to urokinase to reduce risks of relapsing and remitting PD-associated peritonitis. Insufficient data were available to determine if specific antibiotic classes are most effective for reducing treatment failure and relapse, although glycopeptides may improve complete cure rates compared with first generation cephalosporins.</P>
<P>It was unclear if peritoneal lavage improves response to concomitant antimicrobial therapy.</P>
<P>We also found that IP immunoglobulin administration decreased the time for the dialysate inflammatory cell count to fall, but effects on patient-important outcomes, such as treatment failure or risk of relapse, are uncertain. Longer duration of antibiotics had unclear effects on risk of relapse compared with shorter treatment courses, and may increase adverse events.</P>
<P>Oral antibiotics were associated with increased risk of nausea and vomiting compared with IP administration.</P>
<P>Data for automated PD were scant.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-03-05 14:20:45 +1100" MODIFIED_BY="Narelle Willis">
<P>Our review revealed a significant paucity of evidence underlying many widely-used and accepted clinical practices in the treatment of peritonitis, a condition that is associated with significant patient morbidity and mortality. Consequently, some aspects of treatment are uncertain, such as duration of antimicrobial therapy and optimal timing of catheter removal. While valuable information was gained from this review, the few available studies at generally high risk of bias resulted in a lack of evidence in many important areas of clinical practice. Studies tended to focus on choice and route of antibiotic without consideration of other variables such as total duration of therapy, drug dose and the role of patient factors, such as comorbidities and residual kidney function. No RCTs have been conducted to determine if early catheter removal is beneficial in patients not responding to therapy. The follow-up period of most studies was 28 days or fewer; therefore, long-term outcomes, such as technique failure and mortality, were not evaluated. Loss of residual kidney function during peritonitis may be accelerated by aminoglycoside therapy (<LINK REF="REF-Baker-2003" TYPE="REFERENCE">Baker 2003</LINK>; <LINK REF="REF-Shemin-2000" TYPE="REFERENCE">Shemin 2000</LINK>) although this has been refuted by a recent study (<LINK REF="REF-Badve-2012" TYPE="REFERENCE">Badve 2012</LINK>). As a result of these factors, there is insufficient evidence regarding several aspects of management that are clinically important and this makes the provision of definitive treatment guidelines difficult at the present time.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-03-05 14:21:45 +1100" MODIFIED_BY="Narelle Willis">
<P>The risk of bias of included studies was generally moderate-to-high. In particular, inadequate randomisation and concealment methods were common. Definitions of peritonitis, successful treatment, and relapse varied among studies, thereby reducing their comparability. Many studies were conducted in single-centre settings with small patient numbers, and were underpowered to detect short-term (treatment failure and catheter removal), medium-term (relapse and recurrence) or long-term (mortality and technique failure) effects. Similarly, studies did not systematically evaluate adverse events. Hence there was significant potential for type II statistical errors (finding no treatment effect when a treatment effect exists) in most of our analyses. Studies often predated the current era of lower peritonitis rates, newer antibiotic therapies and increased awareness of multiresistant organisms, thereby potentially reducing the applicability of our meta-analyses.</P>
<P>A significant issue was that there was marked heterogeneity among studies of outcome definitions. Treatment failure was variably measured by resolution of symptoms and signs, clearing of dialysate, fall in dialysate white cell count and microbiological eradication of the causative organism. The time frame in which these changes were required to occur also varied, ranging from 48 hours to 28 days. Similarly there was a large degree of variation in the time elapsed after a primary peritonitis episode for a second peritonitis episode to be considered as a relapse (<LINK REF="REF-Li-2010" TYPE="REFERENCE">Li 2010</LINK>).</P>
<P>An additional problem was interaction of endpoints. For example, primary treatment failure often necessitates catheter removal, which is an endpoint in itself. Some studies defined treatment failure as a need to change the antimicrobial agent or catheter removal. In contrast, other studies defined primary failure as ongoing symptoms beyond 48 hours of antibiotic therapy, with catheter removal evaluated as a separate outcome. These factors reduced the comparability of studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-05-09 13:36:38 +1000" MODIFIED_BY="Suetonia Palmer">
<P>While the review was completed according to standardised Cochrane methodology, potential biases in the review process should be considered. We completed a formal search designed by a specialist information manager including data from a wide range of sources, including handsearching, to limit the potential for omission of potentially relevant studies, although there is a possibility that relevant studies may have not been included. There were insufficient studies included in most meta-analyses to enable us to examine for potential publication bias. Most studies did not systematically report all relevant patient-centred outcomes, suggesting that data for mortality and other clinical outcomes were incomplete, and summary estimates were potentially unreliable.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-03-05 17:29:03 +1100" MODIFIED_BY="Narelle Willis">
<P>As far as we are aware, this remains the only published systematic review of RCTs of all PD-associated peritonitis treatment. A review of antimicrobial treatment of PD-associated peritonitis published in 1991 concluded that the optimal empirical treatment was weekly vancomycin in combination with ceftazidime (<LINK REF="REF-Millikin-1991" TYPE="REFERENCE">Millikin 1991</LINK>). However, this review predated many of the studies included in this study, and was not confined to RCTs.</P>
<P>The mainstay of peritonitis treatment is timely administration of empirical antimicrobial agents that are likely to eradicate the most common causative agents. This is endorsed by guidelines of the International Society of Peritoneal Dialysis (ISPD) (<LINK REF="REF-Li-2010" TYPE="REFERENCE">Li 2010</LINK>) and the Australian and New Zealand Society of Nephrology (Caring for Australians with Renal Impairment - CARI, <LINK REF="REF-CARI-2005" TYPE="REFERENCE">CARI 2005</LINK>), both of which state that broad spectrum antibiotic agents designed to cover both gram negative and gram positive organisms should be initiated at the time a diagnosis of peritonitis is suspected. There is, however, insufficient evidence to suggest more specific agents. This has been demonstrated by this review in which we found that in 21 studies comparing different antibiotic classes, the treatment failure rates were generally in the range of 10% to 30%, with only three studies showing a difference between treatment arms (<LINK REF="STD-de-Fijter-2001" TYPE="STUDY">de Fijter 2001</LINK>; <LINK REF="STD-Flanigan-1991" TYPE="STUDY">Flanigan 1991</LINK>; <LINK REF="STD-Lupo-1997" TYPE="STUDY">Lupo 1997</LINK>). In each of these cases the applicability to current practice is low. <LINK REF="STD-de-Fijter-2001" TYPE="STUDY">de Fijter 2001</LINK> found IP ciprofloxacin and rifampicin to be superior to IP cephradine. However, monotherapy with a first generation cephalosporin is uncommon, and in this case, was associated with a low initial response rate of 50%. Furthermore, the broad spectrum of action of both ciprofloxacin and rifampicin predisposes to emergence of multiresistant organisms thereby reducing their desirability as first line agents. In our meta-analysis of two studies comparing IP cephazolin and vancomycin we found vancomycin to be superior. However, this result was strongly influenced by a larger number of patients in <LINK REF="STD-Flanigan-1991" TYPE="STUDY">Flanigan 1991</LINK>, in which the cephazolin dose of 50 mg/L was two and a half times less than that recommended in the current ISPD guidelines (<LINK REF="REF-Li-2010" TYPE="REFERENCE">Li 2010</LINK>).</P>
<P>Similar efficacy rates amongst several antibiotic regimens facilitate consideration of logistical factors and adverse effect profiles when selecting antibiotics (<LINK REF="REF-Kan-2003" TYPE="REFERENCE">Kan 2003</LINK>). Current ISPD guidelines state that there should be centre-specific selection of agents according to local causative micro-organism and resistance patterns (<LINK REF="REF-Li-2010" TYPE="REFERENCE">Li 2010</LINK>). The impact of local microbial resistance on peritonitis outcomes was apparent in two studies comparing oral and IP quinolone use (<LINK REF="STD-Cheng-1993" TYPE="STUDY">Cheng 1993</LINK>; <LINK REF="STD-Cheng-1997" TYPE="STUDY">Cheng 1997</LINK>). In these studies, response rates were low for both treatment arms (41.7% and 55.6% in the oral groups and 66.7% and 70.6% in the IP groups respectively). Micro-organism resistance to quinolones was the major cause of treatment failure, and previous exposure to quinolones was a risk factor for infection with resistant micro-organisms. The emergence of vancomycin-resistant enterococcus is also associated with use of broad spectrum antibiotics (<LINK REF="REF-Carmeli-2002" TYPE="REFERENCE">Carmeli 2002</LINK>; <LINK REF="REF-Oprea-2004" TYPE="REFERENCE">Oprea 2004</LINK>). Of note increasing prevalence of methicillin-resistant <I>Staphylococci </I>(both <I>S. aureus</I> and coagulase negative species) is a relatively recent phenomenon hence limiting the ability of early studies to evaluate this problem.</P>
<P>In this review, we found that studies in which antibiotics (ciprofloxacin, ofloxacin and cephradine) were administered either orally or IP showed no difference in outcomes for the two routes of administration. However, initial antibiotic therapy is commonly administered intraperitoneally as this theoretically achieves higher dialysate antibiotic levels than permitted with other routes. Evidence about the relative importance of dialysate antibiotic levels was unclear (reviewed in <LINK REF="REF-Johnson-2011" TYPE="REFERENCE">Johnson 2011</LINK>). In the study of oral versus IP ciprofloxacin included in this review, dialysate antibiotic levels were lower in the IP group but this did not affect patient outcomes (<LINK REF="STD-Cheng-1993" TYPE="STUDY">Cheng 1993</LINK>). <LINK REF="REF-Booranalertpaisarn-2003" TYPE="REFERENCE">Booranalertpaisarn 2003</LINK> reported that daily dosing of ceftazidime in patients with peritonitis led to serum levels that were above the recommended minimum inhibitory concentration (MIC) throughout 24 hours, whereas dialysate levels were below the MIC for several hours on days one and four. Despite this, the response rate was 90%, suggesting that achieving therapeutic dialysate levels may not be necessary for treatment to be effective.</P>
<P>Benefits of intermittent (daily) dosing of antibiotics include facilitation of outpatient management and continuation of APD. In the general population, daily dosing with aminoglycosides reduces the risk of ototoxicity compared with intermittent dosing (<LINK REF="REF-Deamer-1996" TYPE="REFERENCE">Deamer 1996</LINK>). In this review, intermittent and continuous antibiotic dosing had similar outcomes. Adequate duration of antibiotic activity with daily dosing is facilitated by long drug half-lives. Studies of CAPD patients without peritonitis have shown that serum and dialysate levels of several antibiotics remain above the mean inhibitory concentration for up to 48 hours (<LINK REF="REF-Grabe-1999" TYPE="REFERENCE">Grabe 1999</LINK>; <LINK REF="REF-Manley-1999" TYPE="REFERENCE">Manley 1999</LINK>). Many drugs have peak serum levels six hours after administration suggesting that this should be the minimum dwell time. Post-antibiotic effects of drugs may also contribute to the efficacy of intermittent dosing. The applicability of results from studies of intermittent drug therapy in CAPD to APD is however unclear as drug half-lives are greater and clearances more rapid in cycler dwells compared to non-cycler dwells (<LINK REF="REF-Manley-2002" TYPE="REFERENCE">Manley 2002</LINK>).</P>
<P>The high rate of complications arising from peritonitis despite rapid institution of antibiotic therapy suggests a need exists for adjuvant treatment strategies. One such treatment is administration of IP urokinase, the rationale being to dissolve fibrin and enable access of antibiotics to entrapped bacteria (<LINK REF="REF-Pickering-1989" TYPE="REFERENCE">Pickering 1989</LINK>). <LINK REF="STD-Williams-1989" TYPE="STUDY">Williams 1989</LINK> showed that urokinase was inferior to simultaneous catheter removal and replacement. However, catheter removal could in itself be considered treatment failure. Meta-analysis of three other studies showed no statistically significant difference in outcomes between urokinase and catheter removal. However, it is noteworthy that in <LINK REF="STD-Tong-2005a" TYPE="STUDY">Tong 2005a</LINK>, the actual number of patients achieving a primary response was five more in the urokinase than the control group, and there were three fewer catheter removals. Furthermore, adequately powered, studies in this area may be beneficial, in which the optimal outcome would be permanent transfer to haemodialysis.</P>
<P>Peritoneal lavage is performed at many centres because it has the potential to remove inflammatory cells and micro-organisms from the peritoneal cavity while providing symptomatic relief, and has been used successfully in abdominal surgery (<LINK REF="REF-O_x0027_Brien-1987" TYPE="REFERENCE">O'Brien 1987</LINK>). It has however been the subject of only one RCT (<LINK REF="STD-Ejlersen-1991" TYPE="STUDY">Ejlersen 1991</LINK>), in which patients with hypotension and shock, the same group in which lavage has been used in surgical settings, were excluded. In this study, peritoneal lavage did not improve response rates. This may be a true effect due to inadvertent removal of macrophages and other components of the immune system thereby a reduction of local host defences against infection. However, further studies to evaluate this therapy further may be useful.</P>
<P>A novel strategy is administration of IP immunoglobulin in conjunction with antibiotics with the aim of improving local host defences (<LINK REF="REF-Carozzi-1988" TYPE="REFERENCE">Carozzi 1988</LINK>). In a study of 24 patients (<LINK REF="STD-Coban-2004" TYPE="STUDY">Coban 2004</LINK>) biochemical and clinical parameters of improvement were achieved sooner, and the duration of antibiotic therapy was shorter in the immunoglobulin treatment group. The response rate of 100% was unusually high and there were no relapses during three months of follow-up. In a larger population, a difference in response rates may have become apparent.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-03-05 17:32:10 +1100" MODIFIED_BY="Narelle Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2014-03-05 17:32:10 +1100" MODIFIED_BY="Narelle Willis">
<P>In conclusion, currently available evidence from RCTs is not robust and does not identify an optimal antibiotic regimen for the treatment of PD-associated peritonitis.</P>
<UL>
<LI>Available studies are small, and generally at high risk of bias, lowering the certainty of treatment effects for all available treatments.</LI>
<LI>At the present time, broad spectrum antibiotics should be initiated at the time a diagnosis of peritonitis is made and IP routes and use of glycopeptides may improve outcomes.</LI>
<LI>Intermittent antibiotic dosing appears to be as effective as continuous dosing, however, the applicability of this practice to APD is unclear.</LI>
<LI>There appears to be no role for adjunctive therapies such as urokinase and peritoneal lavage.</LI>
<LI>When choosing antibiotics, the side-effect profile, local drug resistance patterns and previous antibiotic use and infection history in the individual concerned should be considered. Oral antibiotics may increase risks of nausea and vomiting compared with IP administration.</LI>
<LI>IP route of administration may be superior to IV dosing in preventing primary treatment failures.</LI>
<LI>Few data were available on the pharmacokinetics of many commonly used antibiotics when administered intraperitoneally, and information about many new antibiotics is lacking. Data for automated PD were scant.</LI>
<LI>In cases of recurrent peritonitis, dialysis catheters should be removed rather than using IP urokinase.</LI>
</UL>
<P>Currently available evidence from RCTs is inadequate in many areas of clinical practice important in the management of PD-associated peritonitis and is a limiting factor in the provision of definitive treatment guidelines.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-03-05 15:35:22 +1100" MODIFIED_BY="Narelle Willis">
<P>Future research should be adequately powered to assess outcomes such as catheter removal and mortality, and should include long-term follow-up of parameters such as ultrafiltration failure, loss of residual kidney function and technique failure.</P>
<P>Further studies are needed to:</P>
<UL>
<LI>Establish the most effective treatment for PD-associated peritonitis. An essential feature of such studies is inclusion of enough patients to ensure adequate power to assess meaningful long- and short-term outcomes. Short-term outcomes should extend beyond whether cure is achieved without catheter removal, for example duration of systemic inflammation. Study of long-term outcomes should include permanent transfer to haemodialysis, development of ultrafiltration failure patient death and late recurrent episodes of peritonitis beyond four weeks from the original episode.</LI>
<LI>Identify specific interventions that would be of value including early versus late catheter removal. Studies designed to study infections due to specific organisms would also be valuable. An example is a study of glycopeptide versus cephalosporin therapy in peritonitis due to coagulase negative <I>Staphylococcal</I> species. Most studies have included patients on CAPD rather than APD, hence, studies designed to test the efficacy of antibiotics in APD are required. This is particularly applicable to studies of intermittent versus continuous dosing when cycler dwell times may well influence pharmacokinetics. Additional studies including greater numbers of participants comparing IP versus IV dosing of the same antibiotic would also assist in assessing meaningful treatment effects.</LI>
</UL>
<P>In addition, future research should be conducted using standard definitions, with inclusion of information about factors that may influence the response to therapy such as prophylaxis regimens and dialysis solutions used. Current ISPD guidelines provide a comprehensive list of requirements for future studies that should be referred to when designing studies.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-03-05 17:33:44 +1100" MODIFIED_BY="Narelle Willis">
<P>We would like to thank the referees for their comments and feedback during the preparation of this review.</P>
<P>We would like to thank Narelle Willis and Ruth Mitchell from the Cochrane Renal Group for their assistance to update this review.</P>
<P>We would also like to thank Dr Martin Searle from the Department of Nephrology at Christchurch Hospital for his contribution to the updated review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-02-06 14:20:30 +1100" MODIFIED_BY="[Empty name]">
<P>Professor David Johnson is a consultant for Baxter Healthcare Pty Ltd and has previously received research funds from this company. He has also received speakers' honoraria and research grants from Fresenius Medical Care. Angela Ballinger received a student stipend for a summer studentship 2011 to 2012 from the University of Otago to assist with completing this research. Suetonia Palmer received a fellowship administered by the Consorzio Mario Negri Sud from Amgen Dompe for assistance with travel for collaboration and supervision. The other authors had no known conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-04-23 14:51:52 +1000" MODIFIED_BY="[Empty name]">
<P>Screening of titles and abstracts: AB, KW, GFMS, SP<BR/>Study eligibility: AB, KW, GFMS, SP<BR/>Risk of bias assessment, data extraction, data analysis: AB, KW, GFMS, SP<BR/>Writing of review: AB, KW, GFMS, SP, DJ, JC<BR/>Disagreement resolution: DJ, JC<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-05-02 10:52:12 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-05-02 10:52:12 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Altmann-1984" MODIFIED="2011-12-09 07:22:53 +1100" MODIFIED_BY="[Empty name]" NAME="Altmann 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-12-09 07:22:53 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altmann P, Butter K, Cunningham J, Drew P, Goodwin F, Marsh F</AU>
<TI>CAPD peritonitis: 10 or 21 days treatment? [abstract]</TI>
<SO>Kidney International</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>4</NO>
<PG>544</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailie-1987" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Bailie 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailie GR, Morton R, Ganguli L, Keaney M, Waldek S</AU>
<TI>Intravenous or intraperitoneal vancomycin for the treatment of continuous ambulatory peritoneal dialysis associated gram-positive peritonitis?</TI>
<SO>Nephron</SO>
<YR>1987</YR>
<VL>46</VL>
<NO>3</NO>
<PG>316-8</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:28:40 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:28:40 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="3627326"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennett_x002d_Jones-1987" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Bennett-Jones 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bennett-Jones D, Wass V, Mawson P</AU>
<TI>A comparison of intraperitoneal and intravenous/oral antibiotics in CAPD peritonitis</TI>
<SO>Peritoneal Dialysis Bulletin</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>1</NO>
<PG>31-3</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:29:58 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:29:58 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1987123371"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-10 16:30:36 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett-Jones DN, Eaton A, Taube D, Wass V, Mawson P, Neild GH, et al</AU>
<TI>A trial of intraperitoneal versus intravenous antibiotics in the treatment of CAPD peritonitis [abstract]</TI>
<SO>Kidney International</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>4</NO>
<PG>538</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:30:36 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 16:30:36 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00602030"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennett_x002d_Jones-1990" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Bennett-Jones 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett-Jones DN, Russell GI, Barrett A</AU>
<TI>A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1990</YR>
<VL>26 Suppl F</VL>
<PG>73-6</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:31:13 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:31:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2292547"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boeschoten-1985" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Boeschoten 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boeschoten EW, Rietra PJ, Krediet RT, Visser MJ, Arisz L</AU>
<TI>CAPD peritonitis: A prospective randomized trial of oral versus intraperitoneal treatment with cephradine</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1985</YR>
<VL>16</VL>
<NO>6</NO>
<PG>789-97</PG>
<IDENTIFIERS MODIFIED="2014-02-11 11:16:30 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-11 11:16:30 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="3912367"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowley-1988" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Bowley 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowley JA, Pickering SJ, Scantlebury AJ, Ackrill P, Jones DM</AU>
<TI>Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1988</YR>
<VL>21 Suppl A</VL>
<PG>133-9</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:32:28 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:32:28 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2965125"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyce-1988" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Boyce 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyce NW, Wood C, Thomson NM, Hooke D, Holdworth SR, Kerr P, et al</AU>
<TI>Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis - a prospective controlled trial of intermittent vs continuous IP administration [abstract]</TI>
<SO>Kidney International</SO>
<YR>1988</YR>
<VL>33</VL>
<NO>1</NO>
<PG>136</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:33:45 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 16:33:45 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00444512"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boyce NW, Wood C, Thomson NM, Kerr P, Atkins RC</AU>
<TI>Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis - a prospective, randomized comparison of intermittent v continuous therapy</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1988</YR>
<VL>12</VL>
<NO>4</NO>
<PG>304-6</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:34:49 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:34:49 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="3177373"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-11 11:28:10 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munro B</AU>
<TI>"Single dose" vancomycin treatment of continuous ambulatory peritoneal dialysis (CAPD) peritonitis</TI>
<SO>Renal Education</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>3</NO>
<PG>45-7</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:37:20 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:37:20 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00636131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1990" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Chan 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan MK, Cheng IK, Ng WS</AU>
<TI>A randomized prospective trial of three different regimens of treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1990</YR>
<VL>15</VL>
<NO>2</NO>
<PG>155-9</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:38:19 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:38:19 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2405653"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1991" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Cheng 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng IK, Chan CY, Wong WT</AU>
<TI>A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD)</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:38:48 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:38:48 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2049419"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1993" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Cheng 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng IK, Chan CY, Wong WT, Cheng SW, Ritchie CW, Cheung WC, et al</AU>
<TI>A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1993</YR>
<VL>13 Suppl 2</VL>
<PG>S351-4</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:39:26 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:39:26 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8399609"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1997" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Cheng 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng IK, Lui SL, Fang GX, Chau PY, Cheng SW, Chiu FH, et al</AU>
<TI>A randomized prospective comparison of oral versus intraperitoneal ofloxacin as the primary treatment of CADP peritonitis</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>5</NO>
<PG>431-5</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:40:00 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:40:00 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1997337788"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-05 15:33:52 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fang GX, Lo WX, Chan TM, Chau PY, Choy BY, Lo CY, et al</AU>
<TI>A randomised prospective comparison of oral versus intraperitoneal ofloxacin as primary treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD) [abstract]</TI>
<SO>6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong</SO>
<YR>1995</YR>
<PG>126</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1998" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Cheng 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-05 15:59:16 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng IK, Chau PY, Chan TM, Wong A, Tong KL, Li CS, et al</AU>
<TI>A multicentre randomised prospective comparison of oral levofloxacin plus i.p. vancomycin and i.p. netromycin plus i.p. vancomycin as primary treatment of CAPD peritonitis [abstract]</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S433</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00550585"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng IK, Fang GX, Chau PY, Chan TM, Tong KL, Wong AK, et al</AU>
<TI>A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>4</NO>
<PG>371-5</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:41:00 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:41:00 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="10505557"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choy-2001" MODIFIED="2014-03-05 16:00:24 +1100" MODIFIED_BY="Narelle Willis" NAME="Choy 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-03-05 16:00:24 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choy BY, Lo WK, Chan TM, Lui SL, Tang S, Lam MF, et al</AU>
<TI>A randomised prospective comparison of intermittent versus continuous dosing regimens of intraperitoneal cefazolin and tobramycin in the treatment of CAPD peritonitis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>425A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:41:41 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 16:41:41 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00550719"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coban-2004" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Coban 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coban E, Ozdogan M, Tuncer M, Bozcuk H, Ersoy F</AU>
<TI>The value of low-dose intraperitoneal immunoglobulin administration in the treatment of peritoneal dialysis-related peritonitis</TI>
<SO>Journal of Nephrology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>3</NO>
<PG>427-30</PG>
<IDENTIFIERS MODIFIED="2014-02-13 11:14:00 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-13 11:14:00 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15365965"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Fijter-2001" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="de Fijter 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Fijter CW, ter Wee PM, Oe LP, Verbrugh HA</AU>
<TI>Intraperitoneal ciprofloxacin and rifampicin versus cephradine as initial treatment of (C)APD-related peritonitis: a prospective randomized multicenter comparison (CIPPER trial)</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>5</NO>
<PG>480-6</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:43:34 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:43:34 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11757832"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drinovec-1988" MODIFIED="2014-02-13 11:54:20 +1100" MODIFIED_BY="[Empty name]" NAME="Drinovec 1988" YEAR="1988 Feb">
<REFERENCE MODIFIED="2014-02-13 11:54:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drinovec J, Bren A, Gucek A, Lindic J, Kandus A, Ponikvar R</AU>
<TI>The treatment of staphylococcus peritonitis in patients on continuous ambulatory peritoneal dialysis</TI>
<SO>Chemioterapia</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>1</NO>
<PG>46-8</PG>
<IDENTIFIERS MODIFIED="2014-02-13 11:54:20 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-13 11:54:20 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="3378276"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ejlersen-1991" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Ejlersen 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ejlersen E, Brandi L, Lokkegaard H, Ladefoged J, Kopp R, Haarh P</AU>
<TI>Is initial (24 hours) lavage necessary in treatment of CAPD peritonitis?</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>1</NO>
<PG>38-42</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:44:52 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:44:52 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2049421"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flanigan-1991" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Flanigan 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-02-10 16:45:00 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flanigan MJ, Freeman RM, Lawton WJ</AU>
<TI>Vancomycin is superior to cefazolin for treatment of CAPD peritonitis [abstract]</TI>
<SO>Kidney International</SO>
<YR>1988</YR>
<VL>33</VL>
<NO>1</NO>
<PG>245</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Flanigan MJ, Lim VS</AU>
<TI>Initial treatment of dialysis associated peritonitis: A controlled trial of vancomycin versus cefazolin</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>1</NO>
<PG>31-7</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:46:51 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:46:51 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2049420"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedland-1990" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Friedland 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Friedland JS, Iveson TJ, Fraise AP, Winearls CG, Selkon JB, Oliver DO</AU>
<TI>A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD)</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1990</YR>
<VL>26 Suppl F</VL>
<PG>77-81</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:47:09 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:47:09 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2292548"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadallah-2000c" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Gadallah 2000c" YEAR="2000">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gadallah MF, Tamayo A, Sandborn M, Ramdeen G, Moles K</AU>
<TI>Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>233-6</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:48:11 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:48:11 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11045301"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gucek-1994" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Gucek 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gucek A, Bren AF, Lindic J, Hergouth V, Mlinsek D</AU>
<TI>Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients?</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>144-6</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:48:37 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:48:37 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7999813"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gucek-1997" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Gucek 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gucek A, Bren AF, Hergouth V, Lindic J</AU>
<TI>Cefazolin and netilmycin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>218-20</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:49:02 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:49:02 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9360685"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hernandez-2004" MODIFIED="2014-02-10 16:49:39 +1100" MODIFIED_BY="[Empty name]" NAME="Hernandez 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-02-10 16:49:39 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez AG, Alvarez JG, Kiyono JK</AU>
<TI>Cefepime in the treatment of peritonitis associated with continuous ambulatory dialysis</TI>
<SO>Medicina Interna de Mexico</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>3</NO>
<PG>173-82</PG>
<IDENTIFIERS MODIFIED="2013-06-03 16:59:42 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="EMBASE" VALUE="2007502961"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Innes-1994" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Innes 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-02-27 15:05:13 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Innes A, Burden RP, Finch RG, Morgan AG</AU>
<TI>Treatment of resistant CAPD peritonitis with urokinase: a double-blind clinical trial [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>12</NO>
<PG>1408-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00465795"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Innes A, Burden RP, Finch RG, Morgan AG</AU>
<TI>Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: a double-blind clinical trial</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>7</NO>
<PG>797-9</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:51:22 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:51:22 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7970121"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jim_x00e9_nez-1996" MODIFIED="2014-02-10 16:52:26 +1100" MODIFIED_BY="Narelle S Willis" NAME="Jiménez 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-02-10 16:52:26 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jiménez C, Selgas R, Sánchez S, Bajo MA, Sánchez C, Díaz C, et al</AU>
<TI>Initial empiric treatment of peritonitis in CAPD with vancomycin + tobramycin vs. vancomycin + cefotaxime in a CAPD unit</TI>
<TO>Tratamiento empírico inicial de las peritonitis en DPCA con vancomicina + tobramicina vs. vancomicina + cefotaxima. estudio prospectivo randomizado en una unidad de DPCA</TO>
<SO>Nefrología</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>6</NO>
<PG>569</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:51:54 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:51:54 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00401408"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khairullah-2002" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Khairullah 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-02-10 16:54:04 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmad A, Khairullah Q, Provenzano R, Tayeb J, Balakrishnan R, Morrison L</AU>
<TI>Vancomycin (V) vs cefazolin (C) as initial therapy for peritonitis in peritoneal dialysis (PD) patients [abstract no: A1077]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>202A-3A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:53:33 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:53:33 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00550601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-05 16:02:01 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khairullah Q, Balakrishnan R, Provenzano R</AU>
<TI>Comparison of the efficacy of vancomycin vs cefazolin as initial therapy for peritonitis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>284A-5A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:54:37 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:54:37 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00446072"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Khairullah Q, Provenzano R, Tayeb J, Ahmad A, Balakrishnan R, Morrison L</AU>
<TI>Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>339-44</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:55:06 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:55:06 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="12227391"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klaus-1995a" MODIFIED="2014-04-20 16:32:41 +1000" MODIFIED_BY="[Empty name]" NAME="Klaus 1995a" YEAR="1995">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klaus G, Schaefer F, Muller-Wiefel D, Mehls O</AU>
<TI>Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Members of APN Arbeitsgemeinschaft Paidiatrische Nephrologie</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1995</YR>
<VL>11</VL>
<PG>296-301</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:55:38 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:55:38 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8534728"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-05 16:02:32 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer F, Klaus G, Muller-Wiefel D, Mehls O, Mid European Study Group for Pediatric CAPD/CCPD</AU>
<TI>Continuous vs intermittent treatment of peritonitis in children on continuous peritoneal dialysis - results of a prospective randomized trial [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>C45</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:56:30 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:56:30 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00509463"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer F, Klaus G, Muller-Wiefel DE, Mehls O</AU>
<TI>Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>1</NO>
<PG>136-45</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:56:54 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:56:54 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9890319"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leung-2004" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Leung 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leung C, Szeto C, Chow K, Kwan BC, Wang AY, Lui S, et al</AU>
<TI>Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis - a randomized controlled trial. [abstract no: PUB392]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>858A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:57:30 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 16:57:30 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00626024"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leung CB, Szeto CC, Chow KM, Kwan BC, Wang AY, Lui SF, et al</AU>
<TI>Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>5</NO>
<PG>440-6</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:58:14 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 16:58:14 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15490983"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lui-2005" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Lui 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lui SL, Cheng SW, Ng F, Ng SY, Wan KM, Yip T, et al</AU>
<TI>Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function</TI>
<SO>Kidney International</SO>
<YR>2005</YR>
<VL>68</VL>
<NO>5</NO>
<PG>2375-80</PG>
<IDENTIFIERS MODIFIED="2014-02-13 17:06:42 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-13 17:06:42 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="16221243"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lui SL, Cheng SW, Ng F, Yip PS, Tse KC, Lam MF, et al</AU>
<TI>A randomized prospective comparison of intraperitoneal cefazolin plus netilmicin versus cefazolin plus ceftazidime in the treatment of CAPD peritonitis [abstract no: M-PO40056]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>A68</PG>
<IDENTIFIERS MODIFIED="2014-02-10 16:58:58 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 16:58:58 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00626020"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lupo-1997" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Lupo 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lupo A, Rugiu C, Bernich P, Laudon A, Marcantoni C, Mosconi G, et al</AU>
<TI>A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: teicoplanin plus tobramycin versus cephalothin plus tobramycin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1997</YR>
<VL>40</VL>
<NO>5</NO>
<PG>729-32</PG>
<IDENTIFIERS MODIFIED="2014-02-13 17:09:00 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-13 17:09:00 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="9421325"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lye-1993" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Lye 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lye WC, Lee EJ, van der Straaten J</AU>
<TI>Intraperitoneal vancomycin/oral pefloxacin versus intraperitoneal vancomycin/gentamicin in the treatment of continuous ambulatory peritoneal dialysis peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1993</YR>
<VL>13 Suppl 2</VL>
<PG>S348-50</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:00:59 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:00:59 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8399607"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lye-1995" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Lye 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lye WC, Wong PL, Van der Straaten JC, Leong SO, Lee EJ</AU>
<TI>A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1995</YR>
<VL>11</VL>
<PG>179-81</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:01:31 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:01:31 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8534699"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merchant-1992" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Merchant 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anwar N, Merchant M, Were T, Tooth A, Uttley L, Gokal R</AU>
<TI>A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>2</NO>
<PG>167-71</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:02:32 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:02:32 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="7612739"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merchant MR, Anwar N, Were A, Uttley L, Tooth JA, Gokal R</AU>
<TI>Imipenem versus netilmicin and vancomycin in the treatment of CAPD peritonitis</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1992</YR>
<VL>8</VL>
<PG>234-7</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:02:03 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:02:03 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="1361795"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raman-1985" MODIFIED="2014-03-02 17:05:04 +1100" MODIFIED_BY="Narelle S Willis" NAME="Raman 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-02-13 17:12:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raman GV, Maskell R</AU>
<TI>CAPD peritonitis</TI>
<SO>Journal of Hospital Infection</SO>
<YR>1985</YR>
<VL>6</VL>
<NO>1</NO>
<PG>108-9</PG>
<IDENTIFIERS MODIFIED="2014-02-13 17:12:20 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-13 17:12:20 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2859313"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-06 09:38:26 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Searle M, Venkat Raman G</AU>
<TI>Oral treatment of CAPD peritonitis [abstract]</TI>
<SO>Kidney International</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>4</NO>
<PG>597</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tapson-1990" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Tapson 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tapson JS, Orr KE, George JC, Stansfield E, Bint AJ, Ward MK</AU>
<TI>A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1990</YR>
<VL>26 Suppl F</VL>
<PG>63-71</PG>
<IDENTIFIERS MODIFIED="2014-02-13 17:16:45 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-13 17:16:45 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2292546"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tong-2005a" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Tong 2005a" YEAR="2005">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tong MK, Leung KT, Siu YP, Lee HK, Yung CY, Kwan TH, et al</AU>
<TI>Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis</TI>
<SO>Journal of Nephrology</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>204-8</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:06:01 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:06:01 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15931649"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vargemezis-1989" MODIFIED="2014-02-13 17:17:46 +1100" MODIFIED_BY="[Empty name]" NAME="Vargemezis 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-02-13 17:17:46 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vargemezis V, Pasadakis P, Thodis H, Coucudis P, Peihaberis P, Jafer H, et al</AU>
<TI>Vancomycin therapy for gram-positive peritonitis in patients on CAPD</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1989</YR>
<VL>5</VL>
<PG>128-9</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:06:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:06:29 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2577394"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Velasquez_x002d_Jones-1995" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Velasquez-Jones 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Velasquez-Jones L, Sanchez-Aguilar JR, Castelares G, Rada-Cuentas J, Zavala-Lozano N, Tanaka J, et al</AU>
<TI>Efficacy of intraperitoneal vancomycin in children on continuous ambulatory peritoneal dialysis: comparison of intermittent and continuous therapy</TI>
<SO>Boletin Medico del Hospital Infantil de Mexico</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>3</NO>
<PG>154-9</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:06:47 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:06:47 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1995125387"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wale-1992" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Wale 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wale MCJ, Finch RG, Morgan AG, Burden RP, Holliday A</AU>
<TI>A prospective randomised trial of teicoplanin plus aztreonam versus cefuroxime in CAPD peritonitis</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1992</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>S7-14</PG>
<IDENTIFIERS MODIFIED="2008-06-17 16:25:40 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-17 16:25:40 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1992053370"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Were-1992" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Were 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mistry CD, Salgia P, Manos J, Tooth A, Ramsden RT, Marsden A, et al</AU>
<TI>Netilmicin (N) and Vancomycin (V) in the treatment of peritonitis in patients on CAPD [abstract]</TI>
<SO>Kidney International</SO>
<YR>1985</YR>
<VL>28</VL>
<NO>2</NO>
<PG>309</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:08:13 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:08:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00626106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Were AJ, Marsden A, Tooth A, Ramsden R, Mistry CD, Gokal R</AU>
<TI>Netilmycin and vancomycin in the treatment of peritonitis in CAPD patients</TI>
<SO>Clinical Nephrology</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>4</NO>
<PG>209-13</PG>
<IDENTIFIERS MODIFIED="2014-02-13 17:24:43 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-13 17:24:43 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="1582059"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1989" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Williams 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Williams AJ, Boletis I, Johnson BF, Raftery AT, Cohen GL, Moorhead PJ, et al</AU>
<TI>Tenckhoff catheter replacement or intraperitoneal urokinase: a randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>1</NO>
<PG>65-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2488185"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2001" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Wong 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wong KM, Chan YH, Cheung CY, Wai LC, Choi KS, Leung SH, et al</AU>
<TI>Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>1</NO>
<PG>127-31</PG>
<IDENTIFIERS MODIFIED="2014-02-13 17:28:00 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-13 17:28:00 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11431192"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-05-02 10:52:12 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Albin-1986" MODIFIED="2013-06-13 17:05:05 +1000" MODIFIED_BY="[Empty name]" NAME="Albin 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-06-13 17:05:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albin H, Ragnaud JM, Demotes-Mainard F, Vincon G, Couzineau M, Wone C</AU>
<TI>Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>31</VL>
<NO>4</NO>
<PG>479-83</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:05:05 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="3816928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Wali-1992" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Al-Wali 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Wali W, Baillod RA, Brumfitt W, Hamilton-Miller JMT</AU>
<TI>Teicoplanin in the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis: a comparative trial against vancomycin</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1992</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>S1-6</PG>
<IDENTIFIERS MODIFIED="2008-06-17 16:25:55 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-17 16:25:55 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1992053369"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Artic-1997" MODIFIED="2013-06-13 17:05:29 +1000" MODIFIED_BY="[Empty name]" NAME="Artic 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-06-13 17:05:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Artic S, Busch T, Sahin K, Grabensee B, Plum J</AU>
<TI>Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Program &amp; Abstracts</NO>
<PG>260A-1A</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:05:29 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bannister-1987" MODIFIED="2014-02-10 17:14:21 +1100" MODIFIED_BY="[Empty name]" NAME="Bannister 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-02-10 17:14:21 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bannister DK, Acchiardo SR, Moore LW, Kraus AP Jr</AU>
<TI>Nutritional effects of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients</TI>
<SO>Journal of the American Dietetic Association</SO>
<YR>1987</YR>
<VL>87</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:05:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="3794134"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2000" MODIFIED="2013-06-13 17:06:01 +1000" MODIFIED_BY="[Empty name]" NAME="Casey 2000" YEAR="2000 Sep">
<REFERENCE MODIFIED="2013-06-13 17:06:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casey M, Taylor J, Clinard P, Graham A, Mauck V, Spainhour L, et al</AU>
<TI>Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>5</NO>
<PG>566-8</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:05:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="11117248"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavdar-2004" MODIFIED="2014-02-10 17:15:59 +1100" MODIFIED_BY="[Empty name]" NAME="Cavdar 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-06-13 17:06:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavdar C, Saglam F, Sifil A, Celik A, Atay T, Gungor O, et al</AU>
<TI>Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience</TI>
<SO>Renal Failure</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>4</NO>
<PG>417-22</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:06:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="18569916"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-10 17:15:59 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, et al</AU>
<TI>The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>62-6</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:06:25 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15384797"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Celik-1999" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Celik 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Celik A, Cirit M, Tunger A, Akcicek F, Basci A</AU>
<TI>Treatment of CAPD peritonitis with oral trimethoprim/sulfamethoxazole and intraperitoneal aminoglycoside combination</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>3</NO>
<PG>284-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10433171"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chadwick-1999" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Chadwick 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chadwick DH, Agarwal S, Vora BJ, Hair M, McKewan A, Gokal R</AU>
<TI>Outcome of peritonitis treated with intraperitoneal (i.p.) weekly vancomycin and i.p. daily netilmicin</TI>
<SO>Journal of Nephrology</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>5</NO>
<PG>318-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10630696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaimovitz-1994" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Chaimovitz 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaimovitz C</AU>
<TI>Peritoneal dialysis</TI>
<SO>Kidney International</SO>
<YR>1994</YR>
<VL>45</VL>
<NO>4</NO>
<PG>1226-40</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:18:21 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:18:21 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8007595"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danielsson-1997" MODIFIED="2014-02-10 17:22:05 +1100" MODIFIED_BY="[Empty name]" NAME="Danielsson 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-02-10 17:22:05 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Danielsson A, Blohme L, Tranaeus A, Hylander B</AU>
<TI>Prospective randomized study of the impact a subcutaneous rest-period of a PD-catheter has on the incidence of peritonitis [abstract no: A0832]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Program &amp; Abstracts</NO>
<PG>178A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:21:54 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:21:54 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00444979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Fijter-1989" MODIFIED="2014-02-10 17:23:28 +1100" MODIFIED_BY="[Empty name]" NAME="de Fijter 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-06-13 17:08:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Fijter CW, Verbrugh HA, Heezius HC, van Bronswijk H, van der MJ, Oe PL, et al</AU>
<TI>Are intracellularly penetrating antibiotics warranted in CAPD-related peritonitis?</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1989</YR>
<VL>5</VL>
<PG>124-7</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:08:11 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="2577393"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-10 17:23:28 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Fijter CW, Verbrugh HA, Heezius HC, van der Meulen J, et al</AU>
<TI>Are intracellularly penetrating antibiotics warranted in treating CAPD peritonitis caused by Staphylococcus epidermidis? [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>8</NO>
<PG>752</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:23:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:23:21 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00445019"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Groc-1983" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="De Groc 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Groc F, Rottembourg J, Jacq D, Jarlier V, N'Guyen J, Legrain M</AU>
<TI>Peritonitis during continuous ambulatory peritoneal dialysis. Lavage treatment or not? A prospective study</TI>
<TO>Les peritonites au cours de la dialyse peritoneale continue ambulatoire. Traitement par lavage ou non? Etude prospective</TO>
<SO>Nephrologie</SO>
<YR>1983</YR>
<VL>4</VL>
<NO>1</NO>
<PG>24-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6843764"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dratwa-1987" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Dratwa 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dratwa M, Glupczynski Y, Lameire N, Matthys D, Verschraegen G, van Eeckhoute M, et al</AU>
<TI>Aztreonam in CAPD peritonitis</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>8552</NO>
<PG>213-4</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:25:00 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:25:00 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="2885662"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dryden-1993" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Dryden 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dryden M, Eykyn SJ</AU>
<TI>Short-course gentamicin in gram-negative CAPD peritonitis</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8843</NO>
<PG>497</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8094518"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durand-1994" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Durand 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durand PY, Chanliau J, Gamberoni J, Mariot A, Kessler M</AU>
<TI>UV-flash: clinical evaluation in 97 patients; results of a French multicenter trial</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>1</NO>
<PG>86-9</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:26:00 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 17:26:00 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="8312425"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ersoy-1998" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Ersoy 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ersoy FF, Sezer T, Sarikaya M, Suleymanlar G, Yakupoglu G</AU>
<TI>Treatment of CAPD peritonitis with intraperitoneal ampicillin/sulbactam-aminoglycoside combination</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>233-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9576376"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fabbri-1982" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Fabbri 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fabbri L, Grimaldi C, Zucchelli P</AU>
<TI>Peritonitis in CAPD: treatment with chlorhexidine</TI>
<SO>Dialysis and Transplantation</SO>
<YR>1982</YR>
<VL>11</VL>
<NO>6</NO>
<PG>483-6</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:27:26 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:27:26 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1982244782"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flanigan-1994" MODIFIED="2013-06-13 17:11:47 +1000" MODIFIED_BY="[Empty name]" NAME="Flanigan 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-06-13 17:11:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flanigan MJ, Hochstetler LA, Langholdt D, Lim VS</AU>
<TI>Continuous ambulatory peritoneal dialysis catheter infections: diagnosis and management</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>3</NO>
<PG>248-54</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:11:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="7948237"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goffin-1997" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Goffin 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goffin E, Pouthier D, Vandercam B, Gigi J, van Ypersele de Strihou C</AU>
<TI>Oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>1996</YR>
<VL>48</VL>
<NO>6</NO>
<PG>391-2</PG>
<IDENTIFIERS MODIFIED="2013-06-13 17:12:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-13 17:12:39 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9438101"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenbaum-1995" MODIFIED="2013-06-17 10:56:59 +1000" MODIFIED_BY="[Empty name]" NAME="Greenbaum 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-06-17 10:56:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenbaum LA, Goodman WG, Holloway M, Chon Y, Gales B, Salusky IB</AU>
<TI>A prospective evaluation of the peritonitis rates between oral &amp; intraperitoneal calcitriol [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>531</PG>
<IDENTIFIERS MODIFIED="2013-06-17 10:56:59 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guest-1996" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Guest 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guest SS, Erickson LJ</AU>
<TI>Combination therapy involving ciprofloxacin for peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>3</NO>
<PG>316-8</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:00:33 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:00:33 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8761547"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hancock-1989" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Hancock 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hancock K, Hulme B</AU>
<TI>Treatment of CAPD peritonitis with oral ciprofloxacin</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>8</NO>
<PG>759</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:04:14 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:04:14 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1989278988"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN39675087" MODIFIED="2014-02-10 17:33:29 +1100" MODIFIED_BY="[Empty name]" NAME="ISRCTN39675087" YEAR="2006">
<REFERENCE MODIFIED="2014-02-10 17:33:29 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>ISRCTN39675087</AU>
<TI>Efficacy of endoluminal brushes reducing peritonitis in peritoneal dialysis (PD) patients</TI>
<SO>http://controlled-trials.com/ISRCTN39675087</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2014-02-10 17:32:48 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keller-1984" MODIFIED="2014-02-10 17:33:53 +1100" MODIFIED_BY="[Empty name]" NAME="Keller 1984" YEAR="1984 Feb">
<REFERENCE MODIFIED="2014-02-10 17:33:53 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keller E, Jansen A, Pelz K, Hoppe-Seyler G, Schollmeyer P</AU>
<TI>Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1984</YR>
<VL>35</VL>
<NO>2</NO>
<PG>208-13</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:08:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:08:26 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6692648"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klaus-2002" MODIFIED="2014-05-02 10:52:12 +1000" MODIFIED_BY="[Empty name]" NAME="Klaus 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-02-10 17:35:32 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klaus G, van Baum H, Wuhl E, Schaefer F, European Pediatric Peritoneal Dialysis Study Group (EPPS)</AU>
<TI>Efficacy of mupirocin prophylaxis in reducing the incidence of peritoneal dialysis (PD)-related Staphylococcus aureus infections in children on chronic PD: results of a double blind, placebo-controlled trial [abstract]</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>1</NO>
<PG>149</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:35:22 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:35:22 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00401508"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oh J, von BH, Klaus G, Schaefer F</AU>
<TI>Nasal carriage of Staphylococcus aureus in families of children on peritoneal dialysis. European Pediatric Peritoneal Dialysis Study Group (EPPS)</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>324-7</PG>
<IDENTIFIERS MODIFIED="2013-07-01 17:11:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="11045321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lai-1997" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Lai 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lai MN, Kao MT, Chen CC, Cheung SY, Chung WK</AU>
<TI>Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>87-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9068030"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levesque-2003" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Levesque 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levesque R, Lemieux C, Laverdiere M, Pichette V</AU>
<TI>Treatment of gram-positive peritonitis in peritoneal dialysis patients: cefazolin or vancomycin?</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>599-601</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14703205"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Li 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li PK, Ip M, Law MC, Szeto CC, Leung CB, Wong TY, et al</AU>
<TI>Use of intraperitoneal cefepime as monotherapy in treatment of CAPD peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>232-4</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:15:20 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:15:20 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10809249"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McIntosh-1985" MODIFIED="2013-06-17 11:15:27 +1000" MODIFIED_BY="[Empty name]" NAME="McIntosh 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-06-17 11:15:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIntosh ME, Smith WG, Junor BJ, Forrest G, Brodie MJ</AU>
<TI>Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1985</YR>
<VL>28</VL>
<NO>2</NO>
<PG>187-91</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:15:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="3987798"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mylotte-1999" MODIFIED="2013-06-17 11:16:14 +1000" MODIFIED_BY="[Empty name]" NAME="Mylotte 1999" YEAR="1999 Nov">
<REFERENCE MODIFIED="2013-06-17 11:16:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mylotte JM, Kahler L, Jackson E</AU>
<TI>"Pulse" nasal mupirocin maintenance regimen in patients undergoing continuous ambulatory peritoneal dialysis</TI>
<SO>Infection Control and Hospital Epidemiology</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>11</NO>
<PG>741-5</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:16:14 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="10580624"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plum-1997a" MODIFIED="2014-05-02 10:40:56 +1000" MODIFIED_BY="[Empty name]" NAME="Plum 1997a" YEAR="1997">
<REFERENCE MODIFIED="2013-06-17 11:16:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plum J, Artik S, Busch T, Sahin K, Grabensee B</AU>
<TI>Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>5</NO>
<PG>486-92</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:16:44 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="9358531"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Posthuma-1997" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Posthuma 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peers E</AU>
<TI>Icodextrin plus glucose combinations for use in CAPD</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1997</YR>
<VL>17 Suppl 2</VL>
<PG>S68-9</PG>
<IDENTIFIERS MODIFIED="2013-07-04 11:21:05 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="9163801"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, Verbrugh HA, Donker AJ, van Dorp W, Dekker HA, Peers EM, et al</AU>
<TI>Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>174-80</PG>
<IDENTIFIERS MODIFIED="2013-07-04 11:21:32 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="10809240"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA</AU>
<TI>Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>4</NO>
<PG>334-42</PG>
<IDENTIFIERS MODIFIED="2013-07-04 11:21:46 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="10507814"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Donker AJ, Dekker HAT, Oe PL, Verhoef J, et al</AU>
<TI>Ex vivo peritoneal defense characteristics and peritonitis rate in CCPD patients using glucose or icodextrin as daytime dwell [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>223A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:40:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:40:35 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00447263"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Donker AJ, Oe LP, Verbrugh HA, Peers E</AU>
<TI>Disaccharide ("total maltose") levels in CCPD patients using icodextrin [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>513</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:42:41 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:42:41 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00485460"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Donker AJ, Oe LP, Verbrugh HA, Peers E</AU>
<TI>Improved ultrafiltration in CCPD patients using icodextrin (i) instead of glucose (g) for the long daytime dwell [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>513</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:43:22 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:43:22 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00485461"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA</AU>
<TI>Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2000</YR>
<VL>20 Suppl 2</VL>
<PG>S106-13</PG>
<IDENTIFIERS MODIFIED="2013-07-04 11:22:16 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="10911654"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Donker AJ, Oe PL, van Dorp W, Peers EM, et al</AU>
<TI>Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>6</NO>
<PG>602-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9655161"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Donker AJ, Verbrugh HA, Oe PL, van Dorp W, et al</AU>
<TI>Icodextrin (I) use in CCPD patients during peritonitis: serum disaccharide (maltose) levels and ultrafiltratioin (UF) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Program &amp; Abstracts</NO>
<PG>270A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:41:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:41:50 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00447266"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Donker AJ, Verbrugh HA, Oe PL, van Dorp W</AU>
<TI>Peritoneal membrane characteristics in CCPD patients using glucose or icodextrin as daytime dwell [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>223A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:47:30 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:47:30 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00447265"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Niessen H, Donker AJ, Verbrugh HA, Schalkwijk CG</AU>
<TI>Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>43-51</PG>
<IDENTIFIERS MODIFIED="2013-07-04 11:25:02 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="11280495"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al</AU>
<TI>Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>3</NO>
<PG>550-3</PG>
<IDENTIFIERS MODIFIED="2013-07-04 11:25:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="9075139"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Wee PM, et al</AU>
<TI>Icodextrin (I) use in CCPD patients during peritonitis: serum disacharide levels and ultrafiltration (UF) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>9</NO>
<PG>A184</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:48:57 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:48:57 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00261438"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Posthuma N, ter Weel PM, Donker AJ, Peers EM, Oe PL, Verbrugh HA</AU>
<TI>Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>9</NO>
<PG>2341-4</PG>
<IDENTIFIERS MODIFIED="2013-07-04 11:26:15 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="9761519"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qamar-2009" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Qamar 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Qamar M, Sheth H, Bender F H, Piraino B</AU>
<TI>Clinical outcomes in peritoneal dialysis: impact of continuous quality improvement initiatives</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2009</YR>
<VL>25</VL>
<PG>76-9</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:51:15 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:51:15 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=" 19886322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranganathan-2010" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Ranganathan 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranganathan D, Baer R, Fassett RG, Williams N, Han T, Watson M, et al</AU>
<TI>Randomised Controlled Trial to determine the appropriate time to initiate peritoneal dialysis after insertion of catheter to minimise complications (Timely PD study)</TI>
<SO>BMC Nephrology</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Read-1985" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Read 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Read DJ, Will EJ, Guillou PJ, Aparicio SR</AU>
<TI>Extended antibiotic treatment does not prevent early recurrence of CAPD peritonitis</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>8419</NO>
<PG>47</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:41:44 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:41:44 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2856968"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Restrepo-2010" MODIFIED="2013-06-17 11:41:57 +1000" MODIFIED_BY="[Empty name]" NAME="Restrepo 2010" YEAR="2010 Nov">
<REFERENCE MODIFIED="2013-06-17 11:41:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Restrepo C, Chacon J, Manjarres G</AU>
<TI>Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>6</NO>
<PG>619-25</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:41:49 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20634438"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1971" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Sharma 1971" YEAR="1971">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharma BK, Rodriguez H, Gandhi VC, Smith EC, Pillay VK, Dunea G</AU>
<TI>Trial of oral neomycin during peritoneal dialysis</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1971</YR>
<VL>262</VL>
<NO>3</NO>
<PG>175-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4946828"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sit-2007" MODIFIED="2013-06-17 11:43:05 +1000" MODIFIED_BY="[Empty name]" NAME="Sit 2007" YEAR="2007 Mar">
<REFERENCE MODIFIED="2013-06-17 11:43:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME</AU>
<TI>Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients</TI>
<SO>Advances in Therapy</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>2</NO>
<PG>387-93</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:43:05 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:43:05 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17565930"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stegmayr-1991" MODIFIED="2013-06-17 11:43:52 +1000" MODIFIED_BY="[Empty name]" NAME="Stegmayr 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-06-17 11:43:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegmayr BG, Granbom L, Tranaeus A, Wikdahl AM</AU>
<TI>Reduced risk for peritonitis in CAPD with the use of a UV connector box</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>2</NO>
<PG>128-30</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:43:52 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="1854868"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1995" MODIFIED="2014-02-10 17:54:14 +1100" MODIFIED_BY="[Empty name]" NAME="Stein 1995" YEAR="1995 Oct">
<REFERENCE MODIFIED="2013-06-17 11:44:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein A, Baker F, Moorhouse J, Walls J</AU>
<TI>Peritonitis rate: traditional versus low calcium dialysate</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>4</NO>
<PG>632-3</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:44:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="7573018"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-10 17:54:14 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein A, Moorhouse J, Baker F, Walls J</AU>
<TI>Peritonitis rate: traditional versus low-calcium dialysate [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>5</NO>
<PG>742</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:53:58 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:53:58 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00118917"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomae-1982" MODIFIED="2013-06-17 11:46:25 +1000" MODIFIED_BY="[Empty name]" NAME="Thomae 1982" YEAR="1982 Feb 5">
<REFERENCE MODIFIED="2013-06-17 11:46:25 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomae U, Boos W, Adam D</AU>
<TI>Transperitoneal resorption of ampicillin, cefuroxim and gentamicin in continuous ambulatory peritoneal dialysis</TI>
<SO>Medizinische Welt</SO>
<YR>1982</YR>
<VL>33</VL>
<NO>5</NO>
<PG>182-4</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:46:25 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:46:25 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7070273"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Muelen-1989" MODIFIED="2014-02-10 17:55:18 +1100" MODIFIED_BY="[Empty name]" NAME="van der Muelen 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-02-10 17:55:18 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Meulen J, de Fijter CW, et al</AU>
<TI>Initial cephradine (C) monotherapy, frequent cause of complicated peritonitis in continuous ambulatory peritoneal dialysis (CAPD) [abstract]</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1989</YR>
<VL>19</VL>
<NO>2 (Pt II)</NO>
<PG>A48</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:55:18 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:55:18 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00253833"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Varghese-2002" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Varghese 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranganathan D, Varghese JM, Fassett RG, Lipman J, D'Intini V, Healy H, et al</AU>
<TI>Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study</TI>
<SO>BMC Nephrology</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-05 15:05:09 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Varghese JM, Roberts JA, Wallis SC, Boots RJ, Healy H, Fassett RG, et al</AU>
<TI>Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study)</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1249-56</PG>
<IDENTIFIERS MODIFIED="2014-03-05 15:05:09 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-03-05 15:05:09 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="22700884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1996" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Wang 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang AY, Li PK, Lai KN</AU>
<TI>Comparison of intraperitoneal administration of two preparations of vancomycin in causing chemical peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>25</NO>
<PG>172-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9147552"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warady-2003" MODIFIED="2013-06-17 11:47:49 +1000" MODIFIED_BY="[Empty name]" NAME="Warady 2003" YEAR="2003 Sep">
<REFERENCE MODIFIED="2013-06-17 11:47:49 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warady BA, Ellis EN, Fivush BA, Lum GM, Alexander SR, Brewer ED, et al</AU>
<TI>"Flush before fill" in children receiving automated peritoneal dialysis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>5</NO>
<PG>493-8</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:47:49 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="14604204"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watkins-1998" MODIFIED="2014-02-10 17:56:05 +1100" MODIFIED_BY="[Empty name]" NAME="Watkins 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-02-10 17:56:05 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watkins S, Warady B, Ogrinc F, Schlichting L</AU>
<TI>Impact of flush-before-fill methodology on peritonitis rates in patients receiving automated peritoneal dialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>194A</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:56:05 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:56:05 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00448293"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2004b" MODIFIED="2014-02-10 17:56:19 +1100" MODIFIED_BY="[Empty name]" NAME="Wong 2004b" YEAR="2004">
<REFERENCE MODIFIED="2014-02-10 17:56:19 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong FS, Chau S, Chow N, Ho JC, Cheng Y, Yu AW</AU>
<TI>Effect of changing transfer set on relapse of bacterial peritonitis</TI>
<SO>Hong Kong Journal of Nephrology</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>2</NO>
<PG>87-91</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:50:33 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:50:33 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2004491078"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yudis-1995" MODIFIED="2014-02-10 17:57:22 +1100" MODIFIED_BY="[Empty name]" NAME="Yudis 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-02-10 17:57:22 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yudis M, Sirota RA, Stein HD, Snipes ER, Gronich JH</AU>
<TI>Intravenous (iv) vs. intraperitoneal (ip) vancomycin (vanco) in staphylococcal peritonitis (sp) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>569</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:57:22 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:57:22 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00486558"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zacherle-1996" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="Zacherle 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zacherle BJ</AU>
<TI>Oral ciprofloxacin for the first-phase treatment of peritonitis associated with continuous ambulatory peritoneal dialysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>5</NO>
<PG>811-2</PG>
<IDENTIFIERS MODIFIED="2013-06-17 11:57:11 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 11:57:11 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8738819"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1993" MODIFIED="2014-02-10 17:58:13 +1100" MODIFIED_BY="[Empty name]" NAME="Zhang 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-02-10 17:58:13 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang D, Ye R, Wu X, et al</AU>
<TI>A new treatment program for continuous ambulatory peritoneal dialysis-related peritonitis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>Program &amp; Abstracts</NO>
<PG>422</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:58:13 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-10 17:58:13 +1100" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00486575"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-01-09 09:33:41 +1100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN74962920" MODIFIED="2013-06-17 12:02:50 +1000" MODIFIED_BY="[Empty name]" NAME="ISRCTN74962920" YEAR="2004">
<REFERENCE MODIFIED="2013-06-17 12:02:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN74962920</AU>
<TI>A single centre randomised study to assess the need for performing a line change when a peritoneal dialysis patient presents with peritonitis</TI>
<SO>controlled-trials.com/ISRCTN74962920</SO>
<YR>(accessed 17 June 2013)</YR>
<IDENTIFIERS MODIFIED="2013-06-17 12:00:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-17 12:00:47 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISRCTN74962920"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01785641" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NAME="NCT01785641" YEAR="5641">
<REFERENCE MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01785641</AU>
<TI>Single versus combined antibiotic therapy for bacterial peritonitis in CAPD patients</TI>
<SO>http://clinicaltrials.gov/ct2/results?term=NCT01785641</SO>
<YR>(accessed 4 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-03-05 16:28:23 +1100" MODIFIED_BY="Narelle Willis">
<ADDITIONAL_REFERENCES MODIFIED="2014-03-05 16:06:34 +1100" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Alves-1993" MODIFIED="2008-06-17 16:26:12 +1000" MODIFIED_BY="Narelle S Willis" NAME="Alves 1993" TYPE="JOURNAL_ARTICLE">
<AU>Alves FR, Dantas RC, Lugon JR</AU>
<TI>Higher incidence of catheter-related infections in a tropical climate</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1993</YR>
<VL>9</VL>
<PG>244-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8105935"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ates-2000" MODIFIED="2014-02-10 17:58:49 +1100" MODIFIED_BY="Narelle S Willis" NAME="Ates 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ates K, Koc R, Nergizoglu G, Erturk S, Keven K, Sen A, et al</AU>
<TI>The longitudinal effect of a single peritonitis episode on peritoneal membrane transport in CAPD patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>220-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10809247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Badve-2012" MODIFIED="2014-02-10 17:59:26 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Badve 2012" TYPE="JOURNAL_ARTICLE">
<AU>Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville NC, Wiggins KJ, et al</AU>
<TI>Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>1</NO>
<PG>381-7</PG>
<IDENTIFIERS MODIFIED="2014-02-10 17:59:15 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2014-02-10 17:59:15 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="21633101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baker-2003" MODIFIED="2008-06-17 16:26:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Baker 2003" TYPE="JOURNAL_ARTICLE">
<AU>Baker RJ, Senior H, Clemenger M, Brown EA</AU>
<TI>Empirical aminoglycosides for peritonitis do not affect residual renal function</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>3</NO>
<PG>670-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12612992"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bazzato-1980" MODIFIED="2008-06-17 16:26:20 +1000" MODIFIED_BY="Narelle S Willis" NAME="Bazzato 1980" TYPE="JOURNAL_ARTICLE">
<AU>Bazzato G, Landini S, Coli U, Lucatello S, Fracasso A, Moracchiello M</AU>
<TI>A new technique of continuous ambulatory peritoneal dialysis (CAPD): double-bag system for freedom to the patient and significant reduction of peritonitis</TI>
<SO>Clinical Nephrology</SO>
<YR>1980</YR>
<VL>13</VL>
<NO>6</NO>
<PG>251-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7408242"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Booranalertpaisarn-2003" MODIFIED="2014-02-10 18:00:17 +1100" MODIFIED_BY="Narelle S Willis" NAME="Booranalertpaisarn 2003" TYPE="JOURNAL_ARTICLE">
<AU>Booranalertpaisarn V, Eiam-Ong S, Wittayalertpanya S, Kanjanabutr T, Na Ayudhya DP</AU>
<TI>Pharmacokinetics of ceftazidime in CAPD-related peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>574-9</PG>
<IDENTIFIERS MODIFIED="2014-02-10 18:00:17 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 18:00:17 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="14703199"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CARI-2005" MODIFIED="2014-02-10 18:01:44 +1100" MODIFIED_BY="Narelle Willis" NAME="CARI 2005" TYPE="JOURNAL_ARTICLE">
<AU>Australian and New Zealand Society of Nephrology</AU>
<TI>Caring for Australians with Renal Impairment Part 4: Proteinuria, peritonitis and CMV infection guidelines</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>Suppl 3</NO>
<PG>S91-106</PG>
<IDENTIFIERS MODIFIED="2014-02-10 18:01:44 +1100" MODIFIED_BY="Narelle Willis"/>
</REFERENCE>
<REFERENCE ID="REF-Carmeli-2002" MODIFIED="2008-06-17 16:26:29 +1000" MODIFIED_BY="Narelle S Willis" NAME="Carmeli 2002" TYPE="JOURNAL_ARTICLE">
<AU>Carmeli Y, Eliopoulos GM, Samore MH</AU>
<TI>Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>8</NO>
<PG>802-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12141965"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carozzi-1988" MODIFIED="2008-06-17 16:26:31 +1000" MODIFIED_BY="Narelle S Willis" NAME="Carozzi 1988" TYPE="JOURNAL_ARTICLE">
<AU>Carozzi S, Nasini MG, Kunkl A, Cantarella S, Lamperi S</AU>
<TI>Response of CAPD patients with a high incidence of peritonitis to intraperitoneal immunoglobulin therapy</TI>
<SO>ASAIO Transactions</SO>
<YR>1988</YR>
<VL>34</VL>
<NO>3</NO>
<PG>635-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3264176"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Choi-2004" NAME="Choi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E</AU>
<TI>Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>1</NO>
<PG>103-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14712433"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Coles-2000" MODIFIED="2008-06-17 16:26:36 +1000" MODIFIED_BY="Narelle S Willis" NAME="Coles 2000" TYPE="JOURNAL_ARTICLE">
<AU>Coles GA, Topley N</AU>
<TI>Long-term peritoneal membrane changes</TI>
<SO>Advances in Renal Replacement Therapy</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>4</NO>
<PG>289-301</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11073561"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davies-1996" NAME="Davies 1996" TYPE="JOURNAL_ARTICLE">
<AU>Davies SJ, Bryan J, Phillips L, Russell GI</AU>
<TI>Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>3</NO>
<PG>498-506</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8671821"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deamer-1996" MODIFIED="2008-06-17 16:26:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Deamer 1996" TYPE="JOURNAL_ARTICLE">
<AU>Deamer RL, Dial LK</AU>
<TI>The evolution of aminoglycoside therapy: a single daily dose</TI>
<SO>American Family Physician</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>5</NO>
<PG>1782-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8623702"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9310563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fielding-2002" NAME="Fielding 2002" TYPE="JOURNAL_ARTICLE">
<AU>Fielding RE, Clemenger M, Goldberg L, Brown EA</AU>
<TI>Treatment and outcome of peritonitis in automated peritoneal dialysis, using a once-daily cefazolin-based regimen</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>345-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12227392"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fried-1996" MODIFIED="2008-06-17 16:26:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Fried 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fried LF, Bernardini J, Johnston JR, Piraino B</AU>
<TI>Peritonitis influences mortality in peritoneal dialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>10</NO>
<PG>2176-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8915978"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grabe-1999" MODIFIED="2008-06-17 16:26:47 +1000" MODIFIED_BY="Narelle S Willis" NAME="Grabe 1999" TYPE="JOURNAL_ARTICLE">
<AU>Grabe DW, Bailie GR, Eisele G, Frye RF</AU>
<TI>Pharmacokinetics of intermittent intraperitoneal ceftazidime</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>1</NO>
<PG>111-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9915275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grunberg-2005" MODIFIED="2014-03-05 16:06:34 +1100" MODIFIED_BY="Narelle Willis" NAME="Grunberg 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grunberg J, Verocay MC, Rebori A, Ramela V, Amaral C, Hekimian G, et al</AU>
<TI>Twenty years' pediatric chronic peritoneal dialysis in Uruguay: patient and technique survival</TI>
<SO>Pediatric Nephrology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>9</NO>
<PG>1315-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15942784"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heaf-2004" MODIFIED="2008-06-17 16:26:51 +1000" MODIFIED_BY="Narelle S Willis" NAME="Heaf 2004" TYPE="JOURNAL_ARTICLE">
<AU>Heaf J</AU>
<TI>Underutilization of peritoneal dialysis</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>6</NO>
<PG>740-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14871920"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-02-10 18:03:07 +1100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huang-2001" MODIFIED="2008-06-17 16:26:56 +1000" MODIFIED_BY="Narelle S Willis" NAME="Huang 2001" TYPE="JOURNAL_ARTICLE">
<AU>Huang JW, Hung KY, Yen CJ, Wu KD, Tsai TJ</AU>
<TI>Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>3</NO>
<PG>604-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11239039"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2011" MODIFIED="2014-02-10 18:03:47 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Johnson 2011" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW</AU>
<TI>Do antibiotic levels need to be followed in treating peritoneal dialysis-associated peritonitis?</TI>
<SO>Seminars in Dialysis</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>4</NO>
<PG>445-6</PG>
<IDENTIFIERS MODIFIED="2014-02-10 18:03:47 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2014-02-10 18:03:47 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="21801204"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Juergensen-2002" MODIFIED="2008-06-17 16:26:58 +1000" MODIFIED_BY="Narelle S Willis" NAME="Juergensen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Juergensen PH, Gorban-Brennan N, Troidle L, Finkelstein FO</AU>
<TI>Racial differences and peritonitis in an urban peritoneal dialysis center</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>2002</YR>
<VL>18</VL>
<PG>117-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12402601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kan-2003" NAME="Kan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kan GW, Thomas MA, Heath CH</AU>
<TI>A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: is empiric vancomycin still indicated for some patients?</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>5</NO>
<PG>465-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14604199"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kawaguchi-1999" MODIFIED="2008-06-17 16:27:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kawaguchi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kawaguchi Y</AU>
<TI>National comparisons: optimal peritoneal dialysis outcomes among Japanese patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1999</YR>
<VL>19 Suppl 3</VL>
<PG>S9-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10433547"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kawanishi-2005" MODIFIED="2008-06-17 16:27:05 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kawanishi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kawanishi H</AU>
<TI>Encapsulating peritoneal sclerosis</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>3</NO>
<PG>249-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15958037"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Li-2010" MODIFIED="2014-02-10 18:05:09 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Li 2010" TYPE="JOURNAL_ARTICLE">
<AU>Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al</AU>
<TI>Peritoneal dialysis-related infections recommendations: 2010 update</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>4</NO>
<PG>393-423</PG>
<IDENTIFIERS MODIFIED="2014-02-10 18:05:09 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2014-02-10 18:05:09 +1100" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="20628102"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lim-2005" MODIFIED="2008-06-17 16:27:07 +1000" MODIFIED_BY="Narelle S Willis" NAME="Lim 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lim WH, Johnson DW, McDonald SP</AU>
<TI>Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: analysis of ANZDATA</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>2</NO>
<PG>192-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15877681"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manley-1999" MODIFIED="2008-06-17 16:27:11 +1000" MODIFIED_BY="Narelle S Willis" NAME="Manley 1999" TYPE="JOURNAL_ARTICLE">
<AU>Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF</AU>
<TI>Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>1</NO>
<PG>65-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10201343"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manley-2002" MODIFIED="2008-06-17 16:27:13 +1000" MODIFIED_BY="Narelle S Willis" NAME="Manley 2002" TYPE="JOURNAL_ARTICLE">
<AU>Manley HJ, Bailie GR</AU>
<TI>Treatment of peritonitis in APD: pharmacokinetic principles</TI>
<SO>Seminars in Dialysis</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>6</NO>
<PG>418-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12437537"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2004" MODIFIED="2008-06-17 16:27:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="McDonald 2004" TYPE="JOURNAL_ARTICLE">
<AU>McDonald SP, Collins JF, Rumpsfeld M, Johnson DW</AU>
<TI>Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>4</NO>
<PG>340-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15335147"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Millikin-1991" MODIFIED="2008-06-17 16:27:23 +1000" MODIFIED_BY="Narelle S Willis" NAME="Millikin 1991" TYPE="JOURNAL_ARTICLE">
<AU>Millikin SP, Matzke GR, Keane WF</AU>
<TI>Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>3</NO>
<PG>252-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1832968"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Monteon-1998" MODIFIED="2014-02-10 18:05:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Monteon 1998" TYPE="JOURNAL_ARTICLE">
<AU>Monteon F, Correa-Rotter R, Paniagua R, Amato D, Hurtado ME, Medina JL, et al</AU>
<TI>Prevention of peritonitis with disconnect systems in CAPD: a randomized controlled trial. The Mexican Nephrology Collaborative Study Group</TI>
<SO>Kidney International</SO>
<YR>1998</YR>
<VL>54</VL>
<NO>6</NO>
<PG>2123-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9853278"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-1987" MODIFIED="2008-06-17 16:27:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="O'Brien 1987" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien PE, Tait N, Bushell M</AU>
<TI>Management of diffuse peritonitis by prolonged postoperative peritoneal lavage</TI>
<SO>Australian &amp; New Zealand Journal of Surgery</SO>
<YR>1987</YR>
<VL>57</VL>
<NO>3</NO>
<PG>181-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3476071"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oo-2005" MODIFIED="2008-06-17 16:27:33 +1000" MODIFIED_BY="Narelle S Willis" NAME="Oo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Oo TN, Roberts TL, Collins AJ</AU>
<TI>A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>2</NO>
<PG>372-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15685516"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oprea-2004" MODIFIED="2008-06-17 16:27:36 +1000" MODIFIED_BY="Narelle S Willis" NAME="Oprea 2004" TYPE="JOURNAL_ARTICLE">
<AU>Oprea SF, Zaidi N, Donabedian SM, Balasubramaniam M, Hershberger E, Zervos MJ</AU>
<TI>Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>4</NO>
<PG>626-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14973150"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oxton-1994" MODIFIED="2008-06-17 16:27:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Oxton 1994" TYPE="JOURNAL_ARTICLE">
<AU>Oxton LL, Zimmerman SW, Roecker EB, Wakeen M</AU>
<TI>Risk factors for peritoneal dialysis-related infections</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>2</NO>
<PG>137-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8043666"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Passadakis-2001" NAME="Passadakis 2001" TYPE="JOURNAL_ARTICLE">
<AU>Passadakis P, Oreopoulos D</AU>
<TI>The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis</TI>
<SO>Advances Peritoneal Dialysis</SO>
<YR>2001</YR>
<VL>17</VL>
<PG>180-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11510271"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pickering-1989" MODIFIED="2014-02-10 18:06:21 +1100" MODIFIED_BY="Narelle Willis" NAME="Pickering 1989" TYPE="JOURNAL_ARTICLE">
<AU>Pickering SJ, Fleming SJ, Bowley JA, Sissons P, Oppenheim BA, Burnie J, et al</AU>
<TI>Urokinase: a treatment for relapsing peritonitis due to coagulase-negative staphylococci</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>1</NO>
<PG>62-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2494600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piraino-2005" MODIFIED="2014-02-10 18:06:31 +1100" MODIFIED_BY="Narelle S Willis" NAME="Piraino 2005" TYPE="JOURNAL_ARTICLE">
<AU>Piraino, B., Bailie G, Bernardini, J., Boschoten E, Gupta A, Holmes C, et al</AU>
<TI>Peritoneal dialysis-related infections recommendations: 2005 Update</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>2</NO>
<PG>107-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15796137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rigby-1998" MODIFIED="2008-06-17 16:27:45 +1000" MODIFIED_BY="Narelle S Willis" NAME="Rigby 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rigby RJ, Hawley CM</AU>
<TI>Sclerosing peritonitis: the experience in Australia</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>1</NO>
<PG>154-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9481732"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shemin-2000" MODIFIED="2008-06-17 16:27:49 +1000" MODIFIED_BY="Narelle S Willis" NAME="Shemin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Shemin D, Bostom AG, Lambert C, Hill C, Kitsen J, Kliger AS</AU>
<TI>Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>4</NO>
<PG>439-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11007376"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smit-2004" MODIFIED="2008-06-17 16:27:51 +1000" MODIFIED_BY="Narelle S Willis" NAME="Smit 2004" TYPE="JOURNAL_ARTICLE">
<AU>Smit W, van den BN, Schouten N, Aikens E, Struijk DG, Krediet RT</AU>
<TI>Free-water transport in fast transport status: a comparison between CAPD peritonitis and long-term PD</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>298-303</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14675063"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2004" MODIFIED="2014-02-10 18:06:58 +1100" MODIFIED_BY="Narelle S Willis" NAME="Strippoli 2004" TYPE="COCHRANE_REVIEW">
<AU>Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC</AU>
<TI>Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-02-19 19:07:26 +1100" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2012-02-19 19:07:26 +1100" MODIFIED_BY="Suetonia Palmer" TYPE="DOI" VALUE="10.1002/14651858.CD004680.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Szeto-2003" MODIFIED="2008-06-17 16:28:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Szeto 2003" TYPE="JOURNAL_ARTICLE">
<AU>Szeto CC, Chow KM, Wong TY, Leung CB, Li PK</AU>
<TI>Influence of climate on the incidence of peritoneal dialysis-related peritonitis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>580-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14703200"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Troidle-2003" NAME="Troidle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Troidle L, Gorban-Brennan N, Kliger A, Finkelstein FO</AU>
<TI>Continuous peritoneal dialysis-associated peritonitis: a review and current concepts</TI>
<SO>Seminars in Dialysis</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>6</NO>
<PG>428-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14629601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Troidle-2006" MODIFIED="2008-06-17 16:28:06 +1000" MODIFIED_BY="Narelle S Willis" NAME="Troidle 2006" TYPE="JOURNAL_ARTICLE">
<AU>Troidle L, Finkelstein F</AU>
<TI>Treatment and outcome of CPD-associated peritonitis</TI>
<SO>Annals of Clinical Microbiology &amp; Antimicrobials</SO>
<YR>2006</YR>
<VL>5</VL>
<PG>6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16600033"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Voinescu-2002" NAME="Voinescu 2002" TYPE="JOURNAL_ARTICLE">
<AU>Voinescu CG, Khanna R</AU>
<TI>Peritonitis in peritoneal dialysis</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>4</NO>
<PG>249-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12027134"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-02-10 18:09:19 +1100" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Wiggins-2005" MODIFIED="2008-06-11 17:39:45 +1000" MODIFIED_BY="Narelle S Willis" NAME="Wiggins 2005" TYPE="COCHRANE_REVIEW">
<AU>Wiggins KJ, Craig JC, Johnson D, Strippoli GF</AU>
<TI>Treatment for peritoneal dialysis-associated peritonitis. (Protocol)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-06-11 17:39:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-06-11 17:39:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005284"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wiggins-2008" MODIFIED="2014-02-10 18:09:19 +1100" MODIFIED_BY="Narelle Willis" NAME="Wiggins 2008" TYPE="COCHRANE_REVIEW">
<AU>Wiggins KJ, Craig JC, Johnson DW, Strippoli GF</AU>
<TI>Treatment for peritoneal dialysis-associated peritonitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-02-10 18:09:04 +1100" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2014-02-10 18:09:04 +1100" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-03-05 16:28:23 +1100" MODIFIED_BY="Narelle Willis"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-04-15 19:46:20 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-04-15 19:45:32 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-02-11 10:18:54 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altmann-1984">
<CHAR_METHODS MODIFIED="2014-02-11 10:11:15 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: 28 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 10:15:54 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: UK</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: home CAPD patients who presented with uncomplicated peritoneal infection, having been free from peritonitis for 1 month</LI>
<LI>Number: 80</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-11 10:18:54 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>21 days treatment with vancomycin and gentamicin</LI>
<LI>At presentation vancomycin (500 mg IV) and gentamicin (10 mg/L dialysate in alternate bags) was given</LI>
</UL>
<P>Control group</P>
<UL>
<LI>10 days treatment with vancomycin and gentamicin</LI>
<LI>At presentation vancomycin (500 mg IV) and gentamicin (10 mg/L dialysate in alternate bags) was given</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>At 48 hours, according to bacterial sensitivity, vancomycin (15 mg/L dialysate) of gentamicin were continued; both were continued for "sterile" peritonitis</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 10:18:20 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Complete cure</LI>
<LI>Peritonitis relapse</LI>
<LI>Adverse effects (vestibular damage)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-11 10:16:16 +1100" MODIFIED_BY="[Empty name]">
<P>Adverse effects (vestibular damage)</P>
<UL>
<LI>5 patients, all of whom had received at least one 21 day course of gentamicin, developed clinical evidence of vestibular damage; none of those patients who had received only 10 day courses of treatment developed this. The study was therefore terminated</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-15 19:43:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bailie-1987">
<CHAR_METHODS MODIFIED="2014-02-11 10:28:52 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-15 19:43:00 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: UK</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: probable CAPD-associated gram-positive peritonitis</LI>
<LI>Number: 20</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): 11/9</LI>
<LI>Exclusion criteria: Suspected of having gram negative peritonitis; an episode of peritonitis within the previous 4 weeks; no organisms on gram stain</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:32:25 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Vancomycin: 1 g IV loading dose then maintenance dose 25 mg/L IP added to each exchange</LI>
<LI>Total duration of therapy: 14 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 1 g IP loading dose then maintenance dose 25 mg/L IP added to each exchange</LI>
<LI>Total duration of therapy: 14 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 10:28:07 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Successful treatment</LI>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:29:49 +1100" MODIFIED_BY="Narelle Willis">
<P>Definition of peritonitis</P>
<UL>
<LI>The identification of gram-positive organisms on gram stain or any two of abdominal pain, a cloudy dialysate effluent or &gt; 100 WCC/mL of dialysate</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Clearing of dialysate; eradication of the organism; disappearance of physical symptoms</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 20</LI>
<LI>Enrolled/randomised: 20</LI>
<LI>Analysed: 20</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:32:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bennett_x002d_Jones-1987">
<CHAR_METHODS MODIFIED="2014-02-11 10:57:48 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 28 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 10:50:35 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: UK</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: patients receiving CAPD therapy with peritonitis</LI>
<LI>Number: treatment group (36); control group (39)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: associated catheter leak; catheter-tract or severe exit-site infection; fungal peritonitis; septicaemia; bowel perforation; recurrence of peritonitis within 15 days of a previous episode; pre-existing liver disease, diabetes mellitus or epilepsy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:32:39 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Vancomycin: 0.5 g IV (if body surface area &lt; 1.73 m²) or 1.0 g (if body surface area &gt; 1.73 m²) loading dose then vancomycin 0.5 g on day 6</LI>
<LI>Tobramycin: 1.0 mg/kg IV loading dose then 20 to 60 mg on days 2, 4, 6 depending on serum levels</LI>
<LI>Change to oral antibiotics, depending on culture and sensitivity, at day 4.</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 20 mg/L IP and tobramycin 4 mg/L to every exchange for 10 days; one antibiotic could be discontinued at day 4 depending on culture and sensitivity results</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Three rapid exchanges for symptomatic relief then return to usual CAPD regimen</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 10:49:46 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:30:13 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Dialysate WCC &gt; 100/mm³</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>The resolution of symptoms and signs of peritonitis; dialysate WCC &lt; 100/mm³ within 10 days; absence of a subsequent relapse</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Clinical deterioration, or an increase in the dialysate WCC necessitating an alteration in antibiotics administration, continuation of treatment beyond 10 days or catheter removal</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence, with the same organism or no growth, within 15 days of completion of treatment of the previous episode</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 80</LI>
<LI>Enrolled/randomised: 80</LI>
<LI>Analysed: 75</LI>
<LI>Per cent followed: 93.8%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:33:14 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Bennett_x002d_Jones-1990">
<CHAR_METHODS MODIFIED="2014-02-11 11:08:54 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 15 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 11:08:26 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: UK</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: patients &gt; 18 years with a clinical diagnosis of CAPD peritonitis</LI>
<LI>Number: treatment group (22); control group (26)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: leak of dialysis from the exit site; catheter tunnel infection; pregnancy; no demographic data provided</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:33:14 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Oral ciprofloxacin: 750 mg 3 times for 24 hours then 750 mg orally twice daily; further dose adjustments made if peak plasma levels exceeded 10 mg/L</LI>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 25 mg/L and gentamicin 8 mg/L for 48 hours then 4 mg/L</LI>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>An IV loading dose of study antibiotics was given if the patient was systemically unwell or pyrexial, or peripheral WCC &gt; 12 x 10&#8313;/L</LI>
<LI>Oral flucloxacillin 500 mg 4 times/d added to either regimen if <I>S. aureus</I> was isolated</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 11:09:38 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Recurrence of peritonitis</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:30:59 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Cloudy dialysis effluent; &gt; 100 leucocytes/mm³ in dialysis effluent</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Dialysate WCC of &gt; 50/mm³ at completion of treatment</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence of peritonitis within 28 days with either the same organism or no growth</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 61</LI>
<LI>Enrolled/randomised: 51</LI>
<LI>Analysed: 48</LI>
<LI>Per cent followed: 95.1%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:33:27 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Boeschoten-1985">
<CHAR_METHODS MODIFIED="2014-02-11 11:25:43 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: January 1980 to January 1983</LI>
<LI>Follow-up period: 2 weeks after completion of treatment</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 11:18:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: The Netherlands</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: adult patients receiving CAPD therapy</LI>
<LI>Number: 39</LI>
<LI>Mean age (range): 47 years (21-66)</LI>
<LI>Sex (M/F): 20/19</LI>
<LI>Exclusion criteria: gram-negative rods or yeasts shown on gram-stained film.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:33:27 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Oral cephradine: 500 mg loading dose then 250 mg orally with each dialysis exchange</LI>
<LI>Treatment continued until 1 week after dialysate WCC &lt; 100/µL and there had been a negative dialysate culture</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Cephradine: 500 mg IP loading dose then 250 mg IP</LI>
<LI>Treatment continued until 1 week after dialysate WCC &lt; 100/µL and there had been a negative dialysate culture</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Heparin (500 U/L) was added to dialysate as long as the fluid remained cloudy</LI>
<LI>Cephradine replaced by another antibiotic when the causative organism was found to be resistant in vitro</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 11:19:33 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Successful treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-11 11:19:49 +1100" MODIFIED_BY="Narelle Willis">
<P>Definition of peritonitis</P>
<UL>
<LI>Cloudy dialysate with WCC &gt; 100/µL with or without abdominal symptoms</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Disappearance of symptoms and signs within 48 hours</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Persistent clinical symptoms and bacteriological findings</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>An episode of peritonitis with the same causative organism after an initial improvement, either during or within 2 weeks after stopping the antibiotics</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:33:41 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Bowley-1988">
<CHAR_METHODS MODIFIED="2014-02-11 11:24:55 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 11:24:30 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: UK</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: CAPD-associated peritonitis caused by gram-positive organisms</LI>
<LI>Number: 11 patients (12 episodes of peritonitis)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:33:41 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Teicoplanin: IP 50 mg/2 L bag for 48 hours then teicoplanin IP 25 mg/2 L bag for a further 5 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: IP 50 mg/2 L bag for 48 hours then vancomycin IP 25 mg/2 L bag for a further 5 days</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Netilmicin: IP 25 mg in alternate bags for 48 hours (both study arms)</LI>
<LI>Two patients with <I>S. aureus</I> infection were also treated with oral clindamycin for 7 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 11:26:41 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Successful treatment</LI>
<LI>Relapse of peritonitis</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:17:45 +1100" MODIFIED_BY="Narelle Willis">
<P>Definition of peritonitis: NS</P>
<P>Definition of cure</P>
<UL>
<LI>"Judged by clinical criteria"</LI>
</UL>
<P>Definition of treatment failure: NS</P>
<P>Definition of relapse</P>
<UL>
<LI>Further infection with the same organism within 14 days of completion of therapy</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 11</LI>
<LI>Enrolled/randomised: 11</LI>
<LI>Analysed: 11</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:33:58 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Boyce-1988">
<CHAR_METHODS MODIFIED="2014-02-11 11:33:44 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: April 1986 to January 1987</LI>
<LI>Follow-up period: 4 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 11:34:29 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Australia</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: all patients who presented with peritonitis</LI>
<LI>Number: 90</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:33:58 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Vancomycin: 30 mg/kg in a 2 L peritoneal dialysate for a 6 hours dwell; repeated after 1 week</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 1 g IP loading dose then 30 mg/L dialysate continued for 5 days following macroscopic clearing of the dialysate</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>All patients initially managed with 2 to 3 rapid 2L peritoneal lavages with heparinised dialysate</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 11:35:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Recurrence of peritonitis</LI>
<LI>Skin rash</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-11 11:35:16 +1100" MODIFIED_BY="Ann Jones">
<P>Exclusions post randomisation but pre-intervention</P>
<UL>
<LI>All patients with fungal or gram-negative peritonitis were excluded from analysis</LI>
</UL>
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain and cloudy dialysate effluent with a peritoneal WCC &gt; 100/µL</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 90</LI>
<LI>Enrolled/randomised: 90</LI>
<LI>Analysed: 51</LI>
<LI>Per cent followed: 56.7%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:34:47 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Chan-1990">
<CHAR_METHODS MODIFIED="2014-02-11 11:55:31 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 1 October 1987 to 30 September 1998</LI>
<LI>Follow-up period: 28 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 11:58:21 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: university department, teaching hospital</LI>
<LI>Inclusion criteria: CAPD peritonitis</LI>
<LI>Number: treatment group 1 (34); treatment group 2 (36); control group (36)</LI>
<LI>Mean age ± SEM (years): treatment group 1 (44 ± 15); treatment group 2 (22 ± 14); control group (53 ± 14)</LI>
<LI>Sex (M/F): treatment group 1 (18/16); treatment group 2 (22/14); control group (21/15)</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:34:47 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group 1</P>
<UL>
<LI>Oral ofloxacin: 400 mg loading dose on the first day then 300 mg/d</LI>
<LI>Total duration of antibiotic therapy: 10 days</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Oral ofloxacin: 400 mg loading dose on the first day then 300 mg/d</LI>
<LI>Oral rifampicin: 300 mg/d</LI>
<LI>Total duration of antibiotic therapy: 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Cephalothin 250 mg/L IP and tobramycin 8 mg/L</LI>
<LI>Total duration of antibiotic therapy: 10 days</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Two rapid 1 hour exchanges were performed at the time of diagnosis in all patients</LI>
</UL>
<P>Further peritoneal lavage (rate 1 L/h) was performed in 25 patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 11:59:50 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Catheter removal</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:31:42 +1100" MODIFIED_BY="Ann Jones">
<P>Exclusions post randomisation but pre-intervention</P>
<UL>
<LI>Fungal peritonitis (5); tuberculous peritonitis (1)</LI>
</UL>
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain and cloudy effluent with or without fever; patients who responded initially but had another episode more than 28 days after the onset of the first episode were considered to have a new infection and entered into the study as a separate episode</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Complete resolution of symptoms and signs and negative bacterial cultures on repeat sampling, including day 28</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Any episode that required a change in antibiotic therapy</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Repeat infection within 28 days of receiving treatment</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 117 episodes of peritonitis in 85 patients</LI>
<LI>Enrolled/randomised: 117</LI>
<LI>Analysed: 110</LI>
<LI>Per cent followed: 94.9%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:35:22 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Cheng-1991">
<CHAR_METHODS MODIFIED="2014-02-11 12:11:08 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 28 days after treatment</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 12:08:58 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: multicentre, teaching hospital, university hospital</LI>
<LI>Inclusion criteria: patients on CAPD who developed peritonitis</LI>
<LI>Number: treatment group (23); control group (25)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: known sensitivity to quinolones, vancomycin and aztreonam; peritonitis secondary to fungi; tuberculous peritonitis; relapsing peritonitis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:35:11 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Oral ofloxacin: 400 mg loading dose then 300 mg/d for 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 500 mg/L IP loading dose then 30 mg/L IP maintenance dose</LI>
<LI>Aztreonam: 500 mg/L IP loading dose then 250 mg/L IP maintenance dose</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>3 flushes with 1 L 1.5% solution prior to the beginning of treatment if the peritoneal effluent was very turbid</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 12:10:01 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse of peritonitis</LI>
<LI>All-cause mortality</LI>
<LI>Hospitalisation (number of patients and duration of stay)</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:35:22 +1100" MODIFIED_BY="Ann Jones">
<P>Exclusions post randomisation but pre-intervention</P>
<UL>
<LI>3 patients (2 transfers to other hospitals, 1 case of fungal peritonitis)</LI>
</UL>
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain and cloudy peritoneal dialysate occurred with or without fever; peritoneal WCC &gt; 200/mm³ with &gt; 50% polymorphs</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Persistent fever, abdominal pain and cloudy effluent, less than 50% reduction in the total WCC compared to the pretreatment value after 3 days of antibiotic treatment</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence of peritonitis with the same organism within 18 days after stopping treatment</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 48 episodes of peritonitis</LI>
<LI>Enrolled/randomised: 48</LI>
<LI>Analysed: 45</LI>
<LI>Per cent followed: 93.8%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:36:09 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Cheng-1993">
<CHAR_METHODS MODIFIED="2014-02-11 12:15:22 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 28 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-11 12:16:59 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: teaching hospital, university hospital</LI>
<LI>Inclusion criteria: patients on CAPD who developed peritonitis</LI>
<LI>Number: 46</LI>
<LI>Age and sex: groups were comparable with regards to age and sex (data not shown)</LI>
<LI>Exclusion criteria: known sensitivity to fluoroquinolones; peritonitis secondary to fungi; tuberculous peritonitis; relapsing peritonitis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:35:34 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Oral ciprofloxacin: 750 mg twice daily</LI>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Ciprofloxacin: 200 mg IP in the first bag then 25 mg/L in subsequent bags</LI>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<P>Additional treatment</P>
<UL>
<LI>Patients randomised to oral ciprofloxacin with primary treatment failure were given IP ciprofloxacin if the micro-organism was sensitive on culture, or it was a culture negative episode</LI>
<LI>Patients randomised to IP ciprofloxacin were changed to IP vancomycin and amikacin</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-11 12:18:18 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
<LI>Catheter removal</LI>
<LI>Hospitalisation (number of patients and duration of stay)</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:36:09 +1100" MODIFIED_BY="Ann Jones">
<P>Exclusions post randomisation but pre-analysis</P>
<UL>
<LI>Fungal peritonitis (3); tuberculous peritonitis (1); non-compliance with treatment protocol (2)</LI>
</UL>
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain and cloudy peritoneal dialysate occurred with or without fever; peritoneal WCC &gt; 100/mm³ with &gt; 50% polymorphs</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Complete resolution of symptoms and signs with a negative culture, and no further episodes in the following 28 days</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>The persistence of signs and symptoms and if total peritoneal WCC count was more than 50% of the pretreatment value after 3 days of antibiotic treatment</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence with the same micro-organism within 28 days of clearing of the initial peritonitis episode</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 54 episodes in 46 patients</LI>
<LI>Enrolled/randomised: 54</LI>
<LI>Analysed: 48</LI>
<LI>Per cent followed: 88.9%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:36:50 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Cheng-1997">
<CHAR_METHODS MODIFIED="2014-02-13 10:46:12 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 28 days after commencement of treatment</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 10:48:59 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: multicentre, teaching hospital, university</LI>
<LI>Inclusion criteria: patients on CAPD who developed peritonitis</LI>
<LI>Number: treatment group (19 episodes); control group (17 episodes)</LI>
<LI>Age, range (years): treatment group (51.5, 26 to 71); control group (51, 36 to 80)</LI>
<LI>Sex (M/F): treatment group (11/7); control group (6/11)</LI>
<LI>Exclusion criteria: known sensitivity to fluoroquinolones; peritonitis secondary to fungi or tuberculous bacteria; relapsing peritonitis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:36:42 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Oral ofloxacin: 400 mg loading dose then 300 mg/d maintenance dose</LI>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Ofloxacin: 100 mg/L for the first bag then 25 mg/L dialysate in subsequent bags</LI>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Aluminium phosphate binders were stopped in patients receiving pefloxacin orally but not in those receiving the IP drug</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 10:50:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse of peritonitis</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:36:50 +1100" MODIFIED_BY="Ann Jones">
<P>Exclusions post randomisation but pre-intervention</P>
<UL>
<LI>7/41 patients were excluded because of protocol violation after an interim analysis</LI>
</UL>
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain and cloudy peritoneal dialysate occurred with or without fever; peritoneal WCC &gt; 100/mm³ with &gt; 50% polymorphs</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Complete resolution of symptoms and signs with a negative culture, and no further episodes in the following 28 days</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>The persistence of fever, abdominal pain and cloudy peritoneal effluent and if total peritoneal WCC count &gt; 50% of the pretreatment value after 3 days of antibiotic treatment</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence with the same micro-organism within 28 days of clearing of the initial peritonitis episode</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 41 patients</LI>
<LI>Enrolled/randomised: 34 patients (36 peritonitis episodes)</LI>
<LI>Analysed: 33 patients (35 peritonitis episodes)</LI>
<LI>Per cent followed: 94.3%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:37:33 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Cheng-1998">
<CHAR_METHODS MODIFIED="2014-02-13 10:53:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 28 days from clearing of effluent</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 10:54:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: multicentre, teaching hospital</LI>
<LI>Inclusion criteria: patients on CAPD who developed peritonitis</LI>
<LI>Number: treatment group (47); control group (54)</LI>
<LI>Mean age ± SD (years): treatment group (56.5 ± 13.2); control group (56.6 ± 11.0)</LI>
<LI>Sex (M/F): treatment group (25/22); control group (29/25)</LI>
<LI>Exclusion criteria: severe peritonitis with evidence of septicaemia (i.e. high fever and hypotension); peritonitis secondary to tunnel infection; peritonitis secondary to fungi or tuberculous bacteria; relapsing peritonitis; known sensitivity to study medications</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:37:28 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Oral levofloxacin: 300 mg/d</LI>
<UL>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<LI>Vancomycin: 1 g (if &lt; 50 kg) or 2 g (body weight &gt; 50 kg) day 1 and day 7</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Netromycin: 20 mg/L IP loading dose then 20 mg/L in the first exchange of each day</LI>
<UL>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<LI>Vancomycin: 1 g (if &lt; 50 kg) or 2 g (body weight &gt; 50 kg) day 1 and day 7</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 10:55:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:37:33 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain and cloudy peritoneal dialysate occurred with or without fever; peritoneal WCC &gt; 100/mm³ with &gt; 50% polymorphs</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Complete resolution of symptoms and signs with a negative culture, and no further episodes in the following 28 days</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>The persistence of fever, abdominal pain and cloudy peritoneal effluent and if total peritoneal WCC &gt; 50% of the pretreatment value after 3 days of antibiotic treatment</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence with the same micro-organism within 28 days of clearing of the initial peritonitis episode</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 113</LI>
<LI>Enrolled/randomised: 101</LI>
<LI>Analysed: 100</LI>
<LI>Per cent followed: 99%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 15:52:40 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Choy-2001">
<CHAR_METHODS MODIFIED="2014-02-13 11:03:13 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: 14 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-05 15:52:12 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: patients with CAPD peritonitis</LI>
<LI>Number: 147 patients (184 episodes); treatment group (93 episodes); control group (91 episodes)</LI>
<LI>Mean age ± SD (years): treatment group (66.5 ± 1.3); control group (63.9 ± 1.4)</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:38:10 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Intermittent regime: cefazolin (1.5 mg/2 L) + tobramycin (40 mg/2 L) dialysate in one exchange/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Continuous regime: loading doses of cefazolin (2 mg/2 L) + tobramycin (16 mg/2 L) followed by cefazolin (12.5 mg/L) + tobramycin (6 mg/L) dialysate for every exchange</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 11:06:09 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Primary treatment failure</LI>
<LI>Catheter removal</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-05 15:52:40 +1100" MODIFIED_BY="Narelle Willis">
<P>Primary treatment failure</P>
<UL>
<LI>Reported as primary treatment cure</LI>
</UL>
<P>Catheter removal</P>
<UL>
<LI>10 patients from each group required Tenchoff catheter removal (fungal (7); <I>Pseudomonas (9);</I> <I>E. coli (2);</I> mixed gram negative (1); <I>Staphylococcus (1)</I>)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:39:05 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Coban-2004">
<CHAR_METHODS MODIFIED="2014-02-13 11:08:36 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi-RCT</LI>
<LI>Time frame: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 11:17:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Turkey</LI>
<LI>Setting: university hospital</LI>
<LI>Inclusion criteria: CAPD-associated peritonitis; positive dialysate culture with an organism sensitive to the study antibiotics</LI>
<LI>Number: treatment group (12); control group (12)</LI>
<LI>Mean age ± SD (years): treatment group (52.6 ± 5.9); control group (53.2 ± 7.6)</LI>
<LI>Sex (M/F): treatment group (6/6); control group (7/5)</LI>
<LI>Exclusion criteria: completion of antibiotic therapy with 28 days; active exit site infection, tunnel infection; peritonitis attributed to other surgical causes suspected on clinical grounds; presence of peritonitis attributed to fungal or mycobacterial infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:39:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>2 mL (320 mg) IP IgG with each exchange</LI>
<LI>Antibiotics as for control group</LI>
</UL>
<P>Control group</P>
<UL>
<LI>IP ampicillin/sulbactam: 1 g 3 times/d</LI>
<LI>IP netilmicin: 150 mg loading dose; 50 mg/d (added to night exchange)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 11:21:02 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Time for dialysate WCC &lt; 100/mL</LI>
<LI>Time to pain free exchange</LI>
<LI>Relapse</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:17:49 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Two of the following: dialysate WCC &gt; 100/mm³ with more than 50% polymorphs; peritoneal inflammation symptoms; positive dialysate gram stain and subsequent positive culture</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 24</LI>
<LI>Enrolled/randomised: 24</LI>
<LI>Analysed: 24</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 14:18:59 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-de-Fijter-2001">
<CHAR_METHODS MODIFIED="2014-02-13 11:23:06 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: October 1996 to Octobe1999</LI>
<LI>Follow-up period: 28 days from completion of therapy</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-05 14:18:59 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: The Netherlands</LI>
<LI>Setting: multicentre, teaching hospital, university</LI>
<LI>Inclusion criteria: receiving CAPD; &gt; 18 years</LI>
<LI>Number: treatment group (44); control group (54)</LI>
<LI>Age, range (years): treatment group (61.2, 28 to 76); control group (56.9, 22 to 76)</LI>
<LI>Sex (M/F): treatment group (26/18); control group (24/30)</LI>
<LI>Exclusion criteria: pregnancy; lactating females or those using inadequate contraception; underlying rapidly fatal disease (life expectancy &lt; 2 months post-enrolment); use of any concomitant systemic antimicrobial drug within 1 week prior to enrolment; chronic liver disease (SGOT and/ or SGPT repeatedly 3 times over the upper normal limit); evidence or history of hypersensitivity or other contraindications to quinolones, cephalosporins or rifampicin; prior entry into the present study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:38:53 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Ciprofloxacin: 50 mg/L added to all exchanges</LI>
<LI>Rifampicin: 50 mg/L added to all exchanges</LI>
<LI>Ciprofloxacin or cephradine stopped when appropriate following culture results</LI>
<LI>Treatment duration: 14 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Cephradine: 250 mg/L added to all exchanges</LI>
<LI>Treatment duration: 14 days</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 11:26:22 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Bacteriological response</LI>
<LI>Relapse</LI>
<LI>Catheter removal</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:17:49 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Dialysate WCC &gt; 100/mm³ with &gt; 50% polymorphs, with or without clinical symptoms and signs of peritonitis or a positive culture</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Disappearance of all signs and symptoms related to the infection by day 4 and continued through to day 42</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Insufficient lessening of symptoms and signs to qualify as improvement</LI>
<LI>Ongoing symptoms and signs beyond day 4</LI>
<LI>Dialysate WWC &gt; 100/mm³ at day 14</LI>
<LI>Death secondary to uncontrolled infection</LI>
<LI>Catheter removal</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence with the same organism within 28 days</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 367</LI>
<LI>Enrolled/randomised: 367</LI>
<LI>Analysed: 98</LI>
<LI>Per cent followed: 26.7%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:40:22 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drinovec-1988">
<CHAR_METHODS MODIFIED="2014-02-13 11:54:56 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 11:56:25 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Yugoslavia</LI>
<LI>Setting: NS</LI>
<LI>Inclusion criteria: patients who were being treated with CAPD that developed peritonitis with <I>Staphylococcus</I>
</LI>
<LI>Number:20 (54 episodes)</LI>
<LI>Age range: 25 to 73 years</LI>
<LI>Sex (M/F): 9/11</LI>
<LI>Exclusion criteria: none</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:40:22 +1100" MODIFIED_BY="[Empty name]">
<P>Patients with mild forms of peritonitis were administered one combination of two antibiotics: gentamicin + methicillin or gentamicin + cloxacillin or clindamycin + mezlocillin IP</P>
<P>Comparison 1</P>
<UL>
<LI>Treatment: gentamicin + methicillin</LI>
<LI>Control: clindamycin + mezlocillin</LI>
</UL>
<P>Comparison 2</P>
<UL>
<LI>Treatment: gentamicin + methicillin</LI>
<LI>Control: gentamicin + cloxacillin</LI>
</UL>
<P>Comparison 3</P>
<UL>
<LI>Treatment: gentamicin + cloxacillin</LI>
<LI>Control: clindamycin + mezlocillin</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 11:58:00 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment failure</LI>
<LI>Complete cure</LI>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-13 11:59:17 +1100" MODIFIED_BY="[Empty name]">
<P>Definition of peritonitis</P>
<UL>
<LI>Peritonitis was diagnosed when any of two following criteria were present: abdominal pain or soreness, cloudy peritoneal effluent containing WCC &#8805; 100/mm³ and micro-organisms in the peritoneal effluent</LI>
</UL>
<P>Adverse effects</P>
<UL>
<LI>A reversible toxic effect on the nervus vestibularis was observed in 2 patients receiving gentamicin</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>20 patients developed 54 episodes of peritonitis over a 258 month period</LI>
<LI>Results for only 31 peritonitis episodes provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:40:59 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ejlersen-1991">
<CHAR_METHODS MODIFIED="2014-02-13 12:01:23 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 month after cessation of antibiotic treatment</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 12:04:16 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Denmark</LI>
<LI>Setting: multicentre, teaching hospital, university</LI>
<LI>Inclusion criteria: patients on CAPD who developed peritonitis</LI>
<LI>Number: treatment group (18); control group (18)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F):NS</LI>
<LI>Exclusion criteria: patients previously enrolled in the study; profound hypotension and shock; clinical exit site and/ or tunnel infection; poor treatment compliance</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:40:59 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Initial 24 hours of peritoneal lavage (2 L exchanges, no dwell time) with 60 L dialysis fluid containing vancomycin 20 mg/L and netilmicin 10 mg/L; followed by resumption of usual CAPD regimen and 9 days of IP antibiotics in the same concentration (total 10 days of antibiotic treatment)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Initial 2 rapid exchanges followed by routine CAPD schedule</LI>
<LI>Vancomycin 40 mg/L and netilmicin 10 mg/L added to the initial 2 rapid exchanged, followed by ongoing vancomycin 20 mg/L and netilmicin 10 mg/L for a total of 10 days of antibiotic therapy</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 12:05:23 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Time to resolution of peritonitis</LI>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:17:50 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>2/5 possible criteria present: positive Leukostix; cloudy dialysis effluent; abdominal pain; dialysate WCC &gt; 100/µL and &gt; 50% neutrophils; positive culture from dialysis effluent</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Normalisation of WCC in the dialysate effluent</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recrudescence of peritonitis signs and symptoms while still under antibiotic treatment</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 39</LI>
<LI>Enrolled/randomised: 39</LI>
<LI>Analysed: 36</LI>
<LI>Per cent followed: 92.3%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:41:10 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Flanigan-1991">
<CHAR_METHODS MODIFIED="2014-02-13 12:10:12 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi-RCT</LI>
<LI>Time frame: January 1981 to December 1986</LI>
<LI>Follow-up period: 14 days after completion of treatment</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 12:14:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: receiving CAPD or CCPD</LI>
<LI>Number: treatment group (83, 181 episodes); control group (48, 82 episodes)</LI>
<LI>Mean age ± SEM (years): treatment group (42.75 ± 2.10); control group (47.12 ± 2.63)</LI>
<LI>Male: treatment group (46%); control group (51%)</LI>
<LI>Exclusion criteria: allergy to both study drugs</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:41:10 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Cephazolin: 50 mg/L of dialysate IP</LI>
<LI>Total duration of treatment: 14 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 25 mg/L of dialysate IP</LI>
<LI>Total duration of treatment: 14 days</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>2 rapid exchanges at the time of initiation of treatment followed by resumption of the normal dialysis regimen</LI>
<LI>IP heparin 250 U/L</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 13:03:37 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse of peritonitis</LI>
<LI>Catheter removal</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:17:51 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Effluent WCC &gt; 100/ µL and &gt; 50% neutrophils</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Elimination of all symptoms and signs of infection by the initial 14 days of antibiotics, and remaining infection free for another 14 days following completion of antibiotic therapy</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence within 14 days of antibiotic treatment of infection with the same organism or with no growth</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 131</LI>
<LI>Enrolled/randomised: 131</LI>
<LI>Analysed: 95 patients (263 episodes of peritonitis)</LI>
<LI>Per cent followed: 72.5%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 14:17:21 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Friedland-1990">
<CHAR_METHODS MODIFIED="2014-02-13 13:09:59 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: UK</LI>
<LI>Study design: parallel RCT</LI>
<LI>Follow-up period: 28 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-05 14:17:21 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: UK</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: patients with CAPD-associated peritonitis</LI>
<LI>Number: treatment group (20); control group (20)</LI>
<LI>Age range: treatment group (47 to 79 years); control group (22 to 77 years)</LI>
<LI>Sex (M/F): treatment group (11/9); control group (13/7)</LI>
</UL>
<P>Exclusion criteria: known allergy to any study drug; PD catheter leak; catheter tunnel infection; pregnancy; liver disease; history of convulsions<BR/>If any antibiotics had been received in the 48 hours prior to presentation; recurrent peritonitis (any episode within the previous 28 days)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:41:18 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Ciprofloxacin: 20 mg/L IP with each exchange</LI>
<LI>Total duration of treatment: 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 12.5 mg/L IP with each exchange</LI>
<LI>Gentamicin: 4 mg/L to alternate exchanges</LI>
<LI>Total duration of treatment: 10 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 13:11:57 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse of peritonitis</LI>
<LI>Catheter removal</LI>
<LI>Technique failure</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:17:51 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of cure</P>
<UL>
<LI>No further episodes of CAPD peritonitis in the following 28 days</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 40</LI>
<LI>Enrolled/randomised: 40</LI>
<LI>Analysed: 40</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 15:53:43 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Gadallah-2000c">
<CHAR_METHODS MODIFIED="2014-02-13 13:17:34 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi-RCT</LI>
<LI>Time frame: 3 years</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 13:18:24 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: USA</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: first episode of PD-associated peritonitis</LI>
<LI>Number: treatment group (40); control group (40)</LI>
<LI>Mean age ± SE (years): treatment group (45.1 ± 12.8); control group (48.2 ± 3.3)</LI>
<LI>Sex (M/F): treatment group (19/21); control group (18/22)</LI>
<LI>Exclusion criteria: exit-site or tunnel infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-05 15:53:43 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Urokinase: 5000 IU/2.5 mL normal saline, administered intraluminally; 4 hour dwell</LI>
<LI>IP antibiotics</LI>
</UL>
<P>Control group</P>
<UL>
<LI>IP antibiotics</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 13:18:58 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Duration of peritonitis</LI>
<LI>Severity of symptoms and signs of peritonitis</LI>
<LI>Recurrence of peritonitis</LI>
<LI>Relapse</LI>
<LI>Catheter removal</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:17:52 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of treatment failure</P>
<UL>
<LI>Persistent peritonitis without improvement in dialysate WCC after 4 days of treatment with specific antibiotic therapy</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Peritonitis caused by the same organism within 3 months of the initial episode of peritonitis or three episodes of peritonitis due to the same organism within a 6 month period</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 80</LI>
<LI>Enrolled/randomised: 80</LI>
<LI>Analysed: 80</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:41:57 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Gucek-1994">
<CHAR_METHODS MODIFIED="2014-02-13 13:21:07 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: November 1991 to June 1993</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 13:22:45 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Slovenia</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: adults receiving CAPD therapy who developed peritonitis</LI>
<LI>Number: 23</LI>
<LI>Mean age ± SD: 53.5 ± 11 years</LI>
<LI>Sex (M/F): 15/8</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:41:57 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Oral ofloxacin: 300 mg loading dose then 200 mg/d for an average of 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Cephazolin: 100 mg IP loading dose then 250 mg IP/exchange for 10 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 13:23:07 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:17:53 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>2/3 criteria: abdominal discomfort and pain; cloudy peritoneal effluent with WCC &gt; 100/mm³; positive microbiological findings of the effluent</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 23</LI>
<LI>Enrolled/randomised: 23</LI>
<LI>Analysed: 23</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 16:42:04 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Gucek-1997">
<CHAR_METHODS MODIFIED="2014-02-13 13:27:05 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: November 1993 to September 1996</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-05 16:42:04 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Slovenia</LI>
<LI>Setting: university</LI>
<LI>Inclusion criteria: CAPD-associated peritonitis</LI>
<LI>Number: 34 (52 episodes)</LI>
<LI>Mean age ± SD: 57.2 ± 13.6 years</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:42:20 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Cephazolin: 500 mg IP loading dose then 250 mg/exchange maintenance dose</LI>
<LI>Netilmicin: 80 mg to 120 mg IP loading dose then 40 mg IP daily maintenance dose</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 2 g IP every 5 to 7 days</LI>
<LI>Ceftazidime: 1 g IP loading dose then 250 mg IP/exchange maintenance dose</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 13:29:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:16:51 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>2/3 criteria: abdominal discomfort and pain; cloudy peritoneal effluent with WCC &gt; 100/mm³; positive microbiological findings of the effluent</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Failure to show considerable clinical improvement within 2-5 days of initial antibiotic treatment</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 34 patients (52 episodes)</LI>
<LI>Enrolled/randomised: 34 patients (52 episodes)</LI>
<LI>Analysed: 34 patients (52 episodes)</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 15:54:29 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Hernandez-2004">
<CHAR_METHODS MODIFIED="2014-02-13 13:30:15 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: quasi-RCT</LI>
<LI>Time Frame: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 13:33:09 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Mexico</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: patients who had clinical data of peritonitis associated with CAPD were randomly selected from the CAPD Program of the nephrology service of Hospital Regional</LI>
<LI>Number: treatment group (20); control group (20)</LI>
<LI>Age (years): treatment group (53.3); control group (52.8)</LI>
<LI>Sex (M/F): treatment group (11/9); control group (15/5)</LI>
<LI>Exclusion criteria: unclear</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-05 15:54:29 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Cefepime IP: 500 mg/dL at onset, and afterwards at 125 mg/dL, in dialysis solution at 1.5%, refilled 4 times/d for 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Cefotaxim-amikacin IP: at the onset, cefotaxime was administered at doses of 250 mg/L, with amikacin at 25 mg/dL, in dialysis solution at 1.5%, refilled 4 times/d for 10 days</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>At 48 and 96 hours, control was taken of the cytochemistry of the initial dialysis fluid, of the culture and of gram-stain. Addition of another antimicrobial in the case of identification of fungi, mycobacteria, or bacteroides</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 13:33:58 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Complete cure</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-13 13:34:11 +1100" MODIFIED_BY="[Empty name]">
<P>Definition of cure</P>
<UL>
<LI>Normal leukocyte count in cytochemical of the dialysis liquid, as well as remission of clinical signs and symptoms</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 14:16:10 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Innes-1994">
<CHAR_METHODS MODIFIED="2014-02-13 13:35:19 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting/ design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 13:53:03 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: UK</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: resistant PD-associated peritonitis (no resolution of peritonitis within 4 days of appropriate antibiotic therapy) or recurrent peritonitis (a third episode of peritonitis with the same organism within 6 months despite appropriate antibiotic therapy)</LI>
<LI>Number: treatment group (12); control group (12)</LI>
<LI>Age: median 57 years (range 32 to 76 years)</LI>
<LI>Sex (M/F): 14/10</LI>
<LI>Exclusion criteria: fungal peritonitis; culture negative peritonitis; tunnel or exit site infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-13 13:36:59 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>5000 Plough Units of urokinase/5 mL of normal saline, administered via IP route; 2 hour dwell</LI>
<LI>14 days of antibiotics (determined by causative organism)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo (5 mL normal saline)</LI>
<LI>14 days of antibiotics (determined by causative organism)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 13:37:05 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:16:10 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>2/3 criteria: dialysate WCC &gt; 100 mm³; positive dialysate culture; abdominal pain</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Disappearance of symptoms and signs related to infection and a decrease in the dialysate WCC &lt; 100/mm³ for 4 weeks after therapy</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>No clinical improvement, or modification of therapy due to clinical deterioration, or catheter removal</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 73</LI>
<LI>Enrolled/randomised: 73</LI>
<LI>Analysed: 65</LI>
<LI>Per cent followed: 89.0%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 15:55:10 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Jim_x00e9_nez-1996">
<CHAR_METHODS MODIFIED="2014-02-13 13:54:32 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-05 15:55:10 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Spain</LI>
<LI>Setting: NS</LI>
<LI>Inclusion criteria: NS</LI>
<LI>Number: 24 (67 episodes)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: unclear</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-13 13:55:46 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Vancomycin and cefotaxime</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin and tobramycin</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-13 13:55:59 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Recurrence of peritonitis</LI>
<LI>Catheter removal</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:12:25 +1100" MODIFIED_BY="Narelle Willis">
<P>Definition of treatment success</P>
<UL>
<LI>Resolution of peritonitis within 4 days of urokinase or placebo in the case of persistent infection, or no recurrence with the same organism within 6 months for recurrent infection</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 24</LI>
<LI>Enrolled/randomised: 24</LI>
<LI>Analysed: 24</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:43:27 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Khairullah-2002">
<CHAR_METHODS MODIFIED="2014-02-13 14:02:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 1 October 1997 to 20 September 1999</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-13 14:05:19 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: USA</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: PD-associated peritonitis</LI>
<LI>Number: 30 (51 episodes)</LI>
<LI>Mean age (range): 48 years (26 to 74)</LI>
<LI>Sex (M/F): 17/13</LI>
<LI>Exclusion criteria: sensitivities to penicillin or vancomycin; already receiving antibiotics; known to be noncompliant; could not follow instructions; &lt; 18 years; pregnancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:43:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Cephazolin: 1 g IP loading dose then 125 mg/L with each exchange for 2 to 3 weeks according to culture results</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 1 g/L IP loading dose, repeated at day 5 or day 8 according to residual kidney function, for 2 weeks</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Gentamicin: 40 mg/d IP added to one exchange (both groups)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 11:49:59 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
<LI>Catheter removal</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:12:18 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Effluent WCC &gt; 100/mm³ with &gt; 50% neutrophils</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Elimination of all signs and symptoms of peritonitis by the prescribed duration of treatment; infection free for 2 weeks after cessation of treatment</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Infection with the same micro-organism within 2 weeks of treatment</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 91 patients</LI>
<LI>Enrolled/randomised: 91 patients</LI>
<LI>Analysed: 30 patients (51 episodes)</LI>
<LI>Per cent followed: 82.4%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:43:59 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Klaus-1995a">
<CHAR_METHODS MODIFIED="2014-02-17 15:43:59 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: June 1993 to January 1997</LI>
<LI>Follow-up period: median 19 months (range 1 to 44)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 12:01:36 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Germany</LI>
<LI>Setting: multicentre; 13 mid-European paediatric dialysis centres</LI>
<LI>Inclusion criteria: children and adolescents; CAPD therapy; &gt; 4 weeks without peritonitis, exit site infections or other infections treated with antibiotics in prevalent CPD patients</LI>
<LI>Number: treatment group 1 (40); treatment group 2 (41); control group 1 (40); control group 2 (43)</LI>
<LI>Median age (range): 11.4 years (0.7 to 21.8)</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: patients receiving continuous local or systemic antibiotics</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 12:02:21 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group 1</P>
<UL>
<LI>Teicoplanin: 7.5 mg/kg body weight loading dose then 20 mg/L dialysate added to each dialysate exchange</LI>
<LI>Ceftazidime: 250 mg/L dialysate loading dose then 125 mg/L added to each dialysate exchange</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Teicoplanin: 15 mg/kg loading dose day 1 and day 7</LI>
<LI>Ceftazidime: 500 mg/L dialysate loading dose then 250 mg/L once daily added to long (9 to 12 hour) dwell</LI>
</UL>
<P>Control group 1</P>
<UL>
<LI>Vancomycin: 15 mg/kg body weight loading dose then 30 mg/L dialysate added to each dialysate exchange</LI>
<LI>Ceftazidime: 250 mg/L dialysate loading dose then 125 mg/L added to each dialysate exchange</LI>
</UL>
<P>Control group 2</P>
<UL>
<LI>Vancomycin: 30 mg/kg body weight day 1 and day 7</LI>
<LI>Ceftazidime: 500 mg/L dialysate loading dose then 250 mg/L once daily added to long (9 to 12 hour) dwell</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Heparin 200 IU/L IP until the dialysate completely cleared</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 12:03:52 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
<LI>Side effects of treatment</LI>
<LI>Loss of residual kidney function</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:12:11 +1100" MODIFIED_BY="Ann Jones">
<P>Exclusions post randomisation but pre-intervention</P>
<UL>
<LI>2 patients</LI>
</UL>
<P>Definition of peritonitis</P>
<UL>
<LI>Dialysate WCC &gt; 100/µL with &gt; 50% polymorphonuclear neutrophils</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>A decrease in the disease severity score (DSS) by 2 or, if less than 2 initially, when the dialysate WCC had decreased by 50% or more</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Deterioration of clinical status after 60 h (increase in the DSS)</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence of peritonitis with the same organism within 4 weeks after termination of antibiotic treatment</LI>
</UL>
<P>Additional data requested from authors</P>
<UL>
<LI>Outcomes based on modality of PD</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 152 patients</LI>
<LI>Enrolled/randomised: 90 (195 episodes)</LI>
<LI>Analysed: 195</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 15:55:58 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Leung-2004">
<CHAR_METHODS MODIFIED="2014-02-17 12:06:39 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi-RCT</LI>
<LI>Time frame: March 2001 to February 2002</LI>
<LI>Follow-up period: 120 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 12:13:44 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: single centre; university teaching hospital</LI>
<LI>Inclusion criteria: PD-associated peritonitis</LI>
<LI>Number: treatment group (51); control group (51)</LI>
<LI>Mean age ± SD (years): treatment group (61.0 ± 12.2); control group (57.1 ± 12.2)</LI>
<LI>Sex (M/F): treatment group (26/25); control group (25/26)</LI>
<LI>Exclusion criteria: recurrent peritonitis within 30 days prior to presentation, concomitant antibiotics for other indications, catheter leak or malfunction, and known allergy to imipenem / cilastatin, ceftazidime, or cefazolin</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-05 15:55:58 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Iimipenem/cilastin IP: loading dose 500 mg (6 hour dwell) then maintenance dose 100 mg/2 L dialysate bag 4 times/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Cephazolin IP: loading dose 1 g (6 hour dwell) then maintenance dose 250 mg/2 L dialysate bag 4 times/d</LI>
<LI>Ceftazidime IP loading dose 1 g (6 hour dwell) then maintenance dose 250 mg/ 2 L dialysate bag 4 times/d</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Three rapid hourly dialysis cycles at presentation</LI>
<LI>Heparin sodium 1000 U IP/2 L dialysis solution until dialysate cleared</LI>
<LI>Oral nystatin for fungal prophylaxis until antibiotic therapy completed</LI>
<LI>Oral rifampicin added for <I>S. aureus</I> infections and IP netilmicin for <I>Pseudomonas</I> infections, and treatment continued for at least 21 days in these cases</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 12:15:33 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Primary response</LI>
<LI>Complete cure</LI>
<LI>Catheter removal</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:12:04 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Two of abdominal pain, cloudy dialysate or peritoneal effluent WCC &gt; 100/mm³ with &gt; 50% neutrophils and positive gram stain or culture</LI>
</UL>
<P>Definition of primary response</P>
<UL>
<LI>Resolution of abdominal pain, clearing of dialysate and dialysate neutrophil count &lt; 100/µL on day 10</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence of peritonitis by the same organism within 28 days of completion of a course of antibiotics</LI>
</UL>
<P>Complete cure</P>
<UL>
<LI>Complete cure of peritonitis by antibiotics alone, without relapse within 120 days</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 102</LI>
<LI>Enrolled/randomised: 102</LI>
<LI>Analysed: 102</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:45:59 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lui-2005">
<CHAR_METHODS MODIFIED="2014-02-17 12:17:52 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: October 2002 to October 2004</LI>
<LI>Follow-up period: 42 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 12:20:38 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: single centre, university teaching hospital</LI>
<LI>Inclusion criteria: CAPD patients 18 years of age or older with clinical evidence of peritonitis</LI>
<LI>Number: treatment group (51); control group (51)</LI>
<LI>Mean age ± SD (years): treatment group (66.7 ± 12.2); control group (63.7 ± 14.6)</LI>
<LI>Sex (M:F): treatment group (1:1); control group (1.3:1)</LI>
<LI>Exclusion criteria: known hypersensitivity to cephalosporins or amino glycosides; suspected fungal or tuberculous peritonitis; relapsing peritonitis; active exit site infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:45:59 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Ceftazidime: 1 g/2 L dialysate bag IP daily</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Netilmicin: 0.6 mg/kg body weight/2 L dialysate bag IP daily</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Cephazolin 1 g/2 L dialysate bag IP daily</LI>
<LI>Antibiotics changed if there was a failure to respond to assigned antibiotics by day 3; antibiotics either adjusted according to culture results or changed to second line antibiotics (vancomycin and amikacin) if cultures were negative</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 12:21:41 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Primary treatment failure</LI>
<LI>Secondary treatment failure</LI>
<LI>Relapse of peritonitis</LI>
<LI>Catheter removal</LI>
<LI>Decline in residual kidney function</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:11:57 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain and cloudy dialysate, and a dialysate WCC &gt; 100 mm³ with &gt; 50% neutrophils</LI>
</UL>
<P>Definition of primary cure</P>
<UL>
<LI>A complete resolution of signs and symptoms of peritonitis with a negative dialysate culture and no further episodes of peritonitis within 28 days following the cessation of antibiotic treatment</LI>
</UL>
<P>Definition of primary treatment failure</P>
<UL>
<LI>The presence of fever, abdominal pain and turbid peritoneal dialysate, and if the total peritoneal WCC is &gt; 50% of pretreatment values after 3 days of treatment by the assigned antibiotics</LI>
</UL>
<P>Definition of secondary treatment failure</P>
<UL>
<LI>Treatment failure despite adjustment of antibiotics or changing to second line antibiotics</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence of peritonitis with the same micro-organism within 28 days of clearing of the initial antibiotic episode and cessation of antibiotic therapy</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 112</LI>
<LI>Enrolled/randomised: 104</LI>
<LI>Analysed: 102</LI>
<LI>Per cent followed: 98%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:46:14 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Lupo-1997">
<CHAR_METHODS MODIFIED="2014-02-17 13:57:05 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 4 weeks after completion of therapy</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 13:58:16 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: multicentre, university</LI>
<LI>Inclusion criteria: CAPD-associated peritonitis</LI>
<LI>Number: treatment group (39); control group (34)</LI>
<LI>Mean age ± SD (years): treatment group (66.7 ± 12); control group (66.9 ± 13)</LI>
<LI>Sex (M/F): treatment group (23/16); control group (13/16)</LI>
<LI>Exclusion criteria: known or suspected sensitivity to the study drug(s); peritonitis caused by tunnel infection; effective antibiotic therapy in the previous 48 hours</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:46:14 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Teicoplanin: 400 mg IV loading dose then 40 mg IP added to each exchange</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Cephalothin: 2 g IV then 500 mg IP added to each exchange</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Tobramycin 120 mg IM loading dose then 10 mg IP added to each exchange (both groups)</LI>
<LI>In both groups IP antibiotics were given with each exchange in the first week of treatment, in alternate bags in the second week, and in an overnight bag in the third week</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 13:59:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Microbiological eradication</LI>
<LI>Relapse</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:11:51 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>2/3 criteria: dialysate WCC &gt; 100/mm³; positive dialysate culture; abdominal pain</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Disappearance of symptoms and signs related to infection and a decrease in the dialysate WCC &lt; 100/mm³ for 4 weeks after therapy</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>No clinical improvement, or modification of therapy due to clinical deterioration, or catheter removal</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 73</LI>
<LI>Enrolled/randomised: 73</LI>
<LI>Analysed: 65</LI>
<LI>Per cent followed: 89.0%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-15 19:45:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lye-1993">
<CHAR_METHODS MODIFIED="2014-02-17 14:00:40 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 1 January to 31 December 1991</LI>
<LI>Follow-up period: 14 days after completion of treatment</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-15 19:45:05 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Singapore</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: CAPD-associated peritonitis</LI>
<LI>Number: treatment group (33); control group (30)</LI>
<LI>Mean age ± SEM (years): treatment group (61.6 ± 8.5); control group (59.0 ± 12.0)</LI>
<LI>Sex (M/F): treatment group (11/19); control group (9/21)</LI>
<LI>Exclusion criteria: history of allergy to the antibiotics; chronic exit-site or tunnel infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:46:41 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Oral pefloxacin: 400 mg twice daily</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Gentamicin: 80 mg IP loading dose then 15 mg/2 L dialysate bag</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Single dose vancomycin 1 g IP (both groups)</LI>
<LI>Total duration of antibiotic therapy 14 days</LI>
<LI>Antibiotics changed after 72 hours according to culture results</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 14:03:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
<LI>Catheter removal</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:47:09 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Cloudy peritoneal effluent; dialysate WWC &gt; 100/mL with &gt; 50% polymorphonuclear neutrophils</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Resolution of symptoms and signs of peritonitis; clearing of peritoneal fluid; negative bacterial culture</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Persistence of cloudy dialysis effluent after 72 hours of appropriate antibiotic treatment</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Peritonitis with the same pathogen or a negative culture within 14 days after completion of treatment</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 60</LI>
<LI>Enrolled/randomised: 60</LI>
<LI>Analysed: 60</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:47:31 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Lye-1995">
<CHAR_METHODS MODIFIED="2014-02-17 14:06:02 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi-RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period:14 days following completion of antibiotic treatment</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 14:06:58 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Singapore</LI>
<LI>Setting: teaching hospital, university</LI>
<LI>Inclusion criteria: new episode of CAPD peritonitis</LI>
<LI>Number: treatment group (37); control group (36)</LI>
<LI>Mean age ± SD (years): treatment group (59.6 ± 13.1); control group (56.6 ± 11.7)</LI>
<LI>Sex (M/F): treatment group (16/12); control group (14/22)</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:47:18 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Gentamicin: 40 mg IP/d</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Gentamicin: 10 mg/2 L dialysate IP 4 times/d</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Vancomycin 1 g</LI>
<LI>Antibiotics modified after 72 hours according to culture results</LI>
<LI>Total of 14 days of antibiotic therapy</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 14:11:00 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:47:31 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Cloudy peritoneal effluent; dialysate WCC &gt; 100/mL with &gt; 50% polymorphonuclear neutrophils</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Resolution of symptoms and signs of peritonitis; clearing of peritoneal fluid; negative bacterial culture</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Persistence of infection despite adequate antibiotic treatment</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Infection occurring within 14 days of stopping treatment</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 100 episodes</LI>
<LI>Enrolled/randomised: 100</LI>
<LI>Analysed: 100</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:47:42 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Merchant-1992">
<CHAR_METHODS MODIFIED="2014-02-17 14:19:10 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: UK</LI>
<LI>Study design: parallel RCT</LI>
<LI>Follow-up period: 14 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 14:20:24 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: UK</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: CAPD-associated peritonitis</LI>
<LI>Number: treatment group (30); control group (30)</LI>
<LI>Mean age ± SD (years): treatment group (49.4 ± 3.0); control group (55.0 ± 2.5)</LI>
<LI>Sex (M/F): treatment group (17/13); control group (16/14)</LI>
<LI>Exclusion criteria: peritonitis in the preceding 3 months; previous episode of peritonitis during the study period; suspected of having gram negative peritonitis; an episode of peritonitis within the previous 4 weeks No organisms on gram stain</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:47:42 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Imipenem: 1 g IP to alternate exchanges; changed mid-study to 0.5 g IP to alternate exchanges</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 500 mg IP loading dose then 100 mg/d IP</LI>
<LI>Netilmicin: 100 mg (if &gt; 60 kg) or 60 mg (if &lt; 60 kg) IP loading dose then 50 mg/d (if &gt; 60 kg) or 40 mg/d (if &lt; 60 kg) IP</LI>
</UL>
<P>Antibiotics continued for 5 days beyond total clearing of dialysate and a decrease in the dialysate WCC to &lt; 100/mm³</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 14:24:17 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Peritonitis relapse</LI>
<LI>Catheter removal</LI>
<LI>Adverse effects (convulsions)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:07:51 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Dialysate WCC &gt; 100/mm³ with &gt; 50% polymorphonuclear neutrophils</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Clearing of peritoneal fluid; decrease in the dialysate WCC to &lt; 100/mm³</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Insufficient lessening of symptoms and signs to qualify as improvement</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Return of peritonitis with the same organism within 14 days of stopping treatment, or no growth for an initially culture negative episode</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 60</LI>
<LI>Enrolled/randomised: 60</LI>
<LI>Analysed: 56</LI>
<LI>Per cent followed: 93.3%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 15:56:30 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Raman-1985">
<CHAR_METHODS MODIFIED="2014-02-17 14:26:30 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: quasi-RCT</LI>
<LI>Time frame: 1 September 1982 to 31 August 1983 (12 months)</LI>
<LI>Follow-up period: every patient was reviewed 10 days after starting treatment, i.e. 3 days after stopping antibiotics, to confirm resolution of peritonitis</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 14:29:02 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: UK</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: all patients treated by CAPD in the Wessex Region developing peritonitis</LI>
<LI>Number: treatment group (29); control group (29)</LI>
<LI>Mean age ± SD (years): treatment group (53.3 ± 10); control group (46.2 ± 11.5)</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: interference with treatment protocol</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 14:29:27 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Initial IM injection of 750 mg of cefuroxime followed by 375 mg IP added to each CAPD bag for 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Initial IM injection of 500 mg of cephradine followed by oral cephradine 500 mg 4 times/d for 7 days</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>4 rapid 2 L lavage cycles within 1 hour while in the hospital</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 14:29:58 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment failure</LI>
<LI>Successful treatment/complete cure</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-05 15:56:30 +1100" MODIFIED_BY="Narelle Willis">
<P>Exclusions post treatment allocation but pre-intervention</P>
<UL>
<LI>Peritonitis occurring 5 days within catheter insertion (2); post kidney transplantation (1); septicaemia (1); tunnel abscess (1); recurrent gram negative peritonitis (1); non-compliance (1)</LI>
</UL>
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain and cloudy peritoneal dialysate with white blood cells in the CAPD fluid determined by light microscopy</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 14:41:40 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Tapson-1990">
<CHAR_METHODS MODIFIED="2014-02-17 14:36:13 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: December 1988 to March 1990</LI>
<LI>Follow-up period: 28 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 14:40:04 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: UK</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: CAPD therapy; cloudy dialysate attributed to peritonitis</LI>
<LI>Number: treatment group (25); control group (25)</LI>
<LI>Mean age, range (years): treatment group (58.8, 30 to 76); control group (55.3, 30 to 76)</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: vomiting; chronic liver disease; history of convulsions; allergy to compounds of the nalidixic acid/ quinolone class; pregnancy; co-existing antibiotic therapy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 14:41:02 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Ciprofloxacin: 500 mg (if &gt;70 kg) or 250 mg (if &lt; 70 kg) PO four times/d at the time of each dialysis exchange</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 30 mg/2 L dialysate bag</LI>
<LI>Netilmicin: 30 mg to alternate 2 L dialysate bags</LI>
</UL>
<P>Antibiotics modified after 48 hours if appropriate according to sensitivity results</P>
<P>Co-interventions</P>
<UL>
<LI>3 x 2 L dialysate flush exchanges after the diagnosis of peritonitis was established</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 14:41:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Microbiological eradication</LI>
<LI>Relapse</LI>
<LI>Nausea</LI>
<LI>Other side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:41:40 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Dialysate WCC &gt; 100/µL with or without other symptoms and signs</LI>
</UL>
<P>Definition of cure: NS</P>
<P>Definition of treatment failure: NS</P>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 25</LI>
<LI>Enrolled/randomised: 25</LI>
<LI>Analysed: 25</LI>
<LI>Per cent followed: 25%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tong-2005a">
<CHAR_METHODS MODIFIED="2014-02-17 14:42:32 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: March 2000 to July 2003</LI>
<LI>Follow-up period: 28 days</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 14:44:05 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: China</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: resistant PD-associated peritonitis</LI>
<LI>Number: treatment group (44); control group (44)</LI>
<LI>Mean age ± SD (years): treatment group (57.3 ± 13.); control group (58.5 ± 12.8)</LI>
<LI>Sex (M/F): treatment group (23/21); control group (18/26)</LI>
<LI>Exclusion criteria: fungal or mycobacterial peritonitis; surgical cause of acute peritonitis; allergy to urokinase</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:48:12 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Urokinase: 60,000 IU/20 mL normal saline IP, 2 hour dwell period; repeated in 2 days if required</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo: 20 mL normal saline</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Antibiotics</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 14:44:49 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
<LI>Catheter removal</LI>
<LI>Death</LI>
<LI>Length of hospitalisation</LI>
<LI>Side effects attributable to urokinase</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 14:45:06 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>2 of the following: generalised abdominal pain and/ or cloudy dialysate; dialysate WCC &gt; 100/mL and predominant polymorphs; positive gram stain or culture</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Disappearance of symptoms and signs and clearing of dialysate</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Cessation of PD and initiation of haemodialysis</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 95</LI>
<LI>Enrolled/randomised: 88</LI>
<LI>Analysed: 88</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-05 15:56:53 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Vargemezis-1989">
<CHAR_METHODS MODIFIED="2014-03-05 15:56:53 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 14:56:36 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Greece</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: patients who presented with probable CAPD-associated gram-positive peritonitis: identification of gram-positive organisms on gram stain, or any two of abdominal pain, a cloudy effluent, or &gt; 100 WBC/mL dialysate</LI>
<LI>Number: 35; treatment group (40 peritonitis episodes); control group (20 peritonitis episodes)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): 20/15</LI>
<LI>Exclusion criteria: suspected of having gram-negative peritonitis, and episode of peritonitis within the previous 4 weeks, or no organisms on gram stain</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 14:59:19 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Vancomycin IP: A loading dose of 1 g was administered into the first CAPD exchange followed by 30 mg/L into each CAPD exchange for a 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin IV: 2 x 1 g IV doses administered, the first at admission and the second 7 days later</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 14:59:47 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment failure</LI>
<LI>Complete cure</LI>
<LI>Relapse</LI>
<LI>Adverse effects (antibiotic toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:02:11 +1100" MODIFIED_BY="[Empty name]">
<P>Definition of peritonitis</P>
<UL>
<LI>Identification of gram-positive organisms on gram stain, OR any two of the following: abdominal pain; cloudy effluent; &gt; 100 WBC/mL dialysate</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Disappearance of physical symptoms, clearing of dialysate and eradication of the organisms</LI>
</UL>
<P>Adverse effects</P>
<UL>
<LI>2/20 (10%) of patients treated by IV infusion developed allergic reaction with flush and fever at the end of the infusion dose</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Recurrence of peritonitis 2 weeks after administration of the second dose of vancomycin</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-15 19:45:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Velasquez_x002d_Jones-1995">
<CHAR_METHODS MODIFIED="2014-02-17 15:03:52 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel quasi-RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-15 19:45:32 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Mexico</LI>
<LI>Setting: NS</LI>
<LI>Inclusion criteria: new episode of CAPD-associated peritonitis in paediatric patients</LI>
<LI>Number: treatment group (21); control group (10)</LI>
<LI>Age range: 8 to 17 years</LI>
<LI>Sex (M/F): 11/10</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:06:51 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Vancomycin: 30 mg/kg IP for 6 hours day 1 and day 7</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 500 mg/L for 6 hours loading dose then 15 mg/L/exchange for 10 days</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Amikacin: 7.5 mg/kg IP for 6 hours then 20 mg/L/exchange for 10 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 15:07:03 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:08:26 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain; cloudy dialysate; dialysate WCC &gt; 100/mm³, with &gt; 50% polymorphonuclear neutrophils</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Resolution of abdominal pain; clearing of dialysate, with &lt; 100/mm³ leukocytes; negative repeat dialysate culture</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Ongoing symptoms, particularly abdominal pain; failure of dialysate to clear; dialysate WCC &gt; 50% of that at presentation</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:14:20 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Wale-1992">
<CHAR_METHODS MODIFIED="2014-02-17 15:10:17 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 15:12:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: UK</LI>
<LI>Setting: university teaching hospital</LI>
<LI>Inclusion criteria: CAPD therapy; cloudy dialysate attributed to peritonitis</LI>
<LI>Number: treatment group (30); control group (30)</LI>
<LI>Age (years): treatment group (51.3); control group (54.7)</LI>
<LI>Sex (M/F): treatment group (19/11); control group (15/15)</LI>
<LI>Exclusion criteria: &lt; 18 years; allergic to a study medication; pregnant or lactating; received antibiotic therapy in the previous 48 hours; declined to give informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:13:39 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Cefuroxime: 125 mg/L IP added to each exchange</LI>
<UL>
<LI>Continued for a minimum of 10 days and 5 days beyond clearing of dialysate</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Teicoplanin: 20 mg/L added to each exchange</LI>
<UL>
<LI>Continued for a minimum of 10 days and 5 days beyond clearing of dialysate</LI>
</UL>
<LI>Aztreonam: 250 mg/L added to each exchange</LI>
<UL>
<LI>Continued for a minimum of 10 days and 5 days beyond clearing of dialysate</LI>
</UL>
</UL>
<P>Antibiotics modified after 48 hours if appropriate according to sensitivity results</P>
<P>Co-interventions</P>
<UL>
<LI>IV loading dose of 750 mg cefuroxime (treatment group) or 400 mg teicoplanin plus 2 g aztreonam (control group) if the patient had systemic signs suggestive of bacteraemia</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 15:13:59 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
<LI>All-cause mortality</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:14:20 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of cure</P>
<UL>
<LI>Full recovery equated to complete cure; "Improved" was defined as sufficient recovery to allow discontinuation of antibiotics</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Change of antibiotics or tube required</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>infection with indistinguishable organism occurring between 1 week and 6 months after end of antibiotic course</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 60</LI>
<LI>Enrolled/randomised: 60</LI>
<LI>Analysed: 60</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:48:48 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Were-1992">
<CHAR_METHODS MODIFIED="2014-02-17 15:16:24 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 6 months</LI>
<LI>Follow-up period: 14 days after completion of antibiotic therapy</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 15:16:51 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: UK</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: CAPD therapy; peritonitis</LI>
<LI>Number: treatment group (10); control group (10)</LI>
<LI>Mean age ± SD (years): NS</LI>
<LI>Sex (M/F): NS</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:48:48 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Cefuroxime: 40 mg/L IP added to each exchange, continued for 5 days beyond clearing of dialysate</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 50 mg IP daily added to alternate bags (1st and 3rd exchanges), continued for 5 days beyond clearing of dialysate</LI>
<LI>Netilmicin: 50 mg (if &gt; 60 kg) or 30 mg (if &lt; 60 kg) IP day 1 then 25 mg (if &gt; 60 kg) or 20 mg (if &lt; 60 kg) IP added to alternate bags (1st and 3rd exchanges), continued for 5 days beyond clearing of dialysate</LI>
<LI>Vancomycin or netilmicin ceased as soon as an organism was isolated and sensitivities available</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Heparin 500 µ/L added to the dialysate fluid when indicated</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 15:18:52 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Catheter removal</LI>
<LI>Ototoxicity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:19:25 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Cloudy dialysate effluent; WCC &gt; 100/mm³ and &gt; 50% polymorphonuclear cells</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Disappearance of clinical symptoms and signs; dialysate WCC &lt; 100/mm³ for a period of at least 14 days</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Persistence of symptoms and signs after 72 hours of treatment, or catheter removal</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Peritonitis with the same organism within 14 days of stopping antibiotics</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 20</LI>
<LI>Enrolled/randomised: 20</LI>
<LI>Analysed: 20</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:49:10 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Williams-1989">
<CHAR_METHODS MODIFIED="2014-02-17 15:20:14 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 to 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 15:21:37 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: UK</LI>
<LI>Setting: multicentre</LI>
<LI>Inclusion criteria: Adults; CAPD therapy; second recurrence of peritonitis</LI>
<LI>Number: treatment group (17); control group (20)</LI>
<LI>Mean age ± SD (years): treatment group (52.1 ± 4.2); control group (54.1 ± 4.0)</LI>
<LI>Sex (M/F): treatment group (10/7); control group (11/9)</LI>
<LI>Exclusion criteria: NS</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:49:10 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Urokinase injection: 5000 IU/2 mL saline into the Tenckhoff catheter; remained in the catheter for 2 hours; performed on the second and fourth days following recurrence of peritonitis</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Catheter removal and replacement usually within 5 days of recurrence of peritonitis</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>10 days of appropriate IP antibiotics</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 15:22:37 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Recurrence of peritonitis</LI>
<LI>Catheter removal and replacement</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:23:03 +1100" MODIFIED_BY="Ann Jones">
<P>Definition of peritonitis</P>
<UL>
<LI>Abdominal pain or pyrexia; dialysate WCC &gt; 10&#8309;/L</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Clearing of peritoneal fluid by day 10; clinical improvement</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Recurrence of peritonitis (reappearance of peritonitis within 3 weeks of finishing IP antibiotic treatment)</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 37</LI>
<LI>Enrolled/randomised: 37</LI>
<LI>Analysed: 37</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-17 15:49:30 +1100" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Wong-2001">
<CHAR_METHODS MODIFIED="2014-02-17 15:23:59 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 1 January 1998 to 30 June 2000</LI>
<LI>Follow-up period: 28 days from completion of antibiotics</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 15:26:33 +1100" MODIFIED_BY="Ann Jones">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: teaching hospital</LI>
<LI>Inclusion criteria: &#8805; 18 years; CAPD therapy for &gt; 4 weeks before the onset of peritonitis</LI>
<LI>Number: treatment group (39); control group (34)</LI>
<LI>Mean age ± SD (years): treatment group (58 ± 14); control group (59 ± 10)</LI>
<LI>Sex (M/F): treatment group (23/16); control group (18/16)</LI>
<LI>Exclusion criteria: completion of antibiotic therapy for peritonitis within 28 days; active exit site infection, tunnel infection and/or subcutaneous leakage; signs and symptoms of septicaemia with oral temperature &gt; 38.5°C and/ or systolic blood pressure &lt; 100 mm Hg; known history of hypersensitivity to cefepime, vancomycin or netilmicin; known history of aminoglycoside ototoxicity; current antibiotic therapy for any reason; known history of cirrhosis, diverticulosis, and malignancy; peritonitis attributed to other surgical cause suspected on clinical grounds; inability to administer IP drugs; presence of peritonitis attributed to fungus or mycobacterial infection; pregnancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-17 15:49:30 +1100" MODIFIED_BY="Ann Jones">
<P>Treatment group</P>
<UL>
<LI>Cefepime: 2 g IP loading dose, 1 g IP daily for 10 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vancomycin: 1 g IP day 1 and day 7</LI>
<UL>
<LI>Vancomycin ceased day 5 if gram negative bacteria isolated</LI>
</UL>
<LI>Netilmicin: 80 mg IP loading dose, 40 mg IP daily for 10 days</LI>
<UL>
<LI>Netilmicin ceased day 5 if gram positive bacteria isolated</LI>
</UL>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Antibiotics changed if no clinical improvement; antibiotics continued if clinical improvement, even if isolated bacteria was resistant</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-17 15:27:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment failure</LI>
<LI>Relapse</LI>
<LI>Death due to peritonitis</LI>
<LI>Hospitalisation rate</LI>
<LI>Duration of hospitalisation</LI>
<LI>Side effects of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-17 15:28:46 +1100" MODIFIED_BY="Ann Jones">
<P>Exclusions post randomisation but pre-intervention</P>
<UL>
<LI>Fungal peritonitis (6); incorrect diagnosis (2)</LI>
</UL>
<P>Definition of peritonitis</P>
<UL>
<LI>Signs and symptoms of peritoneal inflammation; dialysate WCC &gt; 100/mL, and &gt; 50% polymorphonuclear cells, and bacteria on gram stain or culture</LI>
</UL>
<P>Definition of cure</P>
<UL>
<LI>Clearing of peritoneal fluid by day 10; clinical improvement</LI>
</UL>
<P>Definition of treatment failure</P>
<UL>
<LI>Modification of treatment required because of persistence of signs and symptoms of peritonitis at days 5 through to 10; dialysate WCC &gt; 100 on day 10</LI>
</UL>
<P>Definition of relapse</P>
<UL>
<LI>Dialysate cleared on day 10 but peritonitis due to the same organism occurred within 28 days of completion of antibiotic treatment</LI>
</UL>
<P>Completeness of follow-up</P>
<UL>
<LI>Eligible/considered for inclusion: 81</LI>
<LI>Enrolled/randomised: 81</LI>
<LI>Analysed: 73</LI>
<LI>Per cent followed: 90.1%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CAPD - continuous ambulatory peritoneal dialysis; CCPD - continuous cyclic peritoneal dialysis; IP - intraperitoneal; IV - intravenous; NS - not stated; PD - peritoneal dialysis; WCC - white cell count</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-04-15 19:34:00 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:10:49 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Wali-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:10:49 +1100" MODIFIED_BY="[Empty name]">
<P>Results reported according to individual agents used rather than allocated treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 12:18:48 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albin-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 12:18:48 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:07:56 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Artic-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:07:56 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:08:15 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bannister-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:08:15 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:08:23 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:08:23 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:08:35 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cavdar-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:08:35 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:58:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Celik-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:58:34 +1000" MODIFIED_BY="[Empty name]">
<P>Letter, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:58:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chadwick-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:58:39 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective study, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:58:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaimovitz-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:58:43 +1000" MODIFIED_BY="[Empty name]">
<P>Review article, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:10:09 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Danielsson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:10:09 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:10:32 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Fijter-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:10:32 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:58:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Groc-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:58:49 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:58:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dratwa-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:58:52 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:58:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dryden-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:58:55 +1000" MODIFIED_BY="[Empty name]">
<P>Letter, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-09 16:15:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Durand-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-09 16:15:31 +1000" MODIFIED_BY="[Empty name]">
<P>Considered peritonitis prevention rather than treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:58:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ersoy-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:58:59 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-09 16:15:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fabbri-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-09 16:15:37 +1000" MODIFIED_BY="[Empty name]">
<P>Considered peritonitis prevention rather than treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:11:36 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flanigan-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:11:36 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goffin-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:05 +1000" MODIFIED_BY="[Empty name]">
<P>Letter, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:11:55 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenbaum-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:11:55 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guest-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:08 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hancock-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:11 +1000" MODIFIED_BY="[Empty name]">
<P>Letter, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-12 07:37:54 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN39675087">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-12 07:37:54 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:12:47 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keller-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:12:47 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:12:57 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klaus-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:12:57 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lai-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levesque-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:20 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective study, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:24 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:13:38 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McIntosh-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:13:38 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:13:53 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mylotte-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:13:53 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:14:13 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plum-1997a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:14:13 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:14:05 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Posthuma-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:14:05 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:14:26 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qamar-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:14:26 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-15 19:34:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ranganathan-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-15 19:34:00 +1000" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-09 16:15:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Read-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-09 16:15:48 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective control, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:14:51 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Restrepo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:14:51 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:14:59 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:14:59 +1100" MODIFIED_BY="[Empty name]">
<P>Considers peritonitis prevention rather than treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:15:14 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sit-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:15:14 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:15:22 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stegmayr-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:15:22 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:15:29 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:15:29 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:15:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thomae-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:15:40 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:15:45 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Muelen-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:15:45 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-05 15:05:28 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Varghese-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-05 15:05:28 +1100" MODIFIED_BY="Narelle Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-09 16:15:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-09 16:15:55 +1000" MODIFIED_BY="[Empty name]">
<P>Considered exit site infections rather than peritonitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:15:57 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warady-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:15:57 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:16:03 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watkins-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:16:03 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-11 13:16:13 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wong-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-11 13:16:13 +1100" MODIFIED_BY="[Empty name]">
<P>Not appropriate population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yudis-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:31 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zacherle-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:35 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:59:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:59:40 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-01-09 09:33:41 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-04-15 19:46:20 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-04-15 19:46:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN74962920">
<CHAR_STUDY_NAME MODIFIED="2012-01-11 12:20:03 +1100" MODIFIED_BY="Suetonia Palmer">
<P>A single centre randomised study to assess the need for performing a line change when a peritoneal dialysis patient presents with peritonitis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-02-17 15:50:07 +1100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-15 19:46:18 +1000" MODIFIED_BY="[Empty name]">
<P>Details not provided at time of registration</P>
<P>Target number of participants: 40-50 patients and 40-50 control patients, total 100</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-12 07:39:34 +1100" MODIFIED_BY="[Empty name]">
<P>Antibiotics and no line change compared to antibiotics and a line change</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-15 19:46:20 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure(s): To evaluate whether recurrence of peritonitis is more common in patients who present with peritonitis and receive antibiotics and no line change compared to patients who receive antibiotics and a line change</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-01-12 07:45:35 +1100" MODIFIED_BY="[Empty name]">
<P>01/06/2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-02-11 10:09:05 +1100" MODIFIED_BY="[Empty name]">
<P>Ms Patricia Thorn</P>
<P>Renal Unit<BR/>Churchill Hospital<BR/>Headington</P>
<P>Oxford</P>
<P>UK</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-29 09:18:01 +1100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-03-05 15:30:35 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-NCT01785641">
<CHAR_STUDY_NAME MODIFIED="2014-03-05 15:21:26 +1100" MODIFIED_BY="Narelle Willis">
<P>Single versus combined antibiotic therapy for bacterial peritonitis in continuous ambulatory peritoneal dialysis patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-05 15:23:23 +1100" MODIFIED_BY="Narelle Willis">
<P>Parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-05 15:30:35 +1100" MODIFIED_BY="Narelle Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Age &#8805; 18 years old</LI>
<LI>ESRD patients on continuous ambulatory peritoneal dialysis more than 4 weeks</LI>
<LI>Presence of symptom or sign of peritonitis</LI>
<LI>Presence of WBC &gt; 100 cell/mm³ with PMN &gt;50% in peritoneal dialysate or gram stain positive for gram positive or gram negative bacteria</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Presence of polymicrobial organism, non-fermentative gram negative organism, fungus, mycobacteria in peritoneal fluid or culture-negative</LI>
<LI>Peritonitis from the organisms that required combined antibiotic therapy according to ISPD guideline 2010</LI>
<LI>Hospital-acquired peritonitis</LI>
<LI>Presence of catheter-related infection</LI>
<LI>History of peritonitis within 4 weeks</LI>
<LI>Currently taking antibiotic</LI>
<LI>Allergic to the antibiotic that used in the study(penicillin or cephalosporin or quinolone or aminoglycoside)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-05 15:27:12 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group 1</P>
<UL>
<LI>Ceftazidime+ciprofloxacin</LI>
<LI>2 synergistic antibiotics: ceftazidime IP + ciprofloxacin orally for gram negative bacterial peritonitis</LI>
</UL>
<P>Control group 1</P>
<UL>
<LI>Ceftazidime monotherapy</LI>
<LI>Ceftazidime IP for gram negative bacterial peritonitis</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Cefazolin+gentamicin</LI>
<LI>Cefazolin IP + gentamicin IP for gram positive bacterial peritonitis</LI>
</UL>
<P>Control group 2</P>
<UL>
<LI>Cefazolin monotherapy</LI>
<LI>Cefazolin IP for gram positive bacterial peritonitis</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-05 15:28:07 +1100" MODIFIED_BY="Narelle Willis">
<P>Relapse or recurrent rate</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-03-05 15:28:13 +1100" MODIFIED_BY="Narelle Willis">
<P>December 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-03-05 15:29:32 +1100" MODIFIED_BY="Narelle Willis">
<P>Nalinee Saiprasertkit, MD</P>
<P>Chulalongkorn University</P>
<P>Thailand</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-05-09 16:05:25 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:57:32 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altmann-1984">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:08:05 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailie-1987">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:04:22 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1987">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:20:31 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:24:54 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boeschoten-1985">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...patients were randomized according to their date of catheter implantation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:16:58 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowley-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:26:16 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyce-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:30:56 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chan-1990">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...antibiotic regimens were given code numbers....(which) were then randomly arranged in a table."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:35:32 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-1991">
<DESCRIPTION>
<P>Quote from Methods section of paper: "Patients...were randomised...by referring to a table of random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:38:07 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:47:35 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:48:06 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:57:59 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choy-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 22:55:17 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coban-2004">
<DESCRIPTION>
<P>Consecutive allocation to each study arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:58:11 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drinovec-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:55:16 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ejlersen-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:59:38 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Flanigan-1991">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...letters of the alphabet were alternately placed into one of two groups..." with cephazolin and vancomycin each represented by one group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:01:54 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedland-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:05:51 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...randomization was based on consecutive case approach..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:17:17 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gucek-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:19:17 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gucek-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:58:57 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hernandez-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:21:22 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Innes-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:23:58 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jim_x00e9_nez-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:25:07 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khairullah-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 08:45:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klaus-1995a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:29:24 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leung-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:33:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lui-2005">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...randomization was done by computer generated randomization tables."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:35:36 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lupo-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:41:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lye-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:44:55 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lye-1995">
<DESCRIPTION>
<P>Quote from Methods section of paper: "Patients were alternately assigned to" study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 14:48:27 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Merchant-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-09 16:05:25 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raman-1985">
<DESCRIPTION>
<P>Alternate allocation to treatment with either IP cefuroxime or PO cephradine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 21:40:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tapson-1990">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...patients were randomized using a predetermined randomization code, generated by a computer program, in blocks of ten subjects..." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:26:18 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tong-2005a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:59:08 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vargemezis-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:26:50 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Velasquez_x002d_Jones-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:27:10 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wale-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:27:40 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Were-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:28:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 15:09:24 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:52:29 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Fijter-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-04-15 19:29:07 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:57:35 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altmann-1984">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:08:14 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailie-1987">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:04:28 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1987">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:20:44 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:25:04 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boeschoten-1985">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...patients were randomized according to their date of catheter implantation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:17:06 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowley-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:26:28 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyce-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:29:28 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:36:11 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-1991">
<DESCRIPTION>
<P>Quote from Methods section of paper: "Patients...were randomised...by referring to a table of random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:38:15 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:47:29 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:49:59 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>Quote from Methods section of paper: "Randomization was by random selection of sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:58:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choy-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 22:55:05 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coban-2004">
<DESCRIPTION>
<P>Consecutive allocation to each study arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:58:12 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drinovec-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:55:21 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ejlersen-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:00:41 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Flanigan-1991">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...patients were enrolled into treatment groups based upon the first letter of their last name."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:03:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Friedland-1990">
<DESCRIPTION>
<P>Quote from Methods section of paper: "Patients were randomized by selection of a numbered envelope (not previously seen by the attending physicians)..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 08:46:10 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...randomization was based on consecutive case approach..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:17:22 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gucek-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:19:22 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gucek-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:58:58 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hernandez-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:21:26 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Innes-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:24:06 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jim_x00e9_nez-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:26:27 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khairullah-2002">
<DESCRIPTION>
<P>Quote from Methods section of paper: "Patients were... randomised by the (dialysis) nurse.."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-07 22:10:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klaus-1995a">
<DESCRIPTION>
<P>Performed locally with a blocking factor of 4</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:30:13 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leung-2004">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...patients were randomized according to their date of presentation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:33:25 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lui-2005">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...randomization was done by computer generated randomization tables."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:35:45 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lupo-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:41:06 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lye-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:46:15 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lye-1995">
<DESCRIPTION>
<P>Quote from Methods section of paper: "Patients were alternately assigned to" study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 14:48:39 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Merchant-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-09 16:05:26 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raman-1985">
<DESCRIPTION>
<P>Inadequate. Treatment was allocated by alternation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 21:41:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tapson-1990">
<DESCRIPTION>
<P>Quote from Methods section of paper: "...patients were randomized using a predetermined randomization code, generated by a computer program, in blocks of ten subjects..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:26:22 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tong-2005a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 09:59:15 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vargemezis-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-15 19:29:07 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Velasquez_x002d_Jones-1995">
<DESCRIPTION>
<P>Sequential, non-transparent envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:27:14 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wale-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:27:35 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Were-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:27:54 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 15:10:36 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wong-2001">
<DESCRIPTION>
<P>Quote from paper: "Patients were randomized...by drawing sealed envelopes..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:52:34 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Fijter-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-01-11 12:24:07 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-07-18 13:05:46 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-11 12:24:21 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Altmann-1984">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:19:57 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bailie-1987">
<DESCRIPTION>
<P>Comment: different routes of administration of antibiotic loading dose between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:06:24 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennett_x002d_Jones-1987">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:22:13 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennett_x002d_Jones-1990">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:25:20 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boeschoten-1985">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:17:11 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowley-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:26:46 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boyce-1988">
<DESCRIPTION>
<P>Comment: different frequencies of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:31:30 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chan-1990">
<DESCRIPTION>
<P>Comment: different numbers and routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:36:42 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-1991">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:39:45 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1993">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:47:50 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1997">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:48:40 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-12 07:54:38 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choy-2001">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-02-01 22:56:36 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coban-2004">
<DESCRIPTION>
<P>No placebo for IgG used in control arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-10 08:30:16 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Drinovec-1988">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:56:53 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ejlersen-1991">
<DESCRIPTION>
<P>Quote from Results section of paper: "This study was designed as a ...randomized open trial."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:00:52 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flanigan-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:03:49 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Friedland-1990">
<DESCRIPTION>
<P>Comment: different number and dosing frequencies of antibiotics in study arms precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:06:17 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>Comment: no mention of use of placebo in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:18:37 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gucek-1994">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:19:47 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gucek-1997">
<DESCRIPTION>
<P>Comment: different frequencies of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-12 08:02:35 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hernandez-2004">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:22:44 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Innes-1994">
<DESCRIPTION>
<P>Quote from paper: "Double-blind clinical trial"</P>
<P>Comment: placebo used in control arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:24:12 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jim_x00e9_nez-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:26:44 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khairullah-2002">
<DESCRIPTION>
<P>Comment: different dosing regimens between study arms precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-28 06:47:10 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klaus-1995a">
<DESCRIPTION>
<P>Comment: different antibiotic dosing intervals between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:30:50 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leung-2004">
<DESCRIPTION>
<P>Comment: differences in the number of antibiotics administered in study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:34:11 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lui-2005">
<DESCRIPTION>
<P>Quote from Methods section of paper: "This was a...open-labeled study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:35:49 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lupo-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:41:25 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lye-1993">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 22:46:45 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lye-1995">
<DESCRIPTION>
<P>Comment: different antibiotic dosing intervals between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-02 14:49:30 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Merchant-1992">
<DESCRIPTION>
<P>Quote: "...this open, randomized prospective study"</P>
<P>Comment: different antibiotic dosing frequencies between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-12 08:04:06 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raman-1985">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-28 06:47:40 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tapson-1990">
<DESCRIPTION>
<P>Comment: different routes of antibiotic administration between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-04-02 21:44:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tong-2005a">
<DESCRIPTION>
<P>Quote from Methods section of paper: "This study was...a double-blind, randomized, placebo-controlled... trial."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-18 13:05:46 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vargemezis-1989">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-28 06:48:26 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Velasquez_x002d_Jones-1995">
<DESCRIPTION>
<P>Comment: different antibiotic dosing intervals between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-28 06:49:45 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wale-1992">
<DESCRIPTION>
<P>Comment: different number of antibiotics in treatment regimens between study groups precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 21:02:28 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Were-1992">
<DESCRIPTION>
<P>Comment: different number of antibiotics and dosing intervals between study arms precludes blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-29 21:06:19 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Williams-1989">
<DESCRIPTION>
<P>Comment: unblinded comparisons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-02 15:13:00 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wong-2001">
<DESCRIPTION>
<P>Quote from paper: "The study is a prospective, open-label...clinical trial."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-07 21:54:34 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-de-Fijter-2001">
<DESCRIPTION>
<P>Quote from Methods section of paper: "Treatment was not blinded to patients or clinicians."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-06-21 08:45:16 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-11 12:24:37 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Altmann-1984">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:08:50 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailie-1987">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:05:03 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1987">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:21:43 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:23:33 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boeschoten-1985">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:17:19 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowley-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:26:55 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyce-1988">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:31:35 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:37:04 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:38:20 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-01 22:50:24 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:48:12 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-12 07:54:42 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choy-2001">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:51:49 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coban-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-10 08:30:17 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Drinovec-1988">
<DESCRIPTION>
<P>Open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:55:27 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ejlersen-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:01:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flanigan-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:03:54 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedland-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:05:58 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:17:26 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gucek-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:19:28 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gucek-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-12 08:02:40 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hernandez-2004">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:21:31 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Innes-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:24:18 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jim_x00e9_nez-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:27:05 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khairullah-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-21 08:45:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klaus-1995a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:30:55 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leung-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:34:25 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lui-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:35:53 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lupo-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:41:31 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lye-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 22:42:55 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lye-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-02 14:49:41 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Merchant-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-12 08:04:13 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raman-1985">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-28 06:25:45 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tapson-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-28 06:26:27 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tong-2005a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-12 08:05:19 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vargemezis-1989">
<DESCRIPTION>
<P>Unblinded comparison</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-28 06:26:55 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Velasquez_x002d_Jones-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-28 06:27:20 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wale-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-28 06:27:30 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Were-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-28 06:27:50 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1989">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-02 15:13:27 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-07 21:52:39 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Fijter-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-02-17 15:43:36 +1100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-10 09:57:45 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altmann-1984">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:30:55 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailie-1987">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 11:00:26 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1987">
<DESCRIPTION>
<P>5/80 (6.3%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-17 14:17:26 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennett_x002d_Jones-1990">
<DESCRIPTION>
<P>3/51 (5.8%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 11:20:03 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boeschoten-1985">
<DESCRIPTION>
<P>45/106 (42.5%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:31:29 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bowley-1988">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 11:33:16 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boyce-1988">
<DESCRIPTION>
<P>39/90 (43.3%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 12:01:58 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1990">
<DESCRIPTION>
<P>Withdrawal occurred due to 3 episodes of fungal peritonitis in group 1 but only 1 episode in each of groups 2 and 3, indicating possible attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 12:10:44 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-1991">
<DESCRIPTION>
<P>3/46 (6.5%) patients lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-11 12:15:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1993">
<DESCRIPTION>
<P>6/5454 (11.1%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-13 10:45:56 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1997">
<DESCRIPTION>
<P>8/36 (22.2%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-13 10:52:50 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>1/101 patients (1%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-10 09:58:03 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choy-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:32:24 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coban-2004">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-13 11:59:50 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Drinovec-1988">
<DESCRIPTION>
<P>23/54 episodes (43%) were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:32:43 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ejlersen-1991">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:32:57 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flanigan-1991">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:33:09 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Friedland-1990">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:33:23 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-29 20:48:29 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gucek-1994">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:33:41 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gucek-1997">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-10 09:58:59 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hernandez-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:33:55 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Innes-1994">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:34:10 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jim_x00e9_nez-1996">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-17 15:43:36 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khairullah-2002">
<DESCRIPTION>
<P>9/51 (17.6%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-17 11:51:12 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klaus-1995a">
<DESCRIPTION>
<P>98/152 (64.5%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-17 12:04:57 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leung-2004">
<DESCRIPTION>
<P>1/102 (1%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-17 12:17:20 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lui-2005">
<DESCRIPTION>
<P>2/102 (2%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-17 13:56:40 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lupo-1997">
<DESCRIPTION>
<P>8/73 (11.0%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:34:44 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lye-1993">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:35:05 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lye-1995">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-29 20:39:09 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Merchant-1992">
<DESCRIPTION>
<P>4/60 (6.7%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-10 09:04:59 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Raman-1985">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:29:07 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tapson-1990">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:29:31 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tong-2005a">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-10 09:04:50 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vargemezis-1989">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:29:40 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Velasquez_x002d_Jones-1995">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-17 15:15:10 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wale-1992">
<DESCRIPTION>
<P>7/60 (11.7%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:29:56 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Were-1992">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-28 06:30:06 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Williams-1989">
<DESCRIPTION>
<P>All patients followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-21 08:44:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2001">
<DESCRIPTION>
<P>Comment: 8 patients were excluded after randomisation, 5 in group A and 3 in group B. 6 exclusions were due to fungal peritonitis, but the distribution between groups A and B is not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-13 11:22:33 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Fijter-2001">
<DESCRIPTION>
<P>5/98 (5.1%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 07:53:57 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Altmann-1984">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:40:44 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bailie-1987">
<DESCRIPTION>
<P>Selective outcome reporting </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:40:53 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennett_x002d_Jones-1987">
<DESCRIPTION>
<P>Selective outcome reporting </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:40:59 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bennett_x002d_Jones-1990">
<DESCRIPTION>
<P>Selective outcome reporting </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:41:05 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boeschoten-1985">
<DESCRIPTION>
<P>Selective outcome reporting </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:41:37 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bowley-1988">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:43:28 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boyce-1988">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:44:30 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chan-1990">
<DESCRIPTION>
<P>Selective outcome reporting </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:45:00 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1991">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:45:33 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1993">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:40:24 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1997">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:50:20 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 07:54:55 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choy-2001">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:52:09 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coban-2004">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 07:55:15 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Drinovec-1988">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:55:59 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ejlersen-1991">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:01:35 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Flanigan-1991">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:04:29 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Friedland-1990">
<DESCRIPTION>
<P>All important clinical outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:07:08 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:17:56 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gucek-1994">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:20:55 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gucek-1997">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 08:02:49 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hernandez-2004">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:23:03 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Innes-1994">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:24:44 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jim_x00e9_nez-1996">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:27:34 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khairullah-2002">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:51:06 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klaus-1995a">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:31:31 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leung-2004">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:35:02 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lui-2005">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:40:01 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lupo-1997">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 13:05:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lye-1993">
<DESCRIPTION>
<P>All clinically relevant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:47:16 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lye-1995">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-28 06:30:42 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Merchant-1992">
<DESCRIPTION>
<P>All clinically significant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 08:04:55 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raman-1985">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 21:43:00 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tapson-1990">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tong-2005a">
<DESCRIPTION>
<P>All clinically significant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 08:05:27 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vargemezis-1989">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 20:57:01 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Velasquez_x002d_Jones-1995">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 20:58:06 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wale-1992">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 21:03:22 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Were-1992">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 21:04:11 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Williams-1989">
<DESCRIPTION>
<P>Selective outcome reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wong-2001">
<DESCRIPTION>
<P>All clinically significant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:53:28 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Fijter-2001">
<DESCRIPTION>
<P>All important clinical outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-11 10:17:50 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Altmann-1984">
<DESCRIPTION>
<P>Early termination of study and abstract-only publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 22:16:07 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bailie-1987">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 22:18:36 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1987">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 22:29:57 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bennett_x002d_Jones-1990">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 22:35:56 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boeschoten-1985">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 22:37:50 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowley-1988">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:28:17 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boyce-1988">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:33:29 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chan-1990">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:37:50 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1991">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:38:55 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1993">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:46:40 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-1997">
<DESCRIPTION>
<P>Early termination of study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-17 15:37:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-1998">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-10 08:22:05 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choy-2001">
<DESCRIPTION>
<P>Abstract only publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:52:14 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coban-2004">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 08:02:21 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drinovec-1988">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:57:11 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ejlersen-1991">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:01:42 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flanigan-1991">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:04:48 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedland-1990">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:07:15 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gadallah-2000c">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:18:03 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gucek-1994">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:20:01 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gucek-1997">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 11:26:58 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hernandez-2004">
<DESCRIPTION>
<P>Possible translation errors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:23:09 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Innes-1994">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 20:53:57 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jim_x00e9_nez-1996">
<DESCRIPTION>
<P>Published in abstract form only; possible translation errors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:27:39 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khairullah-2002">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 20:52:56 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klaus-1995a">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:31:56 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leung-2004">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:35:07 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lui-2005">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:40:33 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lupo-1997">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:42:30 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lye-1993">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 22:47:22 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lye-1995">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-01 22:08:15 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Merchant-1992">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 08:04:47 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raman-1985">
<DESCRIPTION>
<P>No adverse events extractable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 21:43:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tapson-1990">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tong-2005a">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 11:31:14 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vargemezis-1989">
<DESCRIPTION>
<P>Not included in meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 20:55:42 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Velasquez_x002d_Jones-1995">
<DESCRIPTION>
<P>Possible translation errors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 20:57:49 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wale-1992">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 21:03:30 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Were-1992">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-29 21:06:25 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Williams-1989">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-02 21:49:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2001">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-07 21:53:34 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Fijter-2001">
<DESCRIPTION>
<P>None apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-06-11 18:07:36 +1000" MODIFIED_BY="Narelle S Willis"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-03-03 15:56:14 +1100" MODIFIED_BY="Narelle Willis" NO="1">
<NAME>Intravenous (IV) versus intraperitoneal (IP) antibiotics</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 15:56:14 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="11.96" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="46" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Primary treatment failure</NAME>
<GROUP_LABEL_1>IV</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-10 09:53:19 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8765" O_E="0.0" SE="0.0" STUDY_ID="STD-Bailie-1987" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="4" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin and tobramycin</NAME>
<DICH_DATA CI_END="9.813044137784994" CI_START="1.2632438198641596" EFFECT_SIZE="3.5208333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9918037522486344" LOG_CI_START="0.10148718222753837" LOG_EFFECT_SIZE="0.5466454672380864" ORDER="8766" O_E="0.0" SE="0.5229763603684907" STUDY_ID="STD-Bennett_x002d_Jones-1987" TOTAL_1="36" TOTAL_2="39" VAR="0.2735042735042735" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 15:56:14 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="47" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>IV</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="92.62160011346378" CI_START="0.2699154405600246" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9667122795130358" LOG_CI_START="-0.5687722708409984" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="8767" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-Bailie-1987" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Hypotension</NAME>
<DICH_DATA CI_END="106.10804192398966" CI_START="0.26106250311144374" EFFECT_SIZE="5.2631578947368425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0257483003090564" LOG_CI_START="-0.5832555022147142" LOG_EFFECT_SIZE="0.721246399047171" ORDER="8768" O_E="0.0" SE="1.5325417483795722" STUDY_ID="STD-Bennett_x002d_Jones-1987" TOTAL_1="37" TOTAL_2="39" VAR="2.348684210526316" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 15:56:14 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Infusion pain</NAME>
<GROUP_LABEL_1>IV</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="8769" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Bailie-1987" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-03-03 15:56:02 +1100" MODIFIED_BY="Narelle Willis" NO="2">
<NAME>Oral versus intraperitoneal (IP) antibiotics (same antibiotic)</NAME>
<DICH_OUTCOME CHI2="0.07366859157967982" CI_END="2.55930012592005" CI_START="0.705213030122356" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3434477275996286" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.4081212180435251" LOG_CI_START="-0.1516796719002851" LOG_EFFECT_SIZE="0.12822077307162" METHOD="MH" MODIFIED="2014-03-03 15:56:02 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.7860683464548862" P_Q="1.0" P_Z="0.3692665193462712" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="41" WEIGHT="100.0" Z="0.8978481521009494">
<NAME>Primary treatment failure</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6746104414217298" CI_START="0.37928140736840954" EFFECT_SIZE="1.1805555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5652113047512454" LOG_CI_START="-0.4210384461851969" LOG_EFFECT_SIZE="0.07208642928302428" ORDER="8773" O_E="0.0" SE="0.5793279857150695" STUDY_ID="STD-Cheng-1997" TOTAL_1="18" TOTAL_2="17" VAR="0.33562091503267977" WEIGHT="32.21761267207241"/>
<DICH_DATA CI_END="3.1251835679030813" CI_START="0.6530228647976504" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.4948755321395932" LOG_CI_START="-0.1850716121681068" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="8772" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Cheng-1993" TOTAL_1="24" TOTAL_2="24" VAR="0.15952380952380954" WEIGHT="67.7823873279276"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.049970748950954644" CI_END="15.346944433737665" CI_START="0.7440775535537238" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.379247973851647" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.1860219206821299" LOG_CI_START="-0.1283817965440123" LOG_EFFECT_SIZE="0.5288200620690588" METHOD="MH" MODIFIED="2014-03-03 15:56:02 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.8231141817179062" P_Q="1.0" P_Z="0.11477418886129562" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="41" WEIGHT="100.0" Z="1.577092733950733">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="33.22482779054145" CI_START="0.48156758255809334" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5214627386046446" LOG_CI_START="-0.31734275594871975" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="8774" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Cheng-1993" TOTAL_1="24" TOTAL_2="24" VAR="1.1666666666666665" WEIGHT="51.0958904109589"/>
<DICH_DATA CI_END="24.66479266218911" CI_START="0.32547517782642" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3920774690361235" LOG_CI_START="-0.48748212704686283" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="8775" O_E="0.0" SE="1.1040626107091993" STUDY_ID="STD-Cheng-1997" TOTAL_1="18" TOTAL_2="17" VAR="1.218954248366013" WEIGHT="48.9041095890411"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0667227259117878" CI_END="2.8292315262982957" CI_START="0.9769432775673208" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6625278103835288" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.4516684888070943" LOG_CI_START="-0.010130651178509203" LOG_EFFECT_SIZE="0.22076891881429256" METHOD="MH" MODIFIED="2014-03-03 15:56:02 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.7961696604031218" P_Q="1.0" P_Z="0.060934403388790775" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="41" WEIGHT="100.0" Z="1.873971137301598">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3829378928201477" CI_START="0.9052782217786982" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.529294024671489" LOG_CI_START="-0.04321792729890015" LOG_EFFECT_SIZE="0.24303804868629444" ORDER="8770" O_E="0.0" SE="0.33629635456727464" STUDY_ID="STD-Cheng-1993" TOTAL_1="24" TOTAL_2="24" VAR="0.11309523809523811" WEIGHT="65.06345543697721"/>
<DICH_DATA CI_END="3.714857767864972" CI_START="0.6146821581908963" EFFECT_SIZE="1.511111111111111" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5699421904212524" LOG_CI_START="-0.21134939255946714" LOG_EFFECT_SIZE="0.17929639893089264" ORDER="8771" O_E="0.0" SE="0.4589345432985839" STUDY_ID="STD-Cheng-1997" TOTAL_1="18" TOTAL_2="17" VAR="0.21062091503267977" WEIGHT="34.936544563022785"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 15:56:02 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Catheter removal</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.61400983214693" CI_START="0.1940427909257189" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3141624788530009" LOG_CI_START="-0.7121024875250384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="8776" O_E="0.0" SE="1.1902380714238083" STUDY_ID="STD-Cheng-1993" TOTAL_1="24" TOTAL_2="24" VAR="1.4166666666666665" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 15:56:02 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Hospitalisation rate</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9531728413643765" CI_START="0.5119874589805663" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.2907406768410487" LOG_CI_START="-0.29074067684104876" LOG_EFFECT_SIZE="0.0" ORDER="8777" O_E="0.0" SE="0.34156502553198664" STUDY_ID="STD-Cheng-1993" TOTAL_1="24" TOTAL_2="24" VAR="0.1166666666666667" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 15:56:02 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
<DICH_DATA CI_END="5.153502458036732" CI_START="0.048510697731429714" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7121024875250384" LOG_CI_START="-1.3141624788530009" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="8778" O_E="0.0" SE="1.1902380714238083" STUDY_ID="STD-Cheng-1993" TOTAL_1="24" TOTAL_2="24" VAR="1.4166666666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-03-05 14:07:27 +1100" MODIFIED_BY="Narelle Willis" NO="3">
<NAME>Oral versus intraperitoneal (IP) antibiotics (different antibiotics)</NAME>
<DICH_OUTCOME CHI2="3.2599255199699946" CI_END="1.3985223751108382" CI_START="0.8008222907057931" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0582853547316848" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.1456694190875488" LOG_CI_START="-0.09646384687265389" LOG_EFFECT_SIZE="0.02460278610744746" METHOD="MH" MODIFIED="2014-03-05 14:07:19 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.8599613830329186" P_Q="0.4943196375133381" P_Z="0.6904106760959536" Q="1.4091461166442283" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="267" TOTAL_2="243" WEIGHT="99.99999999999997" Z="0.3982978092557095">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8361251235403293" CI_END="1.7160935064864256" CI_START="0.8320685303457485" DF="4" EFFECT_SIZE="1.194950794751835" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="40" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.23454094799094755" LOG_CI_START="-0.07984090312594302" LOG_EFFECT_SIZE="0.07735002243250222" MODIFIED="2014-03-04 13:24:14 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.7658668870951185" P_Z="0.33481887840764857" STUDIES="5" TAU2="0.0" TOTAL_1="146" TOTAL_2="158" WEIGHT="59.319022568253246" Z="0.9644529900977136">
<NAME>Oral quinolone versus aminoglycoside/glycopeptide (IP)</NAME>
<DICH_DATA CI_END="3.023278920756713" CI_START="0.8212976713825348" EFFECT_SIZE="1.5757575757575757" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4804782160357716" LOG_CI_START="-0.08549940852194839" LOG_EFFECT_SIZE="0.19748940375691165" ORDER="8779" O_E="0.0" SE="0.3324580582996305" STUDY_ID="STD-Bennett_x002d_Jones-1990" TOTAL_1="22" TOTAL_2="26" VAR="0.11052836052836049" WEIGHT="18.302499167506134"/>
<DICH_DATA CI_END="6.435666974760812" CI_START="0.4717525397902574" EFFECT_SIZE="1.7424242424242424" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.808593562654191" LOG_CI_START="-0.326285753030705" LOG_EFFECT_SIZE="0.241153904811743" ORDER="8780" O_E="0.0" SE="0.6666337277765224" STUDY_ID="STD-Cheng-1991" TOTAL_1="22" TOTAL_2="23" VAR="0.4444005270092226" WEIGHT="4.552076569689023"/>
<DICH_DATA CI_END="1.9140968907643439" CI_START="0.506680635649299" EFFECT_SIZE="0.9848024316109423" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2819639177978103" LOG_CI_START="-0.2952656932845346" LOG_EFFECT_SIZE="-0.006650887743362144" ORDER="8781" O_E="0.0" SE="0.3390675308824267" STUDY_ID="STD-Cheng-1998" TOTAL_1="47" TOTAL_2="54" VAR="0.1149667904987054" WEIGHT="17.5959093733152"/>
<DICH_DATA CI_END="2.7529106241982273" CI_START="0.47445145421675067" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.43979211184824923" LOG_CI_START="-0.3238082178928758" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="8782" O_E="0.0" SE="0.4485426135725302" STUDY_ID="STD-Lye-1993" TOTAL_1="30" TOTAL_2="30" VAR="0.2011904761904762" WEIGHT="10.05487568229085"/>
<DICH_DATA CI_END="2.19205941209886" CI_START="0.3351614803394235" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.34085232079637595" LOG_CI_START="-0.4747459000576024" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="8783" O_E="0.0" SE="0.4790864322059325" STUDY_ID="STD-Tapson-1990" TOTAL_1="25" TOTAL_2="25" VAR="0.22952380952380955" WEIGHT="8.813661775452042"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.022167476666456715" CI_END="1.8145704024045992" CI_START="0.5519117821964559" DF="1" EFFECT_SIZE="1.0007411177282877" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.2587738227888128" LOG_CI_START="-0.2581303345299767" LOG_EFFECT_SIZE="3.217441294180542E-4" MODIFIED="2014-03-04 13:24:27 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.8816424461691056" P_Z="0.9980532135102972" STUDIES="2" TAU2="0.0" TOTAL_1="92" TOTAL_2="56" WEIGHT="21.94263958379432" Z="0.0024399374505616367">
<NAME>Oral quinolone versus cephalosporin (IP)</NAME>
<DICH_DATA CI_END="2.3291323439089724" CI_START="0.4665882886529243" EFFECT_SIZE="1.0424710424710424" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.36719416633477403" LOG_CI_START="-0.3310661661793032" LOG_EFFECT_SIZE="0.01806400007773545" ORDER="8784" O_E="0.0" SE="0.41016157576315976" STUDY_ID="STD-Chan-1990" TOTAL_1="74" TOTAL_2="36" VAR="0.16823251823251822" WEIGHT="12.024698006126107"/>
<DICH_DATA CI_END="2.308009179688051" CI_START="0.3929921451095109" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36323753181468943" LOG_CI_START="-0.40561612995456564" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="8785" O_E="0.0" SE="0.45162844681026676" STUDY_ID="STD-Gucek-1994" TOTAL_1="18" TOTAL_2="20" VAR="0.20396825396825397" WEIGHT="9.917941577668214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4646540309332834" CI_START="0.40399709681221935" DF="0" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.16573505117414566" LOG_CI_START="-0.39362175578781916" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2014-03-05 14:07:19 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="1.0" P_Z="0.4245769539884957" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="18.738337847952405" Z="0.7985059411794897">
<NAME>Oral cephradine versus cefuroxime (IP)</NAME>
<DICH_DATA CI_END="1.4646540309332834" CI_START="0.40399709681221935" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.16573505117414566" LOG_CI_START="-0.39362175578781916" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2011-12-22 11:50:22 +1100" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.3285689572703082" STUDY_ID="STD-Raman-1985" TOTAL_1="29" TOTAL_2="29" VAR="0.10795755968169764" WEIGHT="18.738337847952405"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.332852011797779" CI_END="1.5859938652623113" CI_START="0.6801000091130618" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.038573272435873" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2003015031027206" LOG_CI_START="-0.16742721933445182" LOG_EFFECT_SIZE="0.016437141884134383" METHOD="MH" MODIFIED="2014-03-05 14:07:27 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.7660586570360672" P_Q="0.6875805365207794" P_Z="0.8609089375678842" Q="0.749153055165015" RANDOM="YES" SCALE="196.11" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="249" TOTAL_2="223" WEIGHT="100.0" Z="0.1752172410583594">
<NAME>Primary treatment failure</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.597541579659869" CI_END="1.9377262907228292" CI_START="0.6623605900794681" DF="4" EFFECT_SIZE="1.1329049074550221" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.2872924317324366" LOG_CI_START="-0.17890551562563503" LOG_EFFECT_SIZE="0.05419345805340082" MODIFIED="2014-03-04 13:22:17 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.6272588200020203" P_Z="0.6486241626580755" STUDIES="5" TAU2="0.0" TOTAL_1="146" TOTAL_2="158" WEIGHT="62.217762935784236" Z="0.45567436143499657">
<NAME>Oral quinolone versus aminoglycoside/glycopeptide (IP)</NAME>
<DICH_DATA CI_END="99.16103229177347" CI_START="0.25211516482038504" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9963410392362373" LOG_CI_START="-0.5984010305641998" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="8790" O_E="0.0" SE="1.5241643359811707" STUDY_ID="STD-Tapson-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.3230769230769233" WEIGHT="2.008476336112796"/>
<DICH_DATA CI_END="27.923170541632484" CI_START="0.35228008384068843" EFFECT_SIZE="3.1363636363636362" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.445964728799251" LOG_CI_START="-0.4531119089691529" LOG_EFFECT_SIZE="0.49642640991504905" ORDER="8787" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Cheng-1991" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="3.7494720756696904"/>
<DICH_DATA CI_END="3.094988445096905" CI_START="0.28881668328576693" EFFECT_SIZE="0.9454545454545454" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4906590319538684" LOG_CI_START="-0.5393777236727578" LOG_EFFECT_SIZE="-0.024359345859444693" ORDER="8786" O_E="0.0" SE="0.6050486890192525" STUDY_ID="STD-Bennett_x002d_Jones-1990" TOTAL_1="22" TOTAL_2="26" VAR="0.3660839160839161" WEIGHT="12.745288230308901"/>
<DICH_DATA CI_END="3.3783067448491373" CI_START="0.5262333802246743" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5286990802696782" LOG_CI_START="-0.27882160705307835" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="8789" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Lye-1993" TOTAL_1="30" TOTAL_2="30" VAR="0.22499999999999998" WEIGHT="20.737089008754342"/>
<DICH_DATA CI_END="1.9452069973356152" CI_START="0.33252328377665064" EFFECT_SIZE="0.8042553191489362" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2889658231513217" LOG_CI_START="-0.4781779393483059" LOG_EFFECT_SIZE="-0.0946060580984921" ORDER="8788" O_E="0.0" SE="0.4506240435151497" STUDY_ID="STD-Cheng-1998" TOTAL_1="47" TOTAL_2="54" VAR="0.20306202859394348" WEIGHT="22.97743728493851"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3291323439089724" CI_START="0.4665882886529243" DF="0" EFFECT_SIZE="1.0424710424710424" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.36719416633477403" LOG_CI_START="-0.3310661661793032" LOG_EFFECT_SIZE="0.01806400007773545" MODIFIED="2014-03-04 13:22:33 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="1.0" P_Z="0.9192261367147044" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="36" WEIGHT="27.734501486335418" Z="0.10140856617650248">
<NAME>Oral quinolone versus cephalosporin (IP)</NAME>
<DICH_DATA CI_END="2.3291323439089724" CI_START="0.4665882886529243" EFFECT_SIZE="1.0424710424710424" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.36719416633477403" LOG_CI_START="-0.3310661661793032" LOG_EFFECT_SIZE="0.01806400007773545" ORDER="8791" O_E="0.0" SE="0.41016157576315976" STUDY_ID="STD-Chan-1990" TOTAL_1="74" TOTAL_2="36" VAR="0.16823251823251822" WEIGHT="27.734501486335418"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2813851788805" CI_START="0.15779886857012715" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.3581986158071433" LOG_CI_START="-0.8018961150398559" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-03-05 14:07:27 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="1.0" P_Z="0.4534831371168333" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="10.047735577880353" Z="0.7496207813060897">
<NAME>Oral cephradine versus cefuroxime (IP)</NAME>
<DICH_DATA CI_END="2.2813851788805" CI_START="0.15779886857012715" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3581986158071433" LOG_CI_START="-0.8018961150398559" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2011-12-22 11:51:34 +1100" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.6814453874610599" STUDY_ID="STD-Raman-1985" TOTAL_1="29" TOTAL_2="29" VAR="0.464367816091954" WEIGHT="10.047735577880353"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.065559947168227" CI_END="2.154898612501622" CI_START="0.6356911780363231" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.170405928526507" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" I2="1.6125686995192672" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.3334268415190651" LOG_CI_START="-0.19675381555826316" LOG_EFFECT_SIZE="0.06833651298040104" METHOD="MH" MODIFIED="2014-03-03 16:13:09 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.39720622849536324" P_Q="1.0" P_Z="0.6133826864159209" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.008433992961075807" TOTALS="YES" TOTAL_1="146" TOTAL_2="158" WEIGHT="100.0" Z="0.5052508139734143">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.804912804554734" CI_START="0.8209916893813443" EFFECT_SIZE="2.3636363636363638" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8328225646983041" LOG_CI_START="-0.08566123907311826" LOG_EFFECT_SIZE="0.37358066281259295" ORDER="8792" O_E="0.0" SE="0.5395219329034883" STUDY_ID="STD-Bennett_x002d_Jones-1990" TOTAL_1="22" TOTAL_2="26" VAR="0.29108391608391604" WEIGHT="32.38173891619076"/>
<DICH_DATA CI_END="6.788528809339318" CI_START="0.16100325082334627" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8317756654124154" LOG_CI_START="-0.7931653550216421" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="8793" O_E="0.0" SE="0.9544983989907418" STUDY_ID="STD-Cheng-1991" TOTAL_1="22" TOTAL_2="23" VAR="0.9110671936758894" WEIGHT="10.54801328412814"/>
<DICH_DATA CI_END="5.0393787915372155" CI_START="0.409293479485999" EFFECT_SIZE="1.4361702127659575" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7023770038988435" LOG_CI_START="-0.3879651741082286" LOG_EFFECT_SIZE="0.15720591489530747" ORDER="8794" O_E="0.0" SE="0.6404723926421815" STUDY_ID="STD-Cheng-1998" TOTAL_1="47" TOTAL_2="54" VAR="0.4102048857368007" WEIGHT="23.167725753483616"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="8795" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Lye-1993" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="3.715225696677954"/>
<DICH_DATA CI_END="1.7102905981831071" CI_START="0.190921129188093" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2330699083248472" LOG_CI_START="-0.7191460056974361" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="8796" O_E="0.0" SE="0.5593363414414827" STUDY_ID="STD-Tapson-1990" TOTAL_1="25" TOTAL_2="25" VAR="0.3128571428571429" WEIGHT="30.18729634951953"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3984864430057891" CI_END="2.871838980185089" CI_START="0.48727577485021917" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1829529002943238" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.45816008599592667" LOG_CI_START="-0.31222517924130605" LOG_EFFECT_SIZE="0.07296745337731028" METHOD="MH" MODIFIED="2014-03-03 16:13:09 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.5278723690947491" P_Q="1.0" P_Z="0.7104304242388357" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="66" WEIGHT="100.0" Z="0.3712780789468867">
<NAME>Catheter removal</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.175453940813802" CI_START="0.12753235600238433" EFFECT_SIZE="0.7297297297297297" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6207036973702202" LOG_CI_START="-0.8943796171862356" LOG_EFFECT_SIZE="-0.1368379599080077" ORDER="8797" O_E="0.0" SE="0.8899674387538243" STUDY_ID="STD-Chan-1990" TOTAL_1="74" TOTAL_2="36" VAR="0.792042042042042" WEIGHT="25.854902511997754"/>
<DICH_DATA CI_END="3.9216336868411763" CI_START="0.49979170838333803" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5934670245144897" LOG_CI_START="-0.3012109531580137" LOG_EFFECT_SIZE="0.146128035678238" ORDER="8798" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Lye-1993" TOTAL_1="30" TOTAL_2="30" VAR="0.2761904761904762" WEIGHT="74.14509748800225"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 16:13:09 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="22" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Hospitalisation rate</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6334827909352154" CI_START="0.2973810077398587" EFFECT_SIZE="0.696969696969697" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2131145634571596" LOG_CI_START="-0.5266867711777488" LOG_EFFECT_SIZE="-0.15678610386029457" ORDER="8799" O_E="0.0" SE="0.4345629660402128" STUDY_ID="STD-Cheng-1991" TOTAL_1="22" TOTAL_2="23" VAR="0.1888449714536671" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 16:13:09 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="22" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.456051307841562" CI_START="0.01552437863252912" EFFECT_SIZE="0.36231884057971014" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9271676094276654" LOG_CI_START="-1.8089857735581008" LOG_EFFECT_SIZE="-0.44090908206521773" ORDER="8800" O_E="0.0" SE="1.6072300413435225" STUDY_ID="STD-Cheng-1991" TOTAL_1="22" TOTAL_2="24" VAR="2.583188405797101" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:25:10 +1100" MODIFIED_BY="Narelle Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological eradication</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 13:25:10 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Oral quinolone versus aminoglycoside/glycopeptide (IP)</NAME>
<DICH_DATA CI_END="3.4581352559164484" CI_START="0.46139544840132796" EFFECT_SIZE="1.263157894736842" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5388419755629457" LOG_CI_START="-0.33592669404539166" LOG_EFFECT_SIZE="0.10145764075877704" ORDER="8801" O_E="0.0" SE="0.5138434467026881" STUDY_ID="STD-Tapson-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.2640350877192983" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.604101208293986" CI_END="9.983231200442713" CI_START="1.0665525167189704" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2630722274904556" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" I2="0.0" I2_Q="10.203964088593448" ID="CMP-003.08" LOG_CI_END="0.9992711290028925" LOG_CI_START="0.027982244839104095" LOG_EFFECT_SIZE="0.5136266869209983" METHOD="MH" MODIFIED="2014-03-04 13:26:53 +1100" MODIFIED_BY="Narelle Willis" NO="8" P_CHI2="0.5954952688988724" P_Q="0.3479720970070712" P_Z="0.038182076983740126" Q="4.454539623493436" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="187" TOTAL_2="191" WEIGHT="500.0" Z="2.072894736627149">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.056118233953641496" CI_END="51.99325139054062" CI_START="1.8890532643927307" DF="2" EFFECT_SIZE="9.910500555758656" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="1.715946976826114" LOG_CI_START="0.27624420361040786" LOG_EFFECT_SIZE="0.9960955902182609" MODIFIED="2014-03-04 13:26:53 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.9723309090944375" P_Z="0.006685770890044725" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="81" WEIGHT="100.0" Z="2.712103523460326">
<NAME>Nausea/vomiting (oral quinolone versus aminoglycoside/glycopeptide (IP))</NAME>
<DICH_DATA CI_END="150.92486801003741" CI_START="0.4474114885048664" EFFECT_SIZE="8.217391304347826" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1787608047174105" LOG_CI_START="-0.3492928684061077" LOG_EFFECT_SIZE="0.9147339681556512" ORDER="8802" O_E="0.0" SE="1.4849912416602609" STUDY_ID="STD-Bennett_x002d_Jones-1990" TOTAL_1="22" TOTAL_2="26" VAR="2.205198987807683" WEIGHT="32.43195300066728"/>
<DICH_DATA CI_END="220.96011924822866" CI_START="0.7648439029404385" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.344313895615592" LOG_CI_START="-0.11642719100191873" LOG_EFFECT_SIZE="1.1139433523068367" ORDER="8803" O_E="0.0" SE="1.4454514951439552" STUDY_ID="STD-Lye-1993" TOTAL_1="30" TOTAL_2="30" VAR="2.0893300248138957" WEIGHT="34.23054715162497"/>
<DICH_DATA CI_END="158.84873801621674" CI_START="0.5099190652161856" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2009837688970637" LOG_CI_START="-0.2924987500184138" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="8804" O_E="0.0" SE="1.4646839745484845" STUDY_ID="STD-Tapson-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.1452991452991457" WEIGHT="33.33749984770775"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.259760455310136" CI_START="0.0655318281652329" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Abdominal swelling or pseudo-obstruction</NAME>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" ORDER="8805" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Bennett_x002d_Jones-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" NO="3" P_CHI2="1.0" P_Z="0.49584060533880536" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Hypotension</NAME>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="8806" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Bennett_x002d_Jones-1990" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.29633525231901" CI_START="0.12802943379190032" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.08.04" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" NO="4" P_CHI2="1.0" P_Z="0.49481017826454565" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.68267825417953">
<NAME>Lethargy</NAME>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="8807" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Tapson-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.29633525231901" CI_START="0.12802943379190032" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.08.05" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" NO="5" P_CHI2="1.0" P_Z="0.49481017826454565" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.68267825417953">
<NAME>Myalgia</NAME>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="8808" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Tapson-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-03-04 11:41:09 +1100" MODIFIED_BY="Narelle Willis" NO="4">
<NAME>Any oral versus any intraperitoneal (IP)</NAME>
<DICH_OUTCOME CHI2="3.8200246241667113" CI_END="1.5988467717376496" CI_START="0.7878772391532815" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1223613412559237" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.20380684437319313" LOG_CI_START="-0.10354144559625729" LOG_EFFECT_SIZE="0.0501326993884679" METHOD="MH" MODIFIED="2014-03-04 11:22:43 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.872985358832452" P_Q="0.5129680146437323" P_Z="0.5225668285952658" Q="0.4280080398140799" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="291" TOTAL_2="264" WEIGHT="100.0" Z="0.6393937331418824">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>IP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.332852011797779" CI_END="1.5859938652623113" CI_START="0.6801000091130618" DF="6" EFFECT_SIZE="1.038573272435873" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="34" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.2003015031027206" LOG_CI_START="-0.16742721933445182" LOG_EFFECT_SIZE="0.016437141884134383" MODIFIED="2011-12-22 12:16:14 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7660586570360672" P_Z="0.8609089375678842" STUDIES="7" TAU2="0.0" TOTAL_1="249" TOTAL_2="223" WEIGHT="69.8564475438996" Z="0.1752172410583594">
<NAME>Different</NAME>
<DICH_DATA CI_END="99.16103229177347" CI_START="0.25211516482038504" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9963410392362373" LOG_CI_START="-0.5984010305641998" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-12-22 12:15:17 +1100" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="1.5241643359811707" STUDY_ID="STD-Tapson-1990" TOTAL_1="25" TOTAL_2="25" VAR="2.3230769230769233" WEIGHT="1.403050218168272"/>
<DICH_DATA CI_END="27.923170541632484" CI_START="0.35228008384068843" EFFECT_SIZE="3.1363636363636362" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.445964728799251" LOG_CI_START="-0.4531119089691529" LOG_EFFECT_SIZE="0.49642640991504905" MODIFIED="2011-12-22 12:15:17 +1100" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.115527017606128" STUDY_ID="STD-Cheng-1991" TOTAL_1="22" TOTAL_2="23" VAR="1.2444005270092227" WEIGHT="2.619247993713361"/>
<DICH_DATA CI_END="2.2813851788805" CI_START="0.15779886857012715" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3581986158071433" LOG_CI_START="-0.8018961150398559" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2011-12-22 12:15:42 +1100" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="0.6814453874610599" STUDY_ID="STD-Raman-1985" TOTAL_1="29" TOTAL_2="29" VAR="0.464367816091954" WEIGHT="7.018991133311726"/>
<DICH_DATA CI_END="3.094988445096905" CI_START="0.28881668328576693" EFFECT_SIZE="0.9454545454545454" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4906590319538684" LOG_CI_START="-0.5393777236727578" LOG_EFFECT_SIZE="-0.024359345859444693" MODIFIED="2011-12-22 12:15:17 +1100" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.6050486890192525" STUDY_ID="STD-Bennett_x002d_Jones-1990" TOTAL_1="22" TOTAL_2="26" VAR="0.3660839160839161" WEIGHT="8.903405586924547"/>
<DICH_DATA CI_END="3.3783067448491373" CI_START="0.5262333802246743" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5286990802696782" LOG_CI_START="-0.27882160705307835" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-12-22 12:15:17 +1100" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Lye-1993" TOTAL_1="30" TOTAL_2="30" VAR="0.22499999999999998" WEIGHT="14.486193705532246"/>
<DICH_DATA CI_END="1.9452069973356152" CI_START="0.33252328377665064" EFFECT_SIZE="0.8042553191489362" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2889658231513217" LOG_CI_START="-0.4781779393483059" LOG_EFFECT_SIZE="-0.0946060580984921" MODIFIED="2011-12-22 12:15:17 +1100" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.4506240435151497" STUDY_ID="STD-Cheng-1998" TOTAL_1="47" TOTAL_2="54" VAR="0.20306202859394348" WEIGHT="16.051221423885497"/>
<DICH_DATA CI_END="2.3291323439089724" CI_START="0.4665882886529243" EFFECT_SIZE="1.0424710424710424" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.36719416633477403" LOG_CI_START="-0.3310661661793032" LOG_EFFECT_SIZE="0.01806400007773545" MODIFIED="2011-12-22 12:15:29 +1100" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.41016157576315976" STUDY_ID="STD-Chan-1990" TOTAL_1="74" TOTAL_2="36" VAR="0.16823251823251822" WEIGHT="19.374337482363956"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07366859157967982" CI_END="2.55930012592005" CI_START="0.705213030122356" DF="1" EFFECT_SIZE="1.3434477275996286" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.4081212180435251" LOG_CI_START="-0.1516796719002851" LOG_EFFECT_SIZE="0.12822077307162" MODIFIED="2011-12-22 12:16:41 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7860683464548862" P_Z="0.3692665193462712" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="41" WEIGHT="30.143552456100398" Z="0.8978481521009494">
<NAME>Same</NAME>
<DICH_DATA CI_END="3.6746104414217298" CI_START="0.37928140736840954" EFFECT_SIZE="1.1805555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5652113047512454" LOG_CI_START="-0.4210384461851969" LOG_EFFECT_SIZE="0.07208642928302428" MODIFIED="2011-12-22 12:16:41 +1100" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.5793279857150695" STUDY_ID="STD-Cheng-1997" TOTAL_1="18" TOTAL_2="17" VAR="0.33562091503267977" WEIGHT="9.711532975909396"/>
<DICH_DATA CI_END="3.1251835679030813" CI_START="0.6530228647976504" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.4948755321395932" LOG_CI_START="-0.1850716121681068" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2011-12-22 12:16:41 +1100" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.39940431835899015" STUDY_ID="STD-Cheng-1993" TOTAL_1="24" TOTAL_2="24" VAR="0.15952380952380954" WEIGHT="20.432019480191002"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-03-04 11:41:09 +1100" MODIFIED_BY="Narelle Willis" NO="5">
<NAME>Low versus high dose antibiotic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:14:32 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="7" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.062312639994856" CI_START="1.274222904735756" EFFECT_SIZE="4.380952380952381" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.1778916577664167" LOG_CI_START="0.10524540745685551" LOG_EFFECT_SIZE="0.641568532611636" ORDER="8809" O_E="0.0" SE="0.6300777171164087" STUDY_ID="STD-Merchant-1992" TOTAL_1="7" TOTAL_2="23" VAR="0.39699792960662517" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:14:39 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="7" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="90.22980166621383" CI_START="1.5959250418470132" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.9553500027476491" LOG_CI_START="0.20301248934760063" LOG_EFFECT_SIZE="1.0791812460476249" ORDER="8810" O_E="0.0" SE="1.0293317295817757" STUDY_ID="STD-Merchant-1992" TOTAL_1="7" TOTAL_2="21" VAR="1.0595238095238095" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:14:58 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="7" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Seizures</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.225763228786272" CI_START="0.03206908899315196" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="1.05021587794102" LOG_CI_START="-1.493913377173733" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="8811" O_E="0.0" SE="1.4944341180973264" STUDY_ID="STD-Merchant-1992" TOTAL_1="7" TOTAL_2="23" VAR="2.2333333333333334" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-03-04 14:21:29 +1100" MODIFIED_BY="Narelle Willis" NO="6">
<NAME>Intermittent versus continuous antibiotics</NAME>
<DICH_OUTCOME CHI2="1.6302543244942573" CI_END="1.3272009873028754" CI_START="0.6366989444461112" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9192537558713467" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.12293669608745503" LOG_CI_START="-0.1960658701324033" LOG_EFFECT_SIZE="-0.036564587022474115" METHOD="MH" MODIFIED="2014-02-10 18:15:15 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8033445216334565" P_Q="0.7071341573156058" P_Z="0.6532091671141214" Q="1.3931808704732447" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="171" TOTAL_2="167" WEIGHT="99.99999999999999" Z="0.44930844615361415">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Continuous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.370993947490107" CI_START="0.454610831216262" DF="0" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.13703553751930816" LOG_CI_START="-0.3423602213136036" LOG_EFFECT_SIZE="-0.10266234189714771" NO="1" P_CHI2="1.0" P_Z="0.4012165919031234" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="44.27922167645284" Z="0.8394504497778761">
<NAME>Gentamicin</NAME>
<DICH_DATA CI_END="1.370993947490107" CI_START="0.454610831216262" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.13703553751930816" LOG_CI_START="-0.3423602213136036" LOG_EFFECT_SIZE="-0.10266234189714771" ORDER="8812" O_E="0.0" SE="0.2815994417857306" STUDY_ID="STD-Lye-1995" TOTAL_1="50" TOTAL_2="50" VAR="0.07929824561403508" WEIGHT="44.27922167645284"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23687304644613777" CI_END="2.107284873858069" CI_START="0.18039755871725105" DF="1" EFFECT_SIZE="0.6165622813356214" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.3237232497902162" LOG_CI_START="-0.7437693439714639" LOG_EFFECT_SIZE="-0.21002304709062383" NO="2" P_CHI2="0.6264737690754212" P_Z="0.4405745614516797" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="32" WEIGHT="8.930147091316048" Z="0.7712233520430053">
<NAME>Vancomycin</NAME>
<DICH_DATA CI_END="2.1061100335490566" CI_START="0.13086923076641813" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3234810571224234" LOG_CI_START="-0.8831624503105096" LOG_EFFECT_SIZE="-0.2798406965940431" ORDER="8813" O_E="0.0" SE="0.7087883692477976" STUDY_ID="STD-Boyce-1988" TOTAL_1="30" TOTAL_2="21" VAR="0.5023809523809524" WEIGHT="6.989247063322364"/>
<DICH_DATA CI_END="15.356053493226757" CI_START="0.07879628711463568" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1862796163245504" LOG_CI_START="-1.1034942460081003" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="8814" O_E="0.0" SE="1.3450245012976192" STUDY_ID="STD-Velasquez_x002d_Jones-1995" TOTAL_1="10" TOTAL_2="11" VAR="1.809090909090909" WEIGHT="1.9409000279936832"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8981541823682155" CI_START="0.5260667737208413" DF="0" EFFECT_SIZE="1.2347560975609757" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.4621214863009715" LOG_CI_START="-0.27895912729499245" LOG_EFFECT_SIZE="0.09158117950298951" NO="3" P_CHI2="1.0" P_Z="0.6280903604193089" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="45" WEIGHT="18.529233263640155" Z="0.484416432421799">
<NAME>Tecioplanin/ceftazidime</NAME>
<DICH_DATA CI_END="2.8981541823682146" CI_START="0.5260667737208413" EFFECT_SIZE="1.2347560975609757" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4621214863009714" LOG_CI_START="-0.27895912729499245" LOG_EFFECT_SIZE="0.09158117950298951" ORDER="8815" O_E="0.0" SE="0.4353144208344698" STUDY_ID="STD-Klaus-1995a" TOTAL_1="41" TOTAL_2="45" VAR="0.18949864498644986" WEIGHT="18.529233263640155"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1768094367161557" CI_START="0.5467096129569377" DF="0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="0.3378204114916895" LOG_CI_START="-0.26224328971289" LOG_EFFECT_SIZE="0.037788560889399754" NO="4" P_CHI2="1.0" P_Z="0.8050208154251189" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="28.261397968590945" Z="0.2468545196856416">
<NAME>Vancomycin/ceftazidime</NAME>
<DICH_DATA CI_END="2.1768094367161557" CI_START="0.5467096129569377" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3378204114916895" LOG_CI_START="-0.26224328971289" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="8816" O_E="0.0" SE="0.3524803884507963" STUDY_ID="STD-Klaus-1995a" TOTAL_1="40" TOTAL_2="40" VAR="0.12424242424242427" WEIGHT="28.261397968590945"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1682636671908555" CI_END="1.6152907492919095" CI_START="0.7675418034215933" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.113464491917784" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.20825070589198696" LOG_CI_START="-0.11489796177792048" LOG_EFFECT_SIZE="0.04667637205703326" METHOD="MH" MODIFIED="2014-02-10 18:15:25 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.5300722291401604" P_Q="0.532517658795341" P_Z="0.5712552229448955" Q="3.153233134851124" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="264" TOTAL_2="258" WEIGHT="99.99999999999999" Z="0.5662038393686137">
<NAME>Primary treatment failure</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Continuous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7337064972741856" CI_START="0.2563550665255167" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.23897557676004264" LOG_CI_START="-0.5911580948714051" LOG_EFFECT_SIZE="-0.17609125905568127" NO="1" P_CHI2="1.0" P_Z="0.40568517983629726" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="15.153350877514917" Z="0.8315107254068246">
<NAME>Gentamicin</NAME>
<DICH_DATA CI_END="1.7337064972741856" CI_START="0.2563550665255167" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.23897557676004264" LOG_CI_START="-0.5911580948714051" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="8817" O_E="0.0" SE="0.4876246279442598" STUDY_ID="STD-Lye-1995" TOTAL_1="50" TOTAL_2="50" VAR="0.23777777777777778" WEIGHT="15.153350877514917"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.356053493226757" CI_START="0.07879628711463568" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="1.1862796163245504" LOG_CI_START="-1.1034942460081003" LOG_EFFECT_SIZE="0.04139268515822508" NO="2" P_CHI2="1.0" P_Z="0.9435081469333824" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="32" WEIGHT="1.9916799534154168" Z="0.07086129636476804">
<NAME>Vancomycin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8818" O_E="0.0" SE="0.0" STUDY_ID="STD-Boyce-1988" TOTAL_1="30" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.356053493226757" CI_START="0.07879628711463568" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1862796163245504" LOG_CI_START="-1.1034942460081003" LOG_EFFECT_SIZE="0.04139268515822508" ORDER="8819" O_E="0.0" SE="1.3450245012976192" STUDY_ID="STD-Velasquez_x002d_Jones-1995" TOTAL_1="10" TOTAL_2="11" VAR="1.809090909090909" WEIGHT="1.9916799534154168"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="37.69193322804368" CI_START="0.5113625084256107" DF="0" EFFECT_SIZE="4.390243902439025" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="1.5762484130861099" LOG_CI_START="-0.29127111631896857" LOG_EFFECT_SIZE="0.6424886483835706" NO="3" P_CHI2="1.0" P_Z="0.17747023283885935" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="45" WEIGHT="2.9941560770029474" Z="1.3485852131450193">
<NAME>Teicoplanin/ceftazidime</NAME>
<DICH_DATA CI_END="37.69193322804368" CI_START="0.5113625084256107" EFFECT_SIZE="4.390243902439025" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5762484130861099" LOG_CI_START="-0.29127111631896857" LOG_EFFECT_SIZE="0.6424886483835706" ORDER="8820" O_E="0.0" SE="1.096990215943305" STUDY_ID="STD-Klaus-1995a" TOTAL_1="41" TOTAL_2="45" VAR="1.2033875338753388" WEIGHT="2.9941560770029474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.471918064467685" CI_START="0.5724612935869455" DF="0" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-006.02.04" LOG_CI_END="0.650493837705839" LOG_CI_START="-0.2422538723939893" LOG_EFFECT_SIZE="0.2041199826559248" NO="4" P_CHI2="1.0" P_Z="0.3701129902108148" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="13.102291263790677" Z="0.896261754590929">
<NAME>Vancomycin/ceftazidime</NAME>
<DICH_DATA CI_END="4.471918064467685" CI_START="0.5724612935869455" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.650493837705839" LOG_CI_START="-0.2422538723939893" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="8821" O_E="0.0" SE="0.5244044240850757" STUDY_ID="STD-Klaus-1995a" TOTAL_1="40" TOTAL_2="40" VAR="0.27499999999999997" WEIGHT="13.102291263790677"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7279358555779747" CI_START="0.6950648337916366" DF="0" EFFECT_SIZE="1.0959139784946237" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="25" I2="0.0" ID="CMP-006.02.05" LOG_CI_END="0.23752761656556645" LOG_CI_START="-0.15797468369088627" LOG_EFFECT_SIZE="0.039776466437340105" MODIFIED="2012-01-10 09:38:44 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6934074850649014" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="91" WEIGHT="66.75852182827603" Z="0.39423508585867395">
<NAME>Cefazolin/tobramycin</NAME>
<DICH_DATA CI_END="1.7279358555779747" CI_START="0.6950648337916366" EFFECT_SIZE="1.0959139784946237" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="25" LOG_CI_END="0.23752761656556645" LOG_CI_START="-0.15797468369088627" LOG_EFFECT_SIZE="0.039776466437340105" MODIFIED="2012-01-10 09:38:44 +1100" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.2323200089386011" STUDY_ID="STD-Choy-2001" TOTAL_1="93" TOTAL_2="91" VAR="0.0539725865532317" WEIGHT="66.75852182827603"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4898840149084994" CI_END="1.2846733349684136" CI_START="0.44956030831423943" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7599593019047022" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.10879270988036559" LOG_CI_START="-0.347212039612143" LOG_EFFECT_SIZE="-0.11920966486588869" METHOD="MH" MODIFIED="2014-02-10 18:15:41 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.9211082083681528" P_Q="0.9211858180957848" P_Z="0.30547866086704656" Q="0.489528892754892" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="171" TOTAL_2="167" WEIGHT="99.99999999999999" Z="1.0247553342646494">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Continuous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.024635999788516" CI_START="0.40007191420314997" DF="0" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.306346954714663" LOG_CI_START="-0.3978619358360133" LOG_EFFECT_SIZE="-0.045757490560675115" NO="1" P_CHI2="1.0" P_Z="0.7989503603658891" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="41.93104874437799" Z="0.2547057690558962">
<NAME>Gentamicin</NAME>
<DICH_DATA CI_END="2.024635999788516" CI_START="0.40007191420314997" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.306346954714663" LOG_CI_START="-0.3978619358360133" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="8822" O_E="0.0" SE="0.41365578819969523" STUDY_ID="STD-Lye-1995" TOTAL_1="50" TOTAL_2="50" VAR="0.17111111111111113" WEIGHT="41.93104874437799"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1061100335490566" CI_START="0.13086923076641813" DF="0" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="0.3234810571224234" LOG_CI_START="-0.8831624503105096" LOG_EFFECT_SIZE="-0.2798406965940431" NO="2" P_CHI2="1.0" P_Z="0.3632992072083241" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="32" WEIGHT="14.281728450691778" Z="0.9090964868319408">
<NAME>Vancomycin</NAME>
<DICH_DATA CI_END="2.1061100335490566" CI_START="0.13086923076641813" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3234810571224234" LOG_CI_START="-0.8831624503105096" LOG_EFFECT_SIZE="-0.2798406965940431" ORDER="8823" O_E="0.0" SE="0.7087883692477976" STUDY_ID="STD-Boyce-1988" TOTAL_1="30" TOTAL_2="21" VAR="0.5023809523809524" WEIGHT="14.281728450691778"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8824" O_E="0.0" SE="0.0" STUDY_ID="STD-Velasquez_x002d_Jones-1995" TOTAL_1="10" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2782201700486304" CI_START="0.26977739093882164" DF="0" EFFECT_SIZE="0.7839721254355401" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-006.03.03" LOG_CI_END="0.3575956925335554" LOG_CI_START="-0.5689944497788151" LOG_EFFECT_SIZE="-0.10569937862262985" NO="3" P_CHI2="1.0" P_Z="0.6547596173484768" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="45" WEIGHT="24.219400057553823" Z="0.4471598948195537">
<NAME>Teicoplanin/ceftazidime</NAME>
<DICH_DATA CI_END="2.2782201700486304" CI_START="0.26977739093882164" EFFECT_SIZE="0.7839721254355401" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3575956925335554" LOG_CI_START="-0.5689944497788151" LOG_EFFECT_SIZE="-0.10569937862262985" ORDER="8825" O_E="0.0" SE="0.5442836362894641" STUDY_ID="STD-Klaus-1995a" TOTAL_1="41" TOTAL_2="45" VAR="0.2962446767324816" WEIGHT="24.219400057553823"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1844236592731723" CI_START="0.20346073553896835" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-006.03.04" LOG_CI_END="0.33933687168887666" LOG_CI_START="-0.6915193898002392" LOG_EFFECT_SIZE="-0.17609125905568127" NO="4" P_CHI2="1.0" P_Z="0.5031105304927171" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="19.5678227473764" Z="0.6696035880751974">
<NAME>Vancomycin/ceftazidime</NAME>
<DICH_DATA CI_END="2.1844236592731723" CI_START="0.20346073553896835" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.33933687168887666" LOG_CI_START="-0.6915193898002392" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="8826" O_E="0.0" SE="0.6055300708194983" STUDY_ID="STD-Klaus-1995a" TOTAL_1="40" TOTAL_2="40" VAR="0.3666666666666666" WEIGHT="19.5678227473764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 14:21:29 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="93" TOTAL_2="91" WEIGHT="0.0" Z="0.0">
<NAME>Catheter removal</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Continuous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Continuous</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.238418260805307" CI_START="0.4277358460161374" EFFECT_SIZE="0.978494623655914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3499412400956757" LOG_CI_START="-0.36882435256135865" LOG_EFFECT_SIZE="-0.009441556232841508" MODIFIED="2012-01-11 12:12:31 +1100" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.42220646707380743" STUDY_ID="STD-Choy-2001" TOTAL_1="93" TOTAL_2="91" VAR="0.17825830083894603" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 14:21:29 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Continuous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours continuous</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin</NAME>
<DICH_DATA CI_END="10.57462402764825" CI_START="0.04633734482841692" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0242649353264774" LOG_CI_START="-1.3340688552979638" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="8827" O_E="0.0" SE="1.3852969425533352" STUDY_ID="STD-Boyce-1988" TOTAL_1="30" TOTAL_2="21" VAR="1.919047619047619" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-03-04 11:41:07 +1100" MODIFIED_BY="Narelle Willis" NO="7">
<NAME>First generation cephalosporin versus glycopeptide-based intraperitoneal (IP) antibiotic regimen</NAME>
<DICH_OUTCOME CHI2="3.405508974832013" CI_END="2.7155801063324683" CI_START="1.0121778427789867" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6579053090937157" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="36" I2="41.27162739018605" I2_Q="50.65769228696522" ID="CMP-007.01" LOG_CI_END="0.4338626184801557" LOG_CI_START="0.005256826092563559" LOG_EFFECT_SIZE="0.21955972228635964" METHOD="MH" MODIFIED="2014-02-10 18:18:38 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.1821812765656301" P_Q="0.15456052143559507" P_Z="0.044638862533504554" Q="2.02665835131953" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07767871537613316" TOTALS="YES" TOTAL_1="189" TOTAL_2="181" WEIGHT="100.0" Z="2.008041682029955">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Cephalosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Glycopeptide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cephalosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glycopeptide</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2496655953612101" CI_END="2.219495788886304" CI_START="1.026202983098272" DF="1" EFFECT_SIZE="1.509189583693572" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="34" I2="19.978592376070452" ID="CMP-007.01.01" LOG_CI_END="0.3462543253626579" LOG_CI_START="0.011233272784027302" LOG_EFFECT_SIZE="0.17874379907334256" NO="1" P_CHI2="0.2636164445429062" P_Z="0.036492278890256157" STUDIES="2" TAU2="0.016010282603211773" TOTAL_1="161" TOTAL_2="144" WEIGHT="90.36390643867247" Z="2.091399366977939">
<NAME>Vancomycin-based regimen</NAME>
<DICH_DATA CI_END="2.7341727830120974" CI_START="1.1433929866762247" EFFECT_SIZE="1.7681159420289856" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="23" LOG_CI_END="0.4368259558564109" LOG_CI_START="0.058195524018575" LOG_EFFECT_SIZE="0.24751073993749292" ORDER="8828" O_E="0.0" SE="0.2224093899124099" STUDY_ID="STD-Flanigan-1991" TOTAL_1="141" TOTAL_2="122" VAR="0.04946593672121038" WEIGHT="49.8532158445688"/>
<DICH_DATA CI_END="2.08020687586865" CI_START="0.6922388425423729" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.318106527549548" LOG_CI_START="-0.15974403545429836" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="8829" O_E="0.0" SE="0.2806917861068948" STUDY_ID="STD-Khairullah-2002" TOTAL_1="20" TOTAL_2="22" VAR="0.0787878787878788" WEIGHT="40.510690594103664"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.579378104774573" CI_START="1.0394203795224124" DF="0" EFFECT_SIZE="4.625000000000002" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="1.3134322465320707" LOG_CI_START="0.016791227618032405" LOG_EFFECT_SIZE="0.6651117370750516" NO="2" P_CHI2="1.0" P_Z="0.04435438244024248" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="37" WEIGHT="9.63609356132753" Z="2.0107262246782245">
<NAME>Teicoplanin-based regimen</NAME>
<DICH_DATA CI_END="20.579378104774563" CI_START="1.0394203795224122" EFFECT_SIZE="4.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.3134322465320705" LOG_CI_START="0.016791227618032315" LOG_EFFECT_SIZE="0.6651117370750514" ORDER="8830" O_E="0.0" SE="0.7616533529866655" STUDY_ID="STD-Lupo-1997" TOTAL_1="28" TOTAL_2="37" VAR="0.58011583011583" WEIGHT="9.63609356132753"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7853589531372924" CI_END="1.8654447581954907" CI_START="0.6923011110567447" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1364195874384244" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.27078239271424076" LOG_CI_START="-0.15970497139964837" LOG_EFFECT_SIZE="0.055538710657296195" METHOD="MH" MODIFIED="2014-02-10 18:18:56 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.3755072213690087" P_Q="1.0" P_Z="0.6130504953165647" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="161" TOTAL_2="144" WEIGHT="100.0" Z="0.5057238920828963">
<NAME>Primary treatment failure</NAME>
<GROUP_LABEL_1>Cephalosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Glycopeptide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cephalosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glycopeptide</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7853589531372924" CI_END="1.8654447581954907" CI_START="0.6923011110567447" DF="1" EFFECT_SIZE="1.1364195874384244" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.27078239271424076" LOG_CI_START="-0.15970497139964837" LOG_EFFECT_SIZE="0.055538710657296195" NO="1" P_CHI2="0.3755072213690087" P_Z="0.6130504953165647" STUDIES="2" TAU2="0.0" TOTAL_1="161" TOTAL_2="144" WEIGHT="100.0" Z="0.5057238920828963">
<NAME>Vancomycin-based regimen</NAME>
<DICH_DATA CI_END="2.426254344507148" CI_START="0.7254680053546503" EFFECT_SIZE="1.3267139479905437" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.3849363260548599" LOG_CI_START="-0.1393817360923" LOG_EFFECT_SIZE="0.12277729498127994" ORDER="8831" O_E="0.0" SE="0.30798702512150766" STUDY_ID="STD-Flanigan-1991" TOTAL_1="141" TOTAL_2="122" VAR="0.0948560076431962" WEIGHT="67.41106351415523"/>
<DICH_DATA CI_END="1.9656256022510794" CI_START="0.3462638048774561" EFFECT_SIZE="0.825" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2935008001895438" LOG_CI_START="-0.46059290308969364" LOG_EFFECT_SIZE="-0.08354605145007493" ORDER="8832" O_E="0.0" SE="0.4429583741302575" STUDY_ID="STD-Khairullah-2002" TOTAL_1="20" TOTAL_2="22" VAR="0.19621212121212117" WEIGHT="32.588936485844776"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.204228991691472" CI_END="3.35792532468286" CI_START="0.8426338985052189" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.682112275452183" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.5260710338393214" LOG_CI_START="-0.0743610735290958" LOG_EFFECT_SIZE="0.22585498015511277" METHOD="MH" MODIFIED="2014-02-10 18:19:29 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.5476526535451332" P_Q="0.9062824190728054" P_Z="0.14034786398988897" Q="0.01386010887817397" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="180" TOTAL_2="170" WEIGHT="100.0" Z="1.4744968545175239">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Cephalosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Glycopeptide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cephalosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glycopeptide</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1802853126743449" CI_END="3.793342871594027" CI_START="0.6941980141965585" DF="1" EFFECT_SIZE="1.6227541676505548" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" I2="15.274723046908557" ID="CMP-007.03.01" LOG_CI_END="0.5790220993627937" LOG_CI_START="-0.15851663299348942" LOG_EFFECT_SIZE="0.21025273318465218" NO="1" P_CHI2="0.2772979751893261" P_Z="0.26379450272967864" STUDIES="2" TAU2="0.08114835251824436" TOTAL_1="161" TOTAL_2="144" WEIGHT="93.48344184515221" Z="1.1174675081171475">
<NAME>Vancomycin-based regimen</NAME>
<DICH_DATA CI_END="4.526562125679973" CI_START="0.9329109243015805" EFFECT_SIZE="2.0549645390070923" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6557684853062804" LOG_CI_START="-0.03015982134577302" LOG_EFFECT_SIZE="0.3128043319802537" ORDER="8833" O_E="0.0" SE="0.40291768272729445" STUDY_ID="STD-Flanigan-1991" TOTAL_1="141" TOTAL_2="122" VAR="0.1623426590543327" WEIGHT="76.62497821001448"/>
<DICH_DATA CI_END="3.948957463307797" CI_START="0.1361822158821925" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5964824557040812" LOG_CI_START="-0.8658796034989936" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="8834" O_E="0.0" SE="0.8589987123848253" STUDY_ID="STD-Khairullah-2002" TOTAL_1="20" TOTAL_2="22" VAR="0.7378787878787878" WEIGHT="16.85846363513773"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.524236317637275" CI_START="0.09123731320887883" DF="0" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-007.03.02" LOG_CI_END="1.3122670065122397" LOG_CI_START="-1.0398275124762617" LOG_EFFECT_SIZE="0.136219747017989" NO="2" P_CHI2="1.0" P_Z="0.8204084885822494" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="26" WEIGHT="6.516558154847785" Z="0.2270196167569243">
<NAME>Teicoplanin-based regimen</NAME>
<DICH_DATA CI_END="20.524236317637275" CI_START="0.09123731320887883" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.3122670065122397" LOG_CI_START="-1.0398275124762617" LOG_EFFECT_SIZE="0.136219747017989" ORDER="8835" O_E="0.0" SE="1.3816319635094916" STUDY_ID="STD-Lupo-1997" TOTAL_1="19" TOTAL_2="26" VAR="1.908906882591093" WEIGHT="6.516558154847785"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0739291809404956" CI_END="2.1944121016607094" CI_START="0.4099969939364789" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9485264177336981" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" I2="51.782345839479675" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.3413181896338299" LOG_CI_START="-0.3872193274792533" LOG_EFFECT_SIZE="-0.022950568922711686" METHOD="MH" MODIFIED="2014-02-10 18:19:48 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.14983511346766487" P_Q="1.0" P_Z="0.9017218324998539" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.20104032781559086" TOTALS="YES" TOTAL_1="161" TOTAL_2="144" WEIGHT="100.0" Z="0.12348653969521524">
<NAME>Catheter removal</NAME>
<GROUP_LABEL_1>Cephalosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Glycopeptide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cephalosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glycopeptide</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.426254344507148" CI_START="0.7254680053546503" EFFECT_SIZE="1.3267139479905437" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.3849363260548599" LOG_CI_START="-0.1393817360923" LOG_EFFECT_SIZE="0.12277729498127994" ORDER="8836" O_E="0.0" SE="0.30798702512150766" STUDY_ID="STD-Flanigan-1991" TOTAL_1="141" TOTAL_2="122" VAR="0.0948560076431962" WEIGHT="61.89270445923598"/>
<DICH_DATA CI_END="1.5502811462723083" CI_START="0.19512589747180323" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.19041046539767836" LOG_CI_START="-0.7096850864091907" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="8837" O_E="0.0" SE="0.5287205826761944" STUDY_ID="STD-Khairullah-2002" TOTAL_1="20" TOTAL_2="22" VAR="0.27954545454545454" WEIGHT="38.10729554076402"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:20:00 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological eradication</NAME>
<GROUP_LABEL_1>Cephalosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Glycopeptide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cephalosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glycopeptide</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1271319371795694" CI_START="0.6155525541657804" EFFECT_SIZE="0.8329519450800915" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.051974755651513126" LOG_CI_START="-0.21073486229424482" LOG_EFFECT_SIZE="-0.07938005332136586" ORDER="8838" O_E="0.0" SE="0.15431693001492014" STUDY_ID="STD-Lupo-1997" TOTAL_1="19" TOTAL_2="26" VAR="0.02381371488922976" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-03-04 11:41:06 +1100" MODIFIED_BY="Narelle Willis" NO="8">
<NAME>Teicoplanin versus vancomycin-based intraperitoneal (IP) antibiotic regimen</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9584988559804801" CI_START="0.13355027194294908" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35778175313059035" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-0.018408401139242723" LOG_CI_START="-0.8743552233056414" LOG_EFFECT_SIZE="-0.4463818122224421" METHOD="MH" MODIFIED="2014-02-10 18:20:38 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0409270957232027" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="86" WEIGHT="100.0" Z="2.044267827516103">
<NAME>Primary treatment failure</NAME>
<GROUP_LABEL_1>Teicoplanin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vancomycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours teicoplanin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vancomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8841" O_E="0.0" SE="0.0" STUDY_ID="STD-Bowley-1988" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9584988559804801" CI_START="0.13355027194294908" EFFECT_SIZE="0.35778175313059035" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.018408401139242723" LOG_CI_START="-0.8743552233056414" LOG_EFFECT_SIZE="-0.4463818122224421" ORDER="8842" O_E="0.0" SE="0.5027874003456458" STUDY_ID="STD-Klaus-1995a" TOTAL_1="86" TOTAL_2="80" VAR="0.2527951699463327" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08153814467151714" CI_END="1.1455749467597867" CI_START="0.39648464236319525" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6739457493495233" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.0590235072307554" LOG_CI_START="-0.401773630202852" LOG_EFFECT_SIZE="-0.17137506148604828" METHOD="MH" MODIFIED="2014-02-10 18:20:51 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.77522369630241" P_Q="1.0" P_Z="0.1448790271673424" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="86" WEIGHT="100.0" Z="1.4578603948440874">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Teicoplanin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vancomycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours teicoplanin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vancomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="8839" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Bowley-1988" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="6.279831043934987"/>
<DICH_DATA CI_END="1.1893374851010683" CI_START="0.39748444259288285" EFFECT_SIZE="0.6875631951466128" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.07530510703263235" LOG_CI_START="-0.4006798648145184" LOG_EFFECT_SIZE="-0.16268737889094306" ORDER="8840" O_E="0.0" SE="0.2795959286266267" STUDY_ID="STD-Klaus-1995a" TOTAL_1="86" TOTAL_2="80" VAR="0.07817388330458573" WEIGHT="93.72016895606501"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4865664392210812" CI_END="2.1109660055174224" CI_START="0.4867417897774078" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0136544636535743" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.32448123959137365" LOG_CI_START="-0.3127013653024126" LOG_EFFECT_SIZE="0.005889937144480501" METHOD="MH" MODIFIED="2014-02-10 18:21:03 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.4854629925390491" P_Q="1.0" P_Z="0.9710952065153255" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="86" WEIGHT="100.00000000000001" Z="0.036234713834696855">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Teicoplanin</GROUP_LABEL_1>
<GROUP_LABEL_2>Vancomycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours teicoplanin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vancomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="8843" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Bowley-1988" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="12.007600672367174"/>
<DICH_DATA CI_END="2.4400960335026616" CI_START="0.5106680001492269" EFFECT_SIZE="1.1162790697674418" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.38740691896149865" LOG_CI_START="-0.29186135536949737" LOG_EFFECT_SIZE="0.04777278179600068" ORDER="8844" O_E="0.0" SE="0.3990055467742136" STUDY_ID="STD-Klaus-1995a" TOTAL_1="86" TOTAL_2="80" VAR="0.15920542635658916" WEIGHT="87.99239932763284"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2014-03-04 14:38:31 +1100" MODIFIED_BY="Narelle Willis" NO="9">
<NAME>Comparison of two oral antibiotic regimens</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:21:19 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Regimen 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 1</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1656776995512206" CI_START="0.3535267506142098" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.33559382453239683" LOG_CI_START="-0.45157771848777034" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="8845" O_E="0.0" SE="0.4623884609320271" STUDY_ID="STD-Chan-1990" TOTAL_1="37" TOTAL_2="37" VAR="0.2138030888030888" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 14:38:31 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Catheter removal</NAME>
<GROUP_LABEL_1>Regimen 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 1</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.1143884772951" CI_START="0.18944427418778026" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3245785077461414" LOG_CI_START="-0.722518516418179" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="8847" O_E="0.0" SE="1.202474925287819" STUDY_ID="STD-Chan-1990" TOTAL_1="37" TOTAL_2="37" VAR="1.445945945945946" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 14:38:31 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Change in antibiotics following culture results</NAME>
<GROUP_LABEL_1>Regimen 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 1</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0593713735736316" CI_START="0.03631828161525971" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48563219869250035" LOG_CI_START="-1.4398747081318253" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="8846" O_E="0.0" SE="1.1310522884815182" STUDY_ID="STD-Chan-1990" TOTAL_1="37" TOTAL_2="37" VAR="1.2792792792792793" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:21:47 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="74" TOTAL_2="74" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Regimen 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
<DICH_DATA CI_END="71.34146560736612" CI_START="0.12615384227641566" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8533420270468215" LOG_CI_START="-0.8990995176074968" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="8848" O_E="0.0" SE="1.6167977881353308" STUDY_ID="STD-Chan-1990" TOTAL_1="37" TOTAL_2="37" VAR="2.6140350877192984" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="71.34146560736612" CI_START="0.12615384227641566" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8533420270468215" LOG_CI_START="-0.8990995176074968" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="8849" O_E="0.0" SE="1.6167977881353308" STUDY_ID="STD-Chan-1990" TOTAL_1="37" TOTAL_2="37" VAR="2.6140350877192984" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Fibrinolytic agents versus non-urokinase or placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:22:05 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7895955727932935" CI_START="0.8416417485636074" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" LOG_CI_END="0.25275489670668844" LOG_CI_START="-0.07487273003312624" LOG_EFFECT_SIZE="0.08894108333678108" ORDER="8850" O_E="0.0" SE="0.19245008972987526" STUDY_ID="STD-Tong-2005a" TOTAL_1="44" TOTAL_2="44" VAR="0.037037037037037035" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4944556691223794" CI_END="1.2586920946704292" CI_START="0.3195393622078904" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6341937157896652" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" I2="33.08600444553494" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.09991950457970454" LOG_CI_START="-0.49547563598215405" LOG_EFFECT_SIZE="-0.19777806570122472" METHOD="MH" MODIFIED="2014-02-10 18:22:14 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.2215267843168417" P_Q="1.0" P_Z="0.1928754527690593" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0905503845773961" TOTALS="YES" TOTAL_1="50" TOTAL_2="49" WEIGHT="99.99999999999997" Z="1.302119749719803">
<NAME>Primary treatment failure (persistent peritonitis)</NAME>
<GROUP_LABEL_1>Urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0834355946543175" CI_START="0.14010639528673774" EFFECT_SIZE="0.38961038961038963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.03480309958053465" LOG_CI_START="-0.8535420404861735" LOG_EFFECT_SIZE="-0.4093694704528194" ORDER="8851" O_E="0.0" SE="0.5218183326545478" STUDY_ID="STD-Innes-1994" TOTAL_1="6" TOTAL_2="5" VAR="0.27229437229437226" WEIGHT="33.71047900609813"/>
<DICH_DATA CI_END="1.481675617244624" CI_START="0.4455470835294231" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.17075313410167178" LOG_CI_START="-0.3511063947998478" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="8852" O_E="0.0" SE="0.3065428705230827" STUDY_ID="STD-Tong-2005a" TOTAL_1="44" TOTAL_2="44" VAR="0.09396853146853146" WEIGHT="66.28952099390185"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.749740251508674" CI_END="1.3339122716239815" CI_START="0.31476850630827935" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6479765221714167" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" I2_Q="23.63331940237465" ID="CMP-010.03" LOG_CI_END="0.12512726795949777" LOG_CI_START="-0.5020087268236114" LOG_EFFECT_SIZE="-0.1884407294320568" METHOD="MH" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.416916540570083" P_Q="0.2524904737388104" P_Z="0.23885518948717344" Q="1.3094716074788975" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="91" WEIGHT="200.0" Z="1.1778531163245418">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.41347300459475234" CI_END="1.168858786686124" CI_START="0.21950810637441898" DF="1" EFFECT_SIZE="0.5065313207340411" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="0.0677620459202169" LOG_CI_START="-0.6585494367490987" LOG_EFFECT_SIZE="-0.29539369541444094" NO="1" P_CHI2="0.5202120040426552" P_Z="0.11088007407414466" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0" Z="1.594249899904434">
<NAME>Persistent peritonitis</NAME>
<DICH_DATA CI_END="1.2546302466030175" CI_START="0.12054114613505512" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.09851575329094177" LOG_CI_START="-0.9188646834690403" LOG_EFFECT_SIZE="-0.41017446508904926" ORDER="8853" O_E="0.0" SE="0.5976143046671968" STUDY_ID="STD-Innes-1994" TOTAL_1="6" TOTAL_2="7" VAR="0.35714285714285715" WEIGHT="50.96582466567608"/>
<DICH_DATA CI_END="2.2005023353367763" CI_START="0.2019740844203305" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3425218338048204" LOG_CI_START="-0.6947043519161828" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="8854" O_E="0.0" SE="0.6092717958449424" STUDY_ID="STD-Tong-2005a" TOTAL_1="44" TOTAL_2="44" VAR="0.3712121212121212" WEIGHT="49.034175334323926"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.579155313499883" CI_START="0.31864640395941085" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-010.03.02" LOG_CI_END="0.74656845154428" LOG_CI_START="-0.49669097832768017" LOG_EFFECT_SIZE="0.12493873660829993" NO="2" P_CHI2="1.0" P_Z="0.6936364862031998" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.39392490117918977">
<NAME>Peritonitis commencement</NAME>
<DICH_DATA CI_END="5.579155313499883" CI_START="0.31864640395941085" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.74656845154428" LOG_CI_START="-0.49669097832768017" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="8855" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Gadallah-2000c" TOTAL_1="40" TOTAL_2="40" VAR="0.5333333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.32297160584338636" CI_END="1.3039689002396324" CI_START="0.3734620262610965" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6978415777703036" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.11526723356202112" LOG_CI_START="-0.42775355080622535" LOG_EFFECT_SIZE="-0.15624315862210209" METHOD="MH" MODIFIED="2014-04-15 19:41:38 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5698274013377673" P_Q="0.572120860825502" P_Z="0.259370895923432" Q="0.3191469714249904" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="84" WEIGHT="99.99999999999999" Z="1.1278793465939607">
<NAME>Catheter removal</NAME>
<GROUP_LABEL_1>Urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.565634278432107" CI_START="0.37794010036873404" DF="0" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="0.19469032131814978" LOG_CI_START="-0.4225770259318233" LOG_EFFECT_SIZE="-0.11394335230683675" NO="1" P_CHI2="1.0" P_Z="0.4693162405098351" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="77.39025856885146" Z="0.7235920312134044">
<NAME>Persistent peritonitis</NAME>
<DICH_DATA CI_END="1.565634278432107" CI_START="0.37794010036873404" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.19469032131814978" LOG_CI_START="-0.4225770259318233" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="8856" O_E="0.0" SE="0.3625858952972819" STUDY_ID="STD-Tong-2005a" TOTAL_1="44" TOTAL_2="44" VAR="0.13146853146853146" WEIGHT="77.39025856885146"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8619729107970513" CI_START="0.1342661853726878" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-010.04.02" LOG_CI_END="0.2699733582903616" LOG_CI_START="-0.872033349618324" LOG_EFFECT_SIZE="-0.3010299956639812" NO="2" P_CHI2="1.0" P_Z="0.30147158428945986" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="22.609741431148525" Z="1.0332828094295723">
<NAME>Peritonitis commencement</NAME>
<DICH_DATA CI_END="1.8619729107970513" CI_START="0.1342661853726878" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2699733582903616" LOG_CI_START="-0.872033349618324" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="8857" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Gadallah-2000c" TOTAL_1="40" TOTAL_2="40" VAR="0.44999999999999996" WEIGHT="22.609741431148525"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:25:13 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.686963952426274" CI_START="0.21335773224420376" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.670891613361781" LOG_CI_START="-0.670891613361781" LOG_EFFECT_SIZE="0.0" ORDER="8858" O_E="0.0" SE="0.7881701093115123" STUDY_ID="STD-Tong-2005a" TOTAL_1="44" TOTAL_2="44" VAR="0.6212121212121212" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2014-03-04 11:41:02 +1100" MODIFIED_BY="Narelle Willis" NO="11">
<NAME>Urokinase versus simultaneous catheter removal or replacement</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:25:40 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="17" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence of peritonitis</NAME>
<GROUP_LABEL_1>Urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>Catheter removal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours urokinase</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav catheter removal</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.914020000125591" CI_START="1.1266401398018937" EFFECT_SIZE="2.3529411764705883" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.6914369197318736" LOG_CI_START="0.05178522016750348" LOG_EFFECT_SIZE="0.37161106994968846" ORDER="8859" O_E="0.0" SE="0.37573457465108967" STUDY_ID="STD-Williams-1989" TOTAL_1="17" TOTAL_2="20" VAR="0.1411764705882353" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2014-03-04 11:41:00 +1100" MODIFIED_BY="Narelle Willis" NO="12">
<NAME>Peritoneal lavage</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:25:53 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Lavage</GROUP_LABEL_1>
<GROUP_LABEL_2>Usual care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lavage</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours usual care</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.249789078271847" CI_START="0.5555659716386525" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0511443799583708" LOG_CI_START="-0.2552643626142957" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="8860" O_E="0.0" SE="0.7673909622147558" STUDY_ID="STD-Ejlersen-1991" TOTAL_1="18" TOTAL_2="18" VAR="0.5888888888888888" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:26:01 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Lavage</GROUP_LABEL_1>
<GROUP_LABEL_2>Usual care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lavage</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours usual care</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.249789078271847" CI_START="0.5555659716386525" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0511443799583708" LOG_CI_START="-0.2552643626142957" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="8861" O_E="0.0" SE="0.7673909622147558" STUDY_ID="STD-Ejlersen-1991" TOTAL_1="18" TOTAL_2="18" VAR="0.5888888888888888" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:26:10 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Technique failure</NAME>
<GROUP_LABEL_1>Lavage</GROUP_LABEL_1>
<GROUP_LABEL_2>Usual care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lavage</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours usual care</GRAPH_LABEL_2>
<DICH_DATA CI_END="69.09028858730679" CI_START="0.1302643277951726" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="8862" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Ejlersen-1991" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-10 18:26:19 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Lavage</GROUP_LABEL_1>
<GROUP_LABEL_2>Usual care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lavage</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours usual care</GRAPH_LABEL_2>
<DICH_DATA CI_END="69.09028858730679" CI_START="0.1302643277951726" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="8863" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Ejlersen-1991" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2014-03-04 11:40:58 +1100" MODIFIED_BY="Narelle Willis" NO="13">
<NAME>Intraperitoneal immunoglobulin</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.01" MODIFIED="2014-02-10 18:26:41 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of exchanges for reduction in dialysate WWC &lt; 100/mL</NAME>
<GROUP_LABEL_1>Immunoglobulin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunoglobulin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.4761931506783315" CI_START="-8.12380684932167" EFFECT_SIZE="-7.300000000000001" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="13.9" ORDER="8864" SD_1="0.4" SD_2="1.4" SE="0.42031734043061636" STUDY_ID="STD-Coban-2004" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-17 15:44:19 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Immunoglobulin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immunoglobulin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8865" O_E="0.0" SE="0.0" STUDY_ID="STD-Coban-2004" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2014-03-05 15:18:29 +1100" MODIFIED_BY="Narelle Willis" NO="14">
<NAME>Comparison of two intraperitoneal antibiotic regimens</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="76" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:29:58 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="173" TOTAL_2="169" WEIGHT="0.0" Z="0.0">
<NAME>Failure to achieve complete cure</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-014.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 10:48:43 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Cefepime versus vancomycin/netilmicin</NAME>
<DICH_DATA CI_END="2.6309192288893133" CI_START="0.5461683144051475" EFFECT_SIZE="1.1987179487179487" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.4201075151377251" LOG_CI_START="-0.2626734987736504" LOG_EFFECT_SIZE="0.07871700818203736" MODIFIED="2014-03-04 10:48:43 +1100" MODIFIED_BY="Narelle Willis" ORDER="8866" O_E="0.0" SE="0.4010689473920699" STUDY_ID="STD-Wong-2001" TOTAL_1="39" TOTAL_2="34" VAR="0.16085630056218292" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-014.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 10:54:02 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Cefuroxime verus vancomycin/netilmicin</NAME>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-03-04 10:54:02 +1100" MODIFIED_BY="Narelle Willis" ORDER="8872" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Were-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="18" I2="0.0" ID="CMP-014.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 10:54:54 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin/cefotaxime versus/tobramycin</NAME>
<DICH_DATA CI_END="1.8086806395203798" CI_START="0.798843385888085" EFFECT_SIZE="1.202020202020202" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.2573618898348259" LOG_CI_START="-0.09753835624486423" LOG_EFFECT_SIZE="0.07991176679498083" MODIFIED="2014-03-04 10:54:54 +1100" MODIFIED_BY="Narelle Willis" ORDER="8874" O_E="0.0" SE="0.20847016133176113" STUDY_ID="STD-Jim_x00e9_nez-1996" TOTAL_1="33" TOTAL_2="34" VAR="0.04345980816569051" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-014.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:36:13 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Ciproflozacin verus vancomycin/gentamicin</NAME>
<DICH_DATA CI_END="1.4639602780167191" CI_START="0.8645214074486971" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.1655292930665088" LOG_CI_START="-0.06322424817174624" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2014-03-04 10:59:51 +1100" MODIFIED_BY="Narelle Willis" ORDER="8878" O_E="0.0" SE="0.13437096247164246" STUDY_ID="STD-Friedland-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.018055555555555547" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="17" I2="0.0" ID="CMP-014.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:12 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Cefazolin/ceftazidime versus cefazolin/netilmicin</NAME>
<DICH_DATA CI_END="1.8121265457703464" CI_START="0.6186694130455422" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.2581885223754446" LOG_CI_START="-0.20854135492538034" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2014-03-04 11:06:11 +1100" MODIFIED_BY="Narelle Willis" ORDER="8888" O_E="0.0" SE="0.2741594402766581" STUDY_ID="STD-Lui-2005" TOTAL_1="51" TOTAL_2="51" VAR="0.07516339869281045" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-014.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:12 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Cefapime versus cefotaxime</NAME>
<DICH_DATA CI_END="2.9297807522256587" CI_START="0.19199388881665874" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.46683512149361056" LOG_CI_START="-0.7167125947102105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-04 11:15:23 +1100" MODIFIED_BY="Narelle Willis" ORDER="133" O_E="0.0" SE="0.6952217871538069" STUDY_ID="STD-Hernandez-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.4833333333333332" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="72" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-05 14:02:59 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="276" TOTAL_2="278" WEIGHT="0.0" Z="0.0">
<NAME>Primary treatment failure</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-014.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 10:49:11 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Cefepime versus vancomycin/netilmicin</NAME>
<DICH_DATA CI_END="3.4929296783128096" CI_START="0.4264762483726003" EFFECT_SIZE="1.2205128205128206" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5431898422571342" LOG_CI_START="-0.3701051508691462" LOG_EFFECT_SIZE="0.08654234569399398" MODIFIED="2014-03-04 10:49:11 +1100" MODIFIED_BY="Narelle Willis" ORDER="8867" O_E="0.0" SE="0.5364739998455049" STUDY_ID="STD-Wong-2001" TOTAL_1="39" TOTAL_2="34" VAR="0.28780435251023484" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-014.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:28 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin/cefotaxime versus/tobramycin</NAME>
<DICH_DATA CI_END="1.8333249759848635" CI_START="0.48653420442428946" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2632394550153469" LOG_CI_START="-0.31288662246541127" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2014-03-04 10:55:22 +1100" MODIFIED_BY="Narelle Willis" ORDER="8875" O_E="0.0" SE="0.33841930978227525" STUDY_ID="STD-Jim_x00e9_nez-1996" TOTAL_1="33" TOTAL_2="34" VAR="0.11452762923351159" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-014.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:36:00 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Ciproflozacin verus vancomycin/gentamicin</NAME>
<DICH_DATA CI_END="2.0452762263354756" CI_START="0.03055821956723241" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31075197027588036" LOG_CI_START="-1.514871952931805" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2014-03-04 11:00:09 +1100" MODIFIED_BY="Narelle Willis" ORDER="8879" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Friedland-1990" TOTAL_1="20" TOTAL_2="20" VAR="1.15" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-014.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:28 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Cephazolin/netilmicin versus vancomycin/ceftazidine</NAME>
<DICH_DATA CI_END="2.6485250618561182" CI_START="0.24164392824415276" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4230040868333767" LOG_CI_START="-0.6168241128494895" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-03-04 11:01:27 +1100" MODIFIED_BY="Narelle Willis" ORDER="8882" O_E="0.0" SE="0.6108002317263175" STUDY_ID="STD-Gucek-1997" TOTAL_1="26" TOTAL_2="26" VAR="0.3730769230769231" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-014.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:28 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Cefuroxime versus teicoplanin/aztreonam</NAME>
<DICH_DATA CI_END="3.9216336868411763" CI_START="0.49979170838333803" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5934670245144897" LOG_CI_START="-0.3012109531580137" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2014-03-04 11:02:08 +1100" MODIFIED_BY="Narelle Willis" ORDER="8883" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Wale-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.2761904761904762" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-014.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:28 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Cefazolin/ceftazidime versus imipenem</NAME>
<DICH_DATA CI_END="1.417733179915424" CI_START="0.6521369649209356" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.15159450348880754" LOG_CI_START="-0.18566118208636828" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2014-03-04 11:04:47 +1100" MODIFIED_BY="Narelle Willis" ORDER="8886" O_E="0.0" SE="0.1981056591494263" STUDY_ID="STD-Leung-2004" TOTAL_1="51" TOTAL_2="51" VAR="0.03924585218702867" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="27" I2="0.0" ID="CMP-014.02.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:28 +1100" MODIFIED_BY="Narelle Willis" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Ceiprofloxacin/rifampicin versus cephradine</NAME>
<DICH_DATA CI_END="0.8904419775106168" CI_START="0.2807594501540885" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.05039437453644149" LOG_CI_START="-0.5516656167915209" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-03-04 11:08:19 +1100" MODIFIED_BY="Narelle Willis" ORDER="8891" O_E="0.0" SE="0.2944492090333012" STUDY_ID="STD-de-Fijter-2001" TOTAL_1="44" TOTAL_2="54" VAR="0.0867003367003367" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-014.02.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-05 14:02:59 +1100" MODIFIED_BY="Narelle Willis" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Gentamicin/methicillin versus clindamycin/mezlocillin</NAME>
<DICH_DATA CI_END="106.84853954417758" CI_START="0.3444543519401806" EFFECT_SIZE="6.066666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0287685904005146" LOG_CI_START="-0.46286832386968974" LOG_EFFECT_SIZE="0.7829501332654123" MODIFIED="2014-03-04 11:15:56 +1100" MODIFIED_BY="Narelle Willis" ORDER="134" O_E="0.0" SE="1.4635998572439606" STUDY_ID="STD-Drinovec-1988" TOTAL_1="14" TOTAL_2="12" VAR="2.1421245421245416" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-014.02.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:28 +1100" MODIFIED_BY="Narelle Willis" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Gentamicin/methicillin versus gentamicin/cloxacillin</NAME>
<DICH_DATA CI_END="46.40883948028183" CI_START="0.1689333344207208" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6666007083972372" LOG_CI_START="-0.7722846457127986" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2014-03-04 11:16:17 +1100" MODIFIED_BY="Narelle Willis" ORDER="135" O_E="0.0" SE="1.4326133296814434" STUDY_ID="STD-Drinovec-1988" TOTAL_1="14" TOTAL_2="5" VAR="2.052380952380952" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.02.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:28 +1100" MODIFIED_BY="Narelle Willis" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Gentamicin/cloxacillin verus clindamycin/mezlocillin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-04 11:17:07 +1100" MODIFIED_BY="Narelle Willis" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Drinovec-1988" TOTAL_1="5" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:29:58 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="217" TOTAL_2="223" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-014.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 10:49:31 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Cefepime versus vancomycin/netilmicin</NAME>
<DICH_DATA CI_END="4.830933948556304" CI_START="0.279688747220848" EFFECT_SIZE="1.1623931623931625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6840310995909241" LOG_CI_START="-0.5533250063428122" LOG_EFFECT_SIZE="0.0653530466240559" MODIFIED="2014-03-04 10:49:31 +1100" MODIFIED_BY="Narelle Willis" ORDER="8868" O_E="0.0" SE="0.726829101636984" STUDY_ID="STD-Wong-2001" TOTAL_1="39" TOTAL_2="34" VAR="0.5282805429864252" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-014.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:52 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin/cefotaxime versus/tobramycin</NAME>
<DICH_DATA CI_END="1.5078027130443659" CI_START="0.2534474550446933" EFFECT_SIZE="0.6181818181818182" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.1783445204188096" LOG_CI_START="-0.596112065322787" LOG_EFFECT_SIZE="-0.20888377245198872" MODIFIED="2014-03-04 10:55:43 +1100" MODIFIED_BY="Narelle Willis" ORDER="8876" O_E="0.0" SE="0.4549196320865412" STUDY_ID="STD-Jim_x00e9_nez-1996" TOTAL_1="33" TOTAL_2="34" VAR="0.206951871657754" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-014.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:36:32 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Ciproflozacin verus vancomycin/gentamicin</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-03-04 11:00:32 +1100" MODIFIED_BY="Narelle Willis" ORDER="8880" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Friedland-1990" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-014.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:52 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Cefuroxime versus teicoplanin/aztreonam</NAME>
<DICH_DATA CI_END="3.1005692822786637" CI_START="0.3225214175072657" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.491441440109722" LOG_CI_START="-0.49144144010972196" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-04 11:02:37 +1100" MODIFIED_BY="Narelle Willis" ORDER="8884" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Wale-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.33333333333333337" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-014.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:52 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Cefazolin/ceftazidime versus cefazolin/netilmicin</NAME>
<DICH_DATA CI_END="6.828800070946394" CI_START="0.14643861141206488" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.834344397920369" LOG_CI_START="-0.834344397920369" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-04 11:06:21 +1100" MODIFIED_BY="Narelle Willis" ORDER="8889" O_E="0.0" SE="0.9801960588196068" STUDY_ID="STD-Lui-2005" TOTAL_1="51" TOTAL_2="51" VAR="0.9607843137254901" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-014.03.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:20:52 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Ceiprofloxacin/rifampicin versus cephradine</NAME>
<DICH_DATA CI_END="2.409170441319652" CI_START="0.10003100295601501" EFFECT_SIZE="0.4909090909090909" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.38186752606980373" LOG_CI_START="-0.9998653767403167" LOG_EFFECT_SIZE="-0.3089989253352565" MODIFIED="2014-03-04 11:08:37 +1100" MODIFIED_BY="Narelle Willis" ORDER="8892" O_E="0.0" SE="0.8116367467988428" STUDY_ID="STD-de-Fijter-2001" TOTAL_1="44" TOTAL_2="54" VAR="0.6587542087542088" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:29:58 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Death due to peritonitis</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 10:49:46 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Cefepime versus vancomycin/netilmicin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-04 10:49:46 +1100" MODIFIED_BY="Narelle Willis" ORDER="8869" O_E="0.0" SE="0.0" STUDY_ID="STD-Wong-2001" TOTAL_1="39" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:29:58 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Hospitalisation rate</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-014.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 10:50:05 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Cefepime versus vancomycin/netilmicin</NAME>
<DICH_DATA CI_END="2.0084321529058027" CI_START="0.2780211756065065" EFFECT_SIZE="0.7472527472527473" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.30285716536004353" LOG_CI_START="-0.5559221245897582" LOG_EFFECT_SIZE="-0.12653247961485728" MODIFIED="2014-03-04 10:50:05 +1100" MODIFIED_BY="Narelle Willis" ORDER="8870" O_E="0.0" SE="0.5044512059425584" STUDY_ID="STD-Wong-2001" TOTAL_1="39" TOTAL_2="34" VAR="0.2544710191769015" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:29:58 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Infusion pain</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-014.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 10:50:34 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Cefepime versus vancomycin/netilmicin</NAME>
<DICH_DATA CI_END="62.38822859407902" CI_START="0.1104475179898594" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7951026547642273" LOG_CI_START="-0.9568440392802756" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2014-03-04 10:50:34 +1100" MODIFIED_BY="Narelle Willis" ORDER="8871" O_E="0.0" SE="1.616507110437575" STUDY_ID="STD-Wong-2001" TOTAL_1="39" TOTAL_2="34" VAR="2.613095238095238" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-014.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:29:58 +1100" MODIFIED_BY="Narelle Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="209" TOTAL_2="220" WEIGHT="0.0" Z="0.0">
<NAME>Catheter removal</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-014.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:21:40 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Cefuroxime verus vancomycin/netilmicin</NAME>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-03-04 10:54:17 +1100" MODIFIED_BY="Narelle Willis" ORDER="8873" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Were-1992" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-014.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:21:40 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Vancomycin/cefotaxime versus/tobramycin</NAME>
<DICH_DATA CI_END="1.6685370577398029" CI_START="0.31173831073783725" EFFECT_SIZE="0.7212121212121212" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.22233585665649064" LOG_CI_START="-0.5062098222992417" LOG_EFFECT_SIZE="-0.14193698282137554" MODIFIED="2014-03-04 10:59:07 +1100" MODIFIED_BY="Narelle Willis" ORDER="8877" O_E="0.0" SE="0.4279513381778706" STUDY_ID="STD-Jim_x00e9_nez-1996" TOTAL_1="33" TOTAL_2="34" VAR="0.1831423478482302" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-014.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:36:51 +1100" MODIFIED_BY="Narelle Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Ciproflozacin verus vancomycin/gentamicin</NAME>
<DICH_DATA CI_END="2.0452762263354756" CI_START="0.03055821956723241" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31075197027588036" LOG_CI_START="-1.514871952931805" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2014-03-04 11:00:52 +1100" MODIFIED_BY="Narelle Willis" ORDER="8881" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Friedland-1990" TOTAL_1="20" TOTAL_2="20" VAR="1.15" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-014.07.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:21:40 +1100" MODIFIED_BY="Narelle Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Cefazolin/ceftazidime versus imipenem</NAME>
<DICH_DATA CI_END="2.8948685704493267" CI_START="0.34543882586171615" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4616288511638633" LOG_CI_START="-0.46162885116386326" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-04 11:05:02 +1100" MODIFIED_BY="Narelle Willis" ORDER="8887" O_E="0.0" SE="0.5423261445466404" STUDY_ID="STD-Leung-2004" TOTAL_1="51" TOTAL_2="51" VAR="0.29411764705882354" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-014.07.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:21:40 +1100" MODIFIED_BY="Narelle Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Cefazolin/ceftazidime versus cefazolin/netilmicin</NAME>
<DICH_DATA CI_END="2.646122007357775" CI_START="0.37791152381462845" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4226098647572455" LOG_CI_START="-0.4226098647572454" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-04 11:06:35 +1100" MODIFIED_BY="Narelle Willis" ORDER="8890" O_E="0.0" SE="0.49648625302195015" STUDY_ID="STD-Lui-2005" TOTAL_1="51" TOTAL_2="51" VAR="0.24649859943977592" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-014.07.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:21:40 +1100" MODIFIED_BY="Narelle Willis" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Ceiprofloxacin/rifampicin versus cephradine</NAME>
<DICH_DATA CI_END="3.796477819837069" CI_START="0.04408174625079431" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.579380866942631" LOG_CI_START="-1.3557412097083938" LOG_EFFECT_SIZE="-0.38818017138288136" MODIFIED="2014-03-04 11:08:57 +1100" MODIFIED_BY="Narelle Willis" ORDER="8893" O_E="0.0" SE="1.1367002868335796" STUDY_ID="STD-de-Fijter-2001" TOTAL_1="44" TOTAL_2="54" VAR="1.292087542087542" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-014.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:29:58 +1100" MODIFIED_BY="Narelle Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-014.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:21:54 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Cefuroxime versus teicoplanin/aztreonam</NAME>
<DICH_DATA CI_END="3.7961818474222007" CI_START="0.00971080982989066" EFFECT_SIZE="0.192" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5793470081389256" LOG_CI_START="-2.0127445507318265" LOG_EFFECT_SIZE="-0.7166987712964504" MODIFIED="2014-03-04 11:03:51 +1100" MODIFIED_BY="Narelle Willis" ORDER="8885" O_E="0.0" SE="1.5226074127408329" STUDY_ID="STD-Wale-1992" TOTAL_1="24" TOTAL_2="23" VAR="2.3183333333333334" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-014.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-05 15:18:29 +1100" MODIFIED_BY="Narelle Willis" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="54" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Microbiological eradication</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="26" I2="0.0" ID="CMP-014.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-05 15:18:29 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Ceiprofloxacin/rifampicin versus cephradine</NAME>
<DICH_DATA CI_END="1.010086189647598" CI_START="0.3749167434753191" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="0.004358433278978509" LOG_CI_START="-0.4260651639087648" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2014-03-04 11:11:41 +1100" MODIFIED_BY="Narelle Willis" ORDER="8894" O_E="0.0" SE="0.25283295161924885" STUDY_ID="STD-de-Fijter-2001" TOTAL_1="54" TOTAL_2="54" VAR="0.06392450142450143" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-014.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 13:29:58 +1100" MODIFIED_BY="Narelle Willis" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="104.2878362298181" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="88" TOTAL_2="108" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Regimen 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Regimen 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours regimen 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours regimen 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-014.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:12:50 +1100" MODIFIED_BY="Narelle Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal toxicity</NAME>
<DICH_DATA CI_END="6.546104399300072" CI_START="0.05752269805185529" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8159829272901012" LOG_CI_START="-1.2401607519445013" LOG_EFFECT_SIZE="-0.21208891232720012" MODIFIED="2014-03-04 11:12:50 +1100" MODIFIED_BY="Narelle Willis" ORDER="8895" O_E="0.0" SE="1.2077889752577677" STUDY_ID="STD-de-Fijter-2001" TOTAL_1="44" TOTAL_2="54" VAR="1.4587542087542087" WEIGHT="0.0">
<FOOTNOTE>Ceiprofloxacin/rifampicin versus cephradine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-014.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 11:12:55 +1100" MODIFIED_BY="Narelle Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="9.760333940972664" CI_START="0.0170056472057435" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9894646769126619" LOG_CI_START="-1.7694068349141865" LOG_EFFECT_SIZE="-0.3899710790007623" MODIFIED="2014-03-04 11:12:55 +1100" MODIFIED_BY="Narelle Willis" ORDER="8896" O_E="0.0" SE="1.6205747826813257" STUDY_ID="STD-de-Fijter-2001" TOTAL_1="44" TOTAL_2="54" VAR="2.6262626262626263" WEIGHT="0.0">
<FOOTNOTE>Ceiprofloxacin/rifampicin versus cephradine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2014-03-04 11:40:21 +1100" MODIFIED_BY="Narelle Willis" NO="15">
<NAME>Intravenous (IV) vancomycin and dialysate gentamicin: 21 days versus 10 days</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-02-11 09:44:19 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="21" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>21 days</GROUP_LABEL_1>
<GROUP_LABEL_2>10 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 21 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 10 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.951050765417621" CI_START="0.6124328008131752" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5967126097875223" LOG_CI_START="-0.21294155730969594" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2011-12-20 11:48:19 +1100" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.47559486560567094" STUDY_ID="STD-Altmann-1984" TOTAL_1="21" TOTAL_2="28" VAR="0.22619047619047622" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-04-15 19:41:41 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-03-05 16:21:13 +1100" MODIFIED_BY="Narelle Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAp4AAAHoCAYAAADg5e/SAABwkElEQVR42uydDaRVzduHH5IkSSRJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-04-15 19:41:41 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-04-15 19:41:41 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWkAAAZBCAIAAAD/QffMAABgWElEQVR42u29sW4cyfW+PYCBHxww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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-05-09 16:19:10 +1000" MODIFIED_BY="Narelle S Willis">
<APPENDIX ID="APP-01" MODIFIED="2008-06-11 18:07:31 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2008-06-11 18:06:17 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-11 18:07:31 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<P>#1 PERITONEAL DIALYSIS<BR/>#2 (peritoneal next dialysis)<BR/>#3 pd<BR/>#4 capd<BR/>#5 ccpd<BR/>#6 (#1 or #2 or #3 or #4 or #5)<BR/>#7 PERITONITIS<BR/>#8 peritonitis<BR/>#9 periton*<BR/>#10 infect*<BR/>#11 (#9 and #10)<BR/>#12 PERITONEUM<BR/>#13 BACTERIAL INFECTIONS AND MYCOSES<BR/>#14 (#12 and #13)<BR/>#15 (#7 or #8 or #11 or #14)<BR/>#16 (#6 and #15)</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>1. exp peritoneal dialysis/<BR/>2. peritoneal dialysis.tw.<BR/>3. (PD or CAPD or CCPD).tw.<BR/>4. or/1-3<BR/>5. Peritonitis/<BR/>6. peritonitis.tw.<BR/>7. (periton$ and infect$).tw.<BR/>8. exp Peritoneum/<BR/>9. exp "bacterial infections and mycoses"/<BR/>10. 8 and 9<BR/>11. or/5-7,10<BR/>12. 4 and 11</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<P>1. continuous ambulatory peritoneal dialysis/ or peritoneal dialysis/<BR/>2. peritoneal dialysis.tw.<BR/>3. (PD or CAPD or CCPD).tw.<BR/>4. or/1-3<BR/>5. exp Peritonitis/<BR/>6. peritonitis.tw.<BR/>7. (periton$ and infect$).tw.<BR/>8. exp peritoneal cavity/ or exp peritoneum/<BR/>9. exp Infection/<BR/>10. 8 and 9<BR/>11. or/5-7,10<BR/>12. 4 and 11</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-11-19 12:34:43 +1100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-11-19 12:33:48 +1100" MODIFIED_BY="[Empty name]">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-19 12:34:43 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>:<I> </I>No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_4552_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="4552">
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 98451469</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 98451491</FAX_1>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Department of Emergency and Organ Transplantation</DEPARTMENT>
<ORGANISATION>University of Bari</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bari</CITY>
<ZIP>70100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Department of Clinical Pharmacology and Epidemiology</DEPARTMENT>
<ORGANISATION>Mario Negri Sud Consortium</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Santa Maria Imbaro</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_3" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_4" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Medical-Scientific Office</DEPARTMENT>
<ORGANISATION>Diaverum</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lund</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_5" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Division of Nephrology and Transplantation, Department of Translational Medicine</DEPARTMENT>
<ORGANISATION>Amedeo Avogadro University of Eastern Piedmont</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Novara</CITY>
<ZIP>28100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included: 42 (58 reports; 2433 participants)&lt;/p&gt;&lt;p&gt;Ongoing studies: 2 (2 reports)&lt;/p&gt;&lt;p&gt;Studies excluded: 49 (67 reports)&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 36 (42 reports)&lt;/p&gt;&lt;p&gt;Excluded studies: 21 (21 reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 0&lt;/p&gt;" WIDTH="310">
<FLOWCHARTBOX TEXT="&lt;p&gt;Reports excluded after title and abstract review: 1617&lt;/p&gt;&lt;p&gt;Reports excluded after full text review: 21 (not RCT, wrong population or intervention)&lt;/p&gt;" WIDTH="310">
<FLOWCHARTBOX TEXT="&lt;p&gt;2007 review: 1684 reports screened&lt;/p&gt;&lt;p&gt;(MEDLINE, EMBASE, CENTRAL, Renal Register)&lt;/p&gt;" WIDTH="310"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;New included studies: 6 (7 reports)&lt;/p&gt;&lt;p&gt;Existing included studies: 9 (9 new reports)&lt;/p&gt;&lt;p&gt;New ongoing studies: 2 (2 reports)&lt;/p&gt;&lt;p&gt;New excluded studies: 28 (33 reports) (not RCT, wrong population, intervention or outcomes)&lt;/p&gt;&lt;p&gt;New reports of previously excluded studies: 13 (1 study)&lt;/p&gt;" WIDTH="310">
<FLOWCHARTBOX TEXT="&lt;p&gt;2014 review update: 64 reports&lt;/p&gt;&lt;p&gt;Renal Register (62); other sources (2)&lt;/p&gt;" WIDTH="310"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>